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The delicate balance of coagulation and fibrinolysis allows blood to flow free 
through the vasculature to transport oxygen and nutrients, and to remove waste 
products. If the intricate systems that regulate primary hemostasis, and the 
procoagulant, anti-coagulant and fibrinolytic activities are not finely balanced 
there is a risk for thrombotic or hemorrhagic events. Our genetic makeup as well 
as environmental factors can influence this balance. In primary hemostasis, von 
Willebrand factor (VWF) plays a crucial role in the formation of the platelet plug 
during the initial response of sealing off a wound to the vasculature. It performs 
this task by functioning as a molecular glue between platelets and exposed 
subendothelial structures of the vasculature. A shift in the level of VWF or an 
alteration in its structure may result in a bleeding disorder called von Willebrand 
disease (VWD). In this thesis the effect of mutations of cysteine residues in VWF 
on the synthesis of VWF was studied in a model system and compared with the 
phenotype observed in patients with VWD that carry these mutations. 
 
Discovery of a new disease and a new factor 
Eighty years ago, the first report on "hereditary pseudohemophilia" was 
published by the Finnish MD Erik von Willebrand (1,2). He studied three families 
with a total of 66 members from Åland. The distribution between sexes (16 
females and 7 males), the slightly decreased to normal number of platelets, the 
prolonged bleeding time, and the severe mucocutaneous bleeding, which 
contrasted with the spontaneous deep tissue bleeding or bleeding of the joints 
observed in true hemophilia led von Willebrand to separate this disorder from 
hemophilia. He called it "hereditary pseudohemophilia". In honour of its 
discoverer, the disease was given his name and today is known as von Willebrand 
disease. 
The protein mutated in VWD that distinguishes it from true hemophilia 
remained elusive and the observation of low factor VIII (FVIII) in patients with 
VWD made matters even more confusing. However, the revolutionary discovery 
that FVIII forms a dissociable complex with the protein now known as VWF, 
provided a possible explanation for the occurrence of the two different bleeding 





purification of VWF (4), and the cloning and sequencing of the cDNA and the 
complete VWF gene (5-10). Together with direct sequence analysis of part of the 
VWF protein (11), this led to the prediction of the amino acid sequence of the 
VWF protein. These milestones accelerated the progress of unraveling the diverse 
properties of this complex protein and its role in hemostasis. 
 
Biosynthesis of VWF 
Over the years, knowledge has accumulated on the biosynthesis and the structure 
and function of VWF. We now know that synthesis of VWF is restricted to 
endothelial cells (12,13) and megakaryocytes (14). The study of cultured 
endothelial cells revealed two distinct pathways of secretion for VWF, 
constitutive and regulated secretion (reviewed by Wagner (15) and Sadler (16)). 
Biosynthesis of VWF is a complex process that requires extensive 
post-translational modification of the newly synthesized precursor to yield high 
molecular weight (HMW) multimers ranging from 500 to 20.000 kDa (15,16). 
Synthesis of HMW multimers starts with transcription of the ~178 kbp VWF gene 
(10), which is located on the short arm of chromosome 12 (17,18). The 52 exons of 
the VWF gene (Fig. 1) are transcribed into a ~9 kb mRNA (10). Translation of the 
VWF mRNA starts at exon 2 and yields a 2813 amino acid (aa) long single chain 
precursor protein, preproVWF, with an approximate molecular weight of 350.000 
(10). Exon 2 of VWF codes for the signal peptide (22 aa), whereas exons 3-17 
encode the large VWF-propeptide (741 aa) (10), which is also known as von 
Willebrand antigen II (19). The remaining exons, 18-52, encode the mature VWF 
subunit (2050 aa) (10). 
Examination of the amino acid sequence of preproVWF revealed that VWF 
consists of several repeated domains (A-D, Fig. 2) (8,9). Over 90% of the amino acid 
residues of preproVWF have been mapped to such domains (8). In addition, the 
amino acid sequence appeared to contain an unusual high number of cysteine 
residues (8.2%) (20). It was shown that all these cysteine residues contributed to 
the formation of either intrachain or interchain disulfide bonds (20). Cysteines are 
mainly found at the N- and C-terminal regions of mature VWF (11). The former 
was shown to be necessary for multimerization of VWF; the latter for 
dimerization (Fig. 2) (21,22). 






Fig. 1, schematic overview of the exon distribution in VWF mRNA, its translation 
to preproVWF and the subsequent processing steps. Important steps are removal 
of the signal peptide (SP), dimerization and multimerization of proVWF, and cleavage 
of the VWF-propeptide (PP) resulting in mature multimers lacking the PP. Cysteine 
disulfide bonds formed either at the C-terminus (dimerization) or the N-terminus 





Dimerization and multimerization of VWF 
During the assembly of monomeric VWF to high molecular weight multimers, its 
routing through two intracellular compartments, the endoplasmic reticulum (ER) 
and the Golgi apparatus, are crucial for dimerization and multimerization, 
respectively (Fig. 1). The signal peptide targets preproVWF to the ER. After 
translocation of preproVWF into the ER the signal peptide has served its purpose 
and is cleaved off between aa 22 and 23 (Fig. 2). In the ER, selected asparagine 
(Asn) residues of proVWF are glycosylated by addition of high mannose 
oligosaccharide chains, a process that is a prerequisite for the subsequent 
formation of disulfide linked proVWF (23). The proVWF dimers are formed 
through interchain disulfide bond(s) between cysteine residues located in the 90 
carboxy-terminal residues of VWF, also known as the cystine knot (CK) domain 
(20,24). The dimerization of proVWF generates the first building block in the 
formation of HMW multimers of VWF. These building blocks are transported to 
the Golgi apparatus, where the Asn-linked oligosaccharides are processed and 
subsequently sulfated (25); where O-linked oligosaccharides are added to serine 
and threonine residues; and where the formation of HMW multimers occur (15). 
Multimerization of VWF involves the formation of interchain disulfide bonds 
between cysteine residues in the D3 domains of two proVWF dimers. This domain 
is located at the N-terminus of the proVWF dimer (Fig. 1). Continuous addition of 
building blocks results in a growing proVWF multimer. After removal of the 
VWF-propeptide, comprising the D1 and D2 domains, by cleavage after residue 
763 (Fig. 2), the multimer consists of an even number of mature VWF subunits 
(Fig. 1). The removal of the VWF-propeptide from proVWF has been suggested to 
occur simultaneously with the assembly of proVWF dimers to multimers (26) and 
is most likely catalysed by furin, a subtilisin-like serine protease (27-29). 
Multimerization of VWF in the Golgi apparatus is dependent on the presence of 
the VWF-propeptide (30,31). However, removal of the VWF-propeptide is not 
required for the formation of multimers (32). 
On the basis of these results and the identification of the active site sequence 
of disulfide isomerase, CXXC, in each of the D domains of the VWF-propeptide 
(33), the VWF-propeptide was suggested to have a dual role in the 
multimerization of VWF. Firstly, it was proposed to recognize and align 
N-terminal regions of VWF dimers (30,31) and, secondly, it was proposed to 




facilitate the formation or rearrangement of interchain disulfide bonds by its 
intrinsic disulfide isomerase activity (33). The former was shown not to require 
the VWF-propeptide to be a contiguous part of the VWF protein to assist 
multimerization (31). The latter is supported by the identification of a transient 
disulfide-linked intermediate of the D1-D2 domains of the VWF-propeptide and 
the D'-D3 domains of the multimerization region of VWF (36). If indeed the 
VWF-propeptide would function as a catalyst in disulfide bond formation or in the 
rearrangement of existing disulfide bonds, this may explain how VWF is able to 
form HMW multimers in the acidic milieu of the Golgi. 
 
Storage and secretion of VWF 
The majority of VWF synthesized in the endothelium is secreted via the 
constitutive pathway and only a small amount via the regulated pathway (16). 
 
Fig. 2, overview of preproVWF and the repeated A-D regions. A signalpeptidase 
(SPase) removes the signal peptide (SP, aa 1-22) after translocation of preproVWF 
into the ER. In the Golgi apparatus, furin releases the VWF-propeptide (aa 23-763) 
from proVWF multimers resulting in VWF multimers (aa 764-2813). ADAMTS13 
cleaves VWF multimers between aa 1605 and 1606. Indicated are domains involved 
in the formation of HMW multimers (dimerization, CK domain aa 2724-2813; and 
multimerization, D'-D3 domains aa 769-1242), domains involved in primary (GPIb, 
GPIIb/IIIa and collagen) and secondary hemostasis (FVIII), as well as functional 
domains that are important for in vitro testing of VWF (binding of ristocetin and 
botrocetin). Binding sites (aa): FVIII 764-1035; GPIb 1237-1251, 1277-1305, 1458-
1471; GPIIb/IIIa 2507-2509; collagen 1305-1385, 1711-1761; ristocetin 1237-1251, 
1458-1471; and botrocetin 1277-1406. Adapted from (34,35). Sites for proteolytical 





Regulated secretion of ultra-large VWF multimers from specific endothelial 
storage organelles, Weibel-Palade bodies (37,38), occurs after activation of the 
endothelium. The Weibel-Palade bodies are rod shaped, striated organelles up to 
4 μm in length and approximately 0.1 μm in width that release their content after 
fusing with the plasma membrane (39). Sorting of VWF to these storage organelles 
requires the presence of the VWF-propeptide (40), which is stored in the 
Weibel-Palade bodies at an equimolar ratio with mature VWF (41). After release 
from the storage organelle the VWF-propeptide is cleared four to five times more 
rapidly from the circulation than mature VWF, resulting in the non-equimolar 
ratio of VWF-propeptide over mature VWF observed in plasma (41,42). An 
additional source of regulated release of ultra-large VWF multimers (16) and 
VWF-propeptide (43) are platelets, which are derived from megakaryocytes and 
release VWF upon exocytosis of their α-granules. 
 
Proteolysis of VWF by ADAMTS13 
In normal plasma, HMW multimers of VWF are proteolytically processed to 
smaller fragments. This process is reflected by the triplet structure of a central 
band accompanied by two satellites, observed on VWF multimer gels (44) (Fig. 3). 
Recently the protease mediating this degradation of VWF was identified as 
ADAMTS13 (A Disintegrin and Metalloproteinase with Thrombospondin motifs) 
(reviewed by Plaimauer (45) and Porter (46)). VWF is cleaved by ADAMTS13 
between residues Y1605-M1606, which are located in the A2 domain of VWF 
(Fig. 2) (47). A stretch of 73 aa in VWF, D1596 to R1668, was identified as the 
smallest region of VWF required for recognition and subsequent cleavage by 
ADAMTS13 under static conditions (48). Although the protease and its substrate 
are both present in the circulation, this does not result in the depletion of plasma 
of HMW multimers (49). Normally, the cleavage site in the A2 domain is 
inaccessible to ADAMTS13. It is exposed only after partial unfolding of VWF 
(49,50). In vivo this structural change is most likely induced by the shear stress 
exerted on VWF after binding to the endothelial surface; in vitro, denaturing 
agents such as urea or guanidine are able to make the cleavage site accessible 
(49,50). Padilla and co-workers proposed P-selectin as a candidate for securing 
extremely large VWF multimers to the endothelium, thereby facilitating the 
degradation of these multimers by ADAMTS13 (51). 




The average VWF:Ag level in plasma is approximately 10 μg/mL (10). 
However, a wide range in VWF:Ag levels is observed in healthy individuals, which 
is related to the addition of the ABO blood group antigens to VWF (52,53). 
Individuals with blood group O lack the glycosyltransferase needed to modify the 
precursor H antigen into A antigen (transferase A) or B antigen (transferase B) 
(54). VWF:Ag levels are 25-40% lower in blood group O carriers than in non-O 
blood group carriers (52,53). This variation may to some degree be explained by a 
protective effect of added carbohydrate groups on proteolytic degradation of 
VWF (55). Indeed, a protective effect of non-O compared with blood group O was 
found by Bowen in an in vitro test system (56). In their assay, blood group A 
showed a slightly higher protective effect towards ADAMTS13-mediated 
proteolysis than did blood group B (56). Both non-O blood groups were more 
protective than blood group O (56). Further removal of the terminal sugars on 
N-linked glycans is associated with more rapid cleavage of VWF by ADAMTS13, as 
was demonstrated for VWF lacking the H antigen (Bombay blood group) (57). The 
contribution of this rapid cleavage to the steady state plasma VWF level is 
 
Fig. 3, multimer patterns of pooled normal plasma (NP) and recombinant 
wild-type VWF (rVWF-wt). The distribution of low, intermediate and high molecular 
weight multimers in normal VWF is shown. It reflects ADAMTS13 mediated proteolysis 
of VWF. Recombinant VWF does not show the triplet structure due to the absence of 
ADAMTS13 in vitro. The triplet structure of VWF is indicated on the left with a thick 





however uncertain as only slightly lower VWF:Ag levels were observed in 
individuals with Bombay blood group than in O blood group carriers (57). This 
suggests that apart from receptor-mediated clearance of VWF, increased 
susceptibility and possibly increased ADAMTS13 activity (58) may contribute to 
the lower levels of VWF:Ag observed in blood group O carriers. 
A disturbed balance between secretion of ultra-large VWF multimers from 
the Weibel-Palade bodies and the proteolytic processing of VWF by ADAMTS13 
may result in disease. Thrombocytic thrombocytopenic purpura (TTP), e.g., may 
be caused by a lack of active ADAMTS13 in the circulation, due to mutations in the 
ADAMTS13 gene or autoantibodies, thus leading to the formation of microthrombi 
in the microvasculature of many organs (49,50). Another example is type 2A VWD, 
which is caused by increased ADAMTS13-mediated degradation of VWF due to 
mutations in the A2 domain of VWF (49). 
 
Structure and functional regions of VWF 
The use of proteolytic fragments of VWF, monoclonal antibodies and recombinant 
expression have resulted in the mapping of functional regions of VWF. These 
regions are located in specific domains in VWF (8,9), and are involved in the 
interaction with receptors on platelets, molecules in the extracellular matrix of 
the vasculature and exogenous molecules (Fig. 2). The domain binding to 
glycoprotein Ib (GPIb) on platelets is located in the A1 domain (34); the 
Arg-Gly-Asp (RGD) sequence that interacts with platelet receptor 
glycoprotein IIb/IIIa (GPIIb/IIIa) is located in the C1 domain (59-62); the collagen 
binding sequences are situated in the A1 and A3 domains (34); the D' and D3 
repeats of VWF harbour the binding site of FVIII (63). This protein plays an 
important role in the fortification of the platelet plug by supporting localized 
coagulation resulting in fibrin formation. To date, no specific function has been 
assigned to the D4 domain or any of the B domains of VWF. 
The non-covalent interaction observed between FVIII and VWF has been 
mapped to the first 272 amino acids of mature VWF (63) (Fig. 2). Proteolytic 
removal of the VWF-propeptide has been shown to be vital for the association and 
stabilization of FVIII by VWF (64). Complex formation with VWF makes FVIII less 
susceptible to phospholipid-dependent proteolysis by several proteases (65-70). 
VWF also shields FVIII from interaction with the low density lipoprotein 




receptor-related protein and protects it from being internalized and targeted to 
the endosomal degradation pathway (71). Thus, low levels of VWF or a 
dysfunctional binding site for FVIII can result in reduced plasma FVIII activity. 
This ultimately translates to an increased risk for bleeding like in type 2N VWD 
(72). 
VWF also contains binding sites for exogenous molecules. The ability of 
molecules as ristocetin and botrocetin to induce VWF-mediated aggregation of 
platelets is used in in vitro tests to analyze the functionality of VWF. The specific 
binding sites for these molecules are also indicated in Fig. 2 (34,35). 
Considering the high percentage (8.2%) of cysteines in mature VWF, the 
presence of only six cysteines in the A1-A3 domains -corresponding to only 1%- is 
strikingly low. The A1 and A3 domains each form a large loop that is secured at 
the base by an intrachain disulfide bond between cysteines C1272-C1458 in the A1 
domain and C1686-C1872 in the A3 domain (20). The A2 domain lacks this disulfide 
bond, which otherwise would render the Y1605-M1606 cleavage site for 
ADAMTS13 inaccessible (Fig. 2) (47). 
 
The role of VWF in hemostasis 
VWF has two important functions in blood coagulation. One is to mediate the 
formation of a platelet plug at a site of injury; the other is to function as a carrier 
of FVIII, preventing rapid clearance of FVIII from plasma. VWF functions as a 
molecular glue between the lining of the damaged blood vessel and circulating 
platelets passing by at high velocity, on the one hand, and between the activated 
platelets at the site of injury on the other hand. The adhesiveness of VWF is 
essential for the formation of a platelet plug under high shear conditions in the 
circulation. Other important factors are the presence of the platelet receptors 
GPIb and the integrin αIIbβ3 (GPIIb/IIIa). 
An injury to the vasculature results in the exposure of subendothelial 
structures like collagen. VWF interacts with collagen via its A3 domain (73). 
Subsequently the binding site for the platelet receptor GPIb, located in the A1 
domain of VWF, becomes accessible (74,75). The transient interaction of VWF with 
the platelet GPIb receptor decreases the velocity of the interacting platelets (76). 
The rolling of the platelets over the layer of VWF and additional interactions 





the platelets and subsequent expression of integrins such as GPIIb/IIIa on their 
surface. Firm attachment of the platelet is mediated via binding of GPIIb/IIIa to 
the RGD sequence in the C1 domain of VWF and other adhesive substrates 
containing this sequence such as fibrinogen and possibly fibronectin. Addition of 
second layer of platelets (aggregation) involves binding of VWF to the GPIb and 
GPIIb/IIIa platelet receptors and of fibrin to GPIIb/IIIa. This results in a layer of 
VWF and fibrin coating the adhered platelets which functions as a platform for 
circulating platelets and recruits them to the growing thrombus. The aggregation 
of platelets continues until the injury is sealed off and an unstable platelet plug 
has been formed. In the final stage this plug is reinforced by the formation of a 
stable fibrin network, which involves localized coagulation facilitated by the 
activated platelets and their secreted contents. The above described interactions 
have been reviewed by de Groot (77), Ruggeri (78), and Mendolicchio (75). 
 
VWD 
VWD is a common bleeding disorder (79). Most quantitative or qualitative 
deficiencies in the VWF protein result in mild bleeding from the mucosal areas 
observed as easy bruising or frequent nosebleeds. Normal procedures like dental 
extraction and tonsillectomy are, in VWD patients, often accompanied by 
extended bleeding. In women, VWD may result in heavy menses and extreme 
blood loss during delivery. Extremely low levels of VWF may also cause low FVIII 
activity leading to bleeding symptoms similar to those observed in hemophilia 
patients. 
VWD is subdivided into three different types according to a simplified 
classification introduced by Sadler in 1994 (80). Qualitative VWF defects are 
designated type 2 VWD. Quantitative VWD is divided into partial deficiency (type 
1) and severe deficiency (type 3) of VWF. Mutations causing quantitative VWD are 
spread throughout the entire VWF gene, which due to its size makes the 
identification of mutations causing the disease especially laborious. Quantitative 
VWF defects by definition only affect the level of the VWF protein in the 
circulation and do not influence the distribution between high, intermediate and 
low molecular weight multimers in plasma (80). Type 1 VWD is often dominantly 
inherited and is the most frequent of the VWD subtypes. Previously only a few 
mutations had been detected in type 1 VWD. This has however changed since the 




start of the European Study "Molecular and Clinical Markers for the Diagnosis and 
Management of type 1 VWD" (MCMDM-1VWD) which revealed that 67% of the 
index cases have at least one candidate mutation (81). The majority of these 
mutations were missense mutations (81%) whereas a minority were mutations 
resulting in a null allele (12%) or affecting the promoter region of VWF (6%) (81). 
The rather uncommon type 3 VWD is inherited recessively and is characterized by 
the virtually complete absence of VWF antigen. In contrast to type 1 VWD, type 3 
VWD is mostly caused by large deletions, nonsense mutations and frame shift 
mutations resulting in null alleles, even though missense mutations have been 
described as well (82). Type 2 VWD comprises four subtypes: 2A, 2B and 2M with 
altered interactions with platelets, and type 2N with decreased FVIII binding (80). 
Both types 2A and 2M are caused by decreased platelet-dependent functions. Type 
2A is, however, associated with the absence of HMW multimers, while type 2M is 
not. Finally, type 2B exhibits increased affinity for GPIb. In contrast to 
quantitative VWF defects, mutations leading to qualitative defects are found 
mainly in certain functional domains of VWF, which facilitates the detection of 
the mutation. 
The decreased ristocetin cofactor activity and decreased binding of VWF to 
collagen observed in type 2A VWD is a direct result of the lack of HMW multimers. 
Most of the underlying mutations are found in the A2 domain, while some reside 
in the A1 domain of VWF. They affect either biosynthesis and routing of the 
multimers (referred to as group 1 mutations; (83)) or increase the sensitivity to 
proteolysis by ADAMTS13 in plasma (referred to as group 2 mutations; (47,83,84)). 
The loss of HMW multimers and thrombocytes in blood of patients with type 2B 
VWD is explained by the increased affinity of VWF for GPIb (85). This results in 
spontaneous binding of VWF to platelets without previous activation, and the 
subsequent clearance of the platelet-VWF-complexes. The mutations are found in 
the A1 domain of VWF, which also contains the functional binding site for GPIb 
(86,87). In patients diagnosed with type 2M VWD amino acid residues in the A1 
domain of VWF are mutated. These mutations result in decreased binding of VWF 
to GPIb but do not affect multimer assembly, as the multimer distribution in 
plasma is normal (87). In type 2N VWD mutations have been found in the D' and 
the D3 domains of VWF and correlate with normal multimerization but decreased 





(63) or by the abrogation of VWF-propeptide cleavage, which has been shown to 
be required for optimal binding of FVIII to VWF (64). 
 
Outline of this thesis 
Studies of patients with varying severity of VWD and sequencing of the VWF gene 
has resulted in the identification of several missense mutations in VWF, among 
which mutated cysteine residues. The aim of the work described in this thesis was 
to evaluate how loss of cysteine residues located in different domains of VWF may 
cause quantitative VWF defects of different severity. Candidate missense 
mutations of cysteine residues detected in patients with quantitative VWD were 
studied to assess whether they indeed were the causative mutations. This was 
done by expression of full-length recombinant VWF in mammalian cells. The 
quantity of secreted and intracellular VWF as well as the quality of the produced 
VWF was studied. 
In Chapter 2a, the effect on the level of dimerization and multimerization of 
two type 1 VWD mutations (C1130F and C1149R) was investigated and compared 
with the effects of three type 3 VWD mutations (C2671Y, C2739Y and C2754W). 
Further, we investigated whether the introduction of an alanine instead of a 
tyrosine at position 2671 would have an effect on recombinant VWF expression 
and these results are reported in Chapter 2b. The very low VWF antigen levels 
observed in patients with the C1130F, C1149R or C2671Y mutation were not 
completely reproduced in vitro (Chapter 2a). The hypothesis that increased 
clearance of the mutant protein may occur in vivo was tested. 
ADAMTS13-mediated proteolysis, assessment of the in vivo survival of the 
recombinant proteins in a murine model and the half-life of endogenous mutant 
VWF after infusion of DDAVP were investigated and showed increased clearance 
of all three mutant VWF proteins (Chapter 3). 
In Chapter 4, we investigated a missense mutation of a cysteine residue that 
is neither located in the dimerization nor in the multimerization area of VWF. 
This mutation, C2362F, has been found in a subgroup of patients with autosomal 
recessive severe VWD having low VWF antigen levels, undetectable VWF 
ristocetin cofactor activity, but remarkably high FVIII coagulant activity. 
Expression of the C2362F mutation reproduced the severe VWD phenotype 
regarding the level of multimerized VWF and the quantity of VWF secreted. 




However, a difference in the level of VWF degradation was observed between in 
vitro transfections and patients plasma indicating that the mutant protein may be 
sensitive to proteolytic cleavage in vivo, although this was not observed in the in 
vitro ADAMTS13-mediated assay. 
During the investigation of the role of cysteine residues 2739 and 2754 in 
quantitative type 3 VWD (Chapter 2a), we observed that alterations of cysteine 
residues 2771 (88) and 2773 (89,90), which are also located in the CK domain of 
VWF, were reported to result in a different VWD phenotype, type 2A (the former 
subtype IID). We hypothesized that the difference in phenotype depends on 
whether the mutated cysteine residue is involved in the formation of an 
interchain bond or of an intrachain bond. To test our hypothesis we screened a 
family with type 2A(IID) VWD characteristics and detected a novel mutation, 
C2773S (Chapter 5). This residue is suggested to be involved in an interchain 
disulfide bridge in the CK domain (24) and therefore this finding supports our 
hypothesis that loss of interchain disulfide bonds in the CK domain results in type 
2A(IID) VWD. In Chapter 6 we investigated the possibility that a previously 
reported polymorphism, Y1584C, is associated with an increased risk for bleeding 
in patients treated with vitamin K antagonists. Unfortunately, the low frequency 
of this polymorphism and the small size of the study population did not allow a 
reliable estimate of its possible contribution to the risk of bleeding. The results 
obtained during these studies are summarized and discussed in Chapter 7. 
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In patients classified with type 1 and type 3 von Willebrand disease (VWD) 
missense mutations resulting in the loss of cysteine residues in the D3 domain 
(multimerization area) and in the carboxy-terminus (dimerization area) of the 
von Willebrand factor (VWF) have been identified. We have investigated how 
these structural changes result in a quantitative VWF deficiency and how they 
interfere with the dimerization and multimerization processes. 
The effect of mutations in the multimerization area (C1130F, C1149R) and in 
the dimerization area (C2671Y, C2739Y, C2754W) of human recombinant VWF 
were investigated in transient transfection assays in 293T cells. All mutations 
resulted in reduced secretion of VWF in the medium and in intracellular 
retention. The amino-terminal mutants C1130F and C1149R showed impaired 
multimerization by lacking high molecular weight (HMW) multimers, in 
co-transfection experiments with wild-type VWF, the multimeric pattern was 
consistent with the pattern in the heterozygous type 1 VWD patients. The 
carboxy-terminal mutants C2739Y and C2754W showed strongly reduced to nearly 
absent secretion of VWF, consistent with type 3 VWD. The multimeric pattern of 
C2739Y and C2754W is characterized by the absence of HMW multimers, an excess 
of monomers and intervening odd-numbered multimeric bands, indicating a 
dimerization defect. The carboxy-terminal mutant C2671Y is different, with 
mildly reduced secretion, intermediate intracellular retention and a normal 
multimerization pattern. 
We conclude that, in accordance with a phenotype of quantitative VWF 
deficiency, all cysteine mutants show impaired secretion, although the decrease 
of VWF in vitro appears lower than in the patients, suggesting additional, possibly 






The von Willebrand factor (VWF) is a high molecular weight multimeric 
glycoprotein (0.5-10x106 Da) with adhesive properties. VWF mediates adhesion of 
platelets to the vessel wall and platelet-platelet aggregation. VWF forms a 
non-covalent complex with factor VIII. The unprocessed preproprotein of 2813 
amino acids (aa) is targeted to the endoplasmic reticulum (ER) by the 22 aa long 
signal peptide. In the ER, the proVWF is glycosylated and the subunits are linked 
pairwise through covalent disulfide bonds at the carboxy-terminus. The proVWF 
dimers are further modified when passing through the ER and the Golgi 
apparatus. Multimers are formed from proVWF dimers by disulfide bonds at the 
amino-terminal end of the subunits. After formation of multimers, the 
VWF-propeptide is cleaved off, resulting in VWF multimers consisting of an even 
number of mature VWF subunits (2050 aa) (reviewed by Wagner (1) and Sadler 
(2)). The VWF protein contains a high number of cysteine residues (8.2%) all of 
which participate in forming intra- or interchain disulfide bonds (3). 
Von Willebrand disease (VWD) is the most common inherited bleeding 
disorder. It is caused by dysfunctional VWF or by a deficiency of VWF. VWD is 
divided into three groups (4): type 1 refers to partial VWF deficiency, type 3 is 
characterized by an almost complete VWF deficiency and type 2 involves all 
functional defects of the VWF protein. The molecular basis of the disease has been 
elucidated for most type 2 VWD variants (5). The molecular basis of type 1 and 
type 3 VWD has been difficult to characterize, because mutations are not 
restricted to a specific region in the VWF gene. 
Although type 1 and type 3 VWD are both characterized by a deficiency of 
VWF, the underlying genetic mechanisms appear to be different. Type 1 VWD has 
an autosomal dominant inheritance pattern, however recessive inheritance has 
also been described (6). Inheritance of type 3 VWD is autosomal recessive. The 
heterozygous carriers of type 3 mutations (mainly null alleles) usually have only 
mild or no bleeding symptoms and roughly 50% reduction of VWF levels. 
Therefore, these carriers of type 3 VWD are different from most type 1 VWD 
patients who have VWF levels well below 50%. We previously hypothesized that 
type 1 VWD could possibly be caused by missense mutations, resulting in a 
dominant negative defect, i.e., mutant subunits interacting with normal subunits 
leading to a reduction of more than 50% of VWF levels. Following this hypothesis 
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we previously identified two missense mutations, C1130F and C1149R. These 
mutations, both occur in the D3 domain, which is involved in multimerization (7). 
C1149R has been shown to cause intracellular retention of VWF (7,8) 
(nomenclature of mutations according to reference (9)). 
While mutated cysteines in the multimerization domain cause a dominant 
negative type 1 defect, we hypothesized that loss of cysteines in the dimerization 
domain (the 151 carboxy-terminal amino acid residues (10)) may also be 
responsible for quantitative defects. If mutant proVWF subunits are unable to 
form dimers, it is possible that only wild-type (wt) homodimers are formed (in the 
heterozygous state) and, if only these normal homodimers were transported to 
the Golgi, a reduction of VWF by 50% would be seen. This would mimic the effect 
of a null allele. Using this hypothesis, we have previously investigated VWD type 3 
patients and identified a C2671Y mutation at the carboxy-terminus (11). Other 
C-terminally located cysteine mutations have also been identified in type 3 VWD 
patients (12-15). 
To further investigate the VWF defect due to loss of cysteines in the 
multimerization and dimerization domains, we have expressed five different 
cysteine mutations; the amino-terminal C1130F and C1149R mutations, identified 
in type 1 VWD and the carboxy-terminal C2671Y, C2739Y and C2754W mutations, 
identified in type 3 VWD. 
 
Materials and methods 
Patients and mutations 
The mutations we have expressed in transfections were originally identified in 
VWD patients. The C1130F and C1149R mutations were found previously in type 1 
VWD patients, characterized by high penetrance of the phenotype and very low 
levels (0.10-0.15 IU/mL) of VWF antigen (VWF:Ag) (7). Two compound 
heterozygous type 3 VWD patients were described, one with a C2671Y mutation in 
combination with a deletion of the other allele (11), and one with a C2739Y 
mutation and an insertion of a cytosine (5221insC) on the other allele, leading to a 
premature stop codon (12). One type 3 VWD patient was homozygous for the 







The pSVHVWF1 plasmid contained the full-length normal human cDNA of VWF 
cloned into the expression vector pSV7D (16) as previously described (17) and was 
kindly provided by Dr. Evan J. Sadler (Howard Hughes Medical Institute, St. Louis, 
MO, USA). The construction of mutant plasmid pSVHVWF-C1149R was previously 
described (7). The pSVHVWF-C1130F, C2671Y, C2739Y and C2754W plasmids were 
constructed via a general cloning strategy described in Fig. 1. The oligonucleotides 
used are listed in Table I. Restriction enzymes and T4 DNA ligase were from MBI 
Fermentas (St. Leon-Rot, Germany) or New England Biolabs (Leusden, the 
Netherlands). Oligonucleotides were synthesized on 0.2 μmol scale and purchased 
from Amersham Pharmacia Biotech (Roosendaal, the Netherlands) and were 
either PAGE (nrs 1 and 2) or HPLC purified. Construction of pSVHVWF-C2671Y and 
pSVHVWF-C2739Y required introduction of an SbfI site in pSE280. The SbfI site 
was introduced by annealing of oligonucleotides 1 and 2 (Table I) and ligation of 
the duplex in the PstI and MluI digested pSE280 vector, yielding pSE280+SbfI, 
which was used for subcloning of the longer A-C wt VWF fragment via digestion 
with SbfI and EcoRV. All constructs were transformed and propagated in E. coli 
DH5α. For transfection experiments DNA was purified using a plasmid maxi kit 
(Qiagen, Hilden, Germany). The DNA amount was quantified by measuring 
absorbance at 260 nm with an Ultrospec II spectrophotometer (Pharmacia LKB, 
Bromma, Sweden). DNA preparations used were screened for the respective 
mutations by restriction analysis. 
 
Expression of recombinant VWF 
293T human kidney cells (18) (kindly provided by Dr. J. Evan Sadler) were grown 
in Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose supplemented with 
2 mM L-glutamine, 100 IU/mL penicillin, 100 IU/mL streptomycin and 10% 
(vol/vol) fetal bovine serum which were all from Gibco-BRL (Life Technologies, 
Paisley, United Kingdom). Cells were seeded to reach 50-70% confluence in T25 
flasks (Becton Dickinson Labware, Franklin Lakes, NJ, USA) at transfection. 293T 
cells were transiently transfected using the calcium phosphate precipitation 
method (19). Cells were transfected for 15 hrs, washed twice, then overlaid with 
5 mL Optimem 1 with Glutamax-1 (Gibco-BRL) supplemented with 0.5% human 
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serum albumin (CeAlb® for i.v. use, albumin 20%, CLB, Amsterdam, the 
Netherlands) and cultured at 37°C and 5% CO2. After 21 hrs, when VWF production 
was still linear, conditioned media and cell lysates were collected. The protease 
inhibitor cocktail Complete™ with EDTA (Roche Diagnostics, Mannheim, 
Germany) was added to medium and cell lysate. Medium was centrifuged at 3000 
rpm for 5 minutes at 4°C and supernatant was snap-frozen. The cells were rinsed 
with phosphate buffered saline and lysed with 0.8 mL Passive Lysis Buffer (PLB, 
Promega Corporation, Madison, WI, USA). Crude lysate was spun down at 10,000 
rpm for 2 minutes at 4°C (Eppendorf Centrifuge model 5804R) and supernatant 
was snap-frozen. 
In the single transfections a total of 10 μg wt or mutant construct was used 
per T25 flask. Titration series of co-transfections contained a total amount of 9 μg 
DNA. The molar amount of pSVHVWF promoter was corrected in each 
co-transfection by addition of the plasmid pSVHVWF-cDNA lacking the coding 
region of VWF. Furthermore, a pUC13 plasmid lacking promoter and multiple 
cloning site was used to bring the DNA amount to 9 μg. The pGL3 control plasmid 
harbouring the luciferase gene was included in all transfections to enable 
monitoring of the transfection efficiency. The luciferase activity in cell lysates 
was measured with a Luciferase Assay Substrate (Promega) using a luminometer 
(Lumat LB 9507, Berthold Technologies, Vilvoorde, Belgium). Similar transfection 
efficiencies were obtained for all the constructs in the single transfections. The 
luciferase activity was similar in both the single wt and co-transfection 
experiments that were performed in parallel (data not shown). 
 
Analysis of recombinant VWF 
Quantitative analysis of VWF 
In conditioned medium and lysates the level of recombinant VWF (rVWF) was 
determined by a VWF:Ag Enzyme Linked Immunosorbent Assay (ELISA) as follows. 
A polyclonal rabbit anti-human VWF antibody (A082, Dako, Glostrup, Denmark) 
diluted 1000-fold in 0.1 M sodium-carbonate buffer (pH 9.4) was used to coat 
96-well plates with flat-bottom wells (Greiner, Germany). Plates were coated 
overnight at 4˚C using 120 μL of the dilution per well and washed three times with 







Fig. 1, schematic PCR and cloning schedule in pSE280 and pSVHVWF1. For 
explanation of abbreviations and digestion see Table I. i) Mutations were introduced in 
a short wt VWF B-C fragment inserted in pSE280 (Invitrogen, Leek, the Netherlands). 
Two separate partially overlapping mutant products were generated using a primer 
located in the multiple cloning site (MCS) of pSE280 and a mutagenic primer that 
introduced the appropriate nucleotide change (*). In addition, the latter primer also 
contained a silent nucleotide change to introduce a restriction site, as a marker for the 
presence of the mutation, digestion 1 (Table I). ii) The two overlapping fragments 
were pooled in a new PCR reaction, that was performed in absence of added primers 
to generate the full-length double stranded mutant fragment B-C*. Subsequently, the 
two vector primers were added to generate a sufficient amount of the mutant B-C* 
fragment for exchange with the wt B-C fragment that was cloned via digestion 2 
(Table I) in pSE280. iii) Positive constructs were identified by digestion 1 and then 
both strands were sequenced using combinations of oligonucleotides 3-6 (Table I) and 
CEQ 2000 Dye Terminator Cycle Sequencing (Beckman Coulter, Fullerton, CA, USA). 
The mutant B-C* fragment was cloned via digestion 2 in pSE280 vector harbouring the 
longer wt VWF A-C fragment (Table I). iv) Introduction of the mutant B-C* fragment 
was verified by digestion 1. The mutant A-C* fragment was introduced in the 
pSVHVWF1 cDNA via digestion 3 (Table I). v) Constructs were tested for 
incorporation of the mutation by digestion 1. anker 
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1600 and 3200-fold and used as standard. Conditioned medium was analyzed 
undiluted and 2, 4, 8, 16 and 32-fold diluted. Cell lysates were 8, 16, 32, 64, 128 and 
256-fold diluted. Plasma standard and samples were diluted in sample buffer, PBS 
with 0.2% Bovine Serum Albumin (BSA, Fraction V, Sigma, Steinheim, Germany) 
and 0.1% Tween-20. 100 μL standard or sample was added to each well and 
incubated at room temperature (RT) for two hrs and washed three times. 
Polyclonal rabbit anti-human horseradish peroxidase (HRP) conjugated antibody 
(P226, Dako) was diluted 8000-fold in sample buffer. 100 μL of this dilution was 
added per well and incubated at RT for 2 hrs and washed three times. The 
substrate solution consisted of a 10 mg O-phenylene diamine (OPD, Sigma), 25 mL 
OPD-buffer (~100 mL 0.1 M Na2HPO4 and ~50 mL 0.1 M citric acid to pH 5.0) and 
10 μL 30% H2O2 (Merck, Darmstadt, Germany). 100 μL substrate was added per 
well. The reaction was terminated after 20 minutes by addition of 100 μL 2 M 
H2SO4. The absorbance was read at 492 nm in a Organon Teknika Microwell 
System model 510 reader. 
 
Qualitative analysis of VWF 
VWF multimer analysis by non-reducing agarose gel electrophoresis with sodium 
dodecyl sulfate (SDS, Bio-Rad, Hercules, CA, USA) was essentially performed 
according to the protocol of Raines et al. (20). For all gels Sea-Kem® HGT (P) 
agarose (FMC Bioproducts, Rockland, ME, USA) was used. Samples were applied in 
wells in the 1.2% agarose cathode gel (cathode gel buffer: 0.1 M Tris, 0.15 M 
glycine and 0.1% SDS, pH not adjusted) and passed through the 0.8% agarose 
stacking gel (stacking gel buffer: 0.07 M Tris, 0.004 M EDTA and 0.4% SDS, pH 6.7). 
As the samples reached the separating gel, wells were emptied and filled with 
cathode gel. 1.5% agarose separating gel was used (separating gel buffer: 0.2 M 
Tris, 0.1 M glycine and 0.4% SDS, pH not adjusted). The gels were run horizontally 
for approximately 5 hrs in a 2117 multiphor II electrophoresis unit (LKB, Bromma, 
Sweden) with cooling at 14˚C and voltage at 150 V. VWF was transferred to 
Immobilon™-P PVDF membrane 0.45 μm (Millipore, Bedford, MA, USA) via 
capillary force overnight. For visualization of VWF multimers anti-human VWF 
A082 antibody (Dako) was used in combination with the peroxidase rabbit IgG ABC 
kit from Vectastain (PK-4001, Vector Laboratories Inc., Burlingame, CA, USA). 
PVDF membranes were stained with diaminobenzidine solution (10 mg 
3,3'-diaminobenzidine (Sigma) in 100 mL PBS, to which 1 mL 3% CoCl2 solution in 
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H2O (Sigma), and 20 μL 30% H2O2 (Merck) were added). The reaction was 




Three independent transfection experiments were performed in duplicate for all 
mutant and wt constructs. The mean relative expression of the mutant constructs 
as compared to wt in medium and lysate is shown as percentage of rVWF-wt 
(Fig. 2). The total amount of rVWF produced in wt, C1130F, C1149R, and C2671Y 
transfections was similar and higher than the total rVWF observed in 
Fig. 2, transfections of wt or mutant pSVHVWF constructs in 293T cells. The VWF 
production in medium (left panel) and lysate (right panel) is expressed relative to the 
amount of wt protein. 100% of wt VWF corresponds to 0.37–0.56 µg/mL in conditioned 
medium and 1.0–1.8 µg/mL in cell lysate. Mean and standard deviation values are based 
on three independent experiments with duplicate transfections in each experiment. The 
corresponding multimeric patterns are shown in the lower panel. The construct names are 
indicated below each lane. 293T corresponds to untransfected 293T cells. Normal pooled 





transfections of C2739Y and C2754W, indicating rapid intracellular clearance of 
the C2739Y and C2754W proteins. C1130F and C1149R had a similar expression 
pattern, a considerable reduction in the secretion of rVWF in the medium (~20% 
of wt) and increased intracellular rVWF levels (~280% of wt). Furthermore, loss of 
high molecular weight multimers was seen. The carboxy-terminal mutant C2671Y 
differed from the other mutants in that it showed mildly decreased secretion of 
rVWF in the medium (~40%) and a normal multimeric pattern. The 
carboxy-terminal mutants, C2739Y and C2754W, were poorly secreted (~1% and 
~8%, respectively). The levels in the lysate (~70% and ~125%, respectively) indicate 
that the mutant proteins were indeed expressed and that rVWF was retained in 
the cell. The multimer analysis of rVWF-C2754W in conditioned medium showed 
odd-number multimers (trimer), an excess of monomer and an absence of high 
molecular weight multimers. Secreted rVWF-C2739Y in medium was too low to be 
visualized by multimer analysis. The multimer patterns in cell lysates of both 
rVWF-C2739Y  and rVWF-C2754W were similar, with an intervening band (trimer) 
and an excess of monomer.  
 
Co-transfections 
Co-transfections of wt and mutant constructs were performed with an increasing 
molar ratio of mutant over wt DNA, in order to study a possible interaction 
between mutant and wt VWF subunits. A basal level of 3 μg of wt construct was 
used, to which 1.5 μg, 3 μg or 6 μg mutant VWF construct was added. In 
corresponding wt transfections an increasing amount of wt VWF was added. 
Relative expression of co-transfections versus wt transfections was based on a 
duplicate transfection experiment (Figs. 3-7). The sum of rVWF in medium and 
lysate represents the total amount of rVWF. Overall, the total amount of rVWF 
produced in wt transfections increased linearly with the amount of DNA in the 
transfection. The level of rVWF-wt secreted was constant (about 70% of the total 
rVWF produced), independent of the amount of wt VWF plasmid used, indicating 
that the experimental cell system is not overloaded by 9 μg of DNA. The amount of 
rVWF observed in medium and lysate of co-transfections of all constructs seemed 
to follow an additive model (see C1130F). 
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C1130F VWF and C1149R VWF 
The total amount of rVWF produced in the co-transfections of wt with 
pSVHVWF-C1130F or pSVHVWF-C1149R and the corresponding wt transfections 
was similar, and increased with increasing amounts of transfected DNA (Figs. 3-4). 
However, the relative amount of rVWF secreted in the medium of co-transfections 
decreased compared to wt transfections. This decrease was dose-dependent, as 
was the relative increase of rVWF in the cell. These results indicate that the effect 
on secretion was solely caused by the mutant protein. For C1130F as a 
representative example of the additive model, we observed the following: 6 μg of 
 
Fig. 3, co-transfection of wt and mutant pSVHVWF-C1130F showing the effect of 
increasing amounts of C1130F on VWF secretion and VWF multimer pattern. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 
pooled plasma (NP) was used. Equal amounts of VWF were used in each lane, except 
for the transfection, where only mutant construct was expressed. The expression in 





wt construct alone resulted in 1.80 μg rVWF in the medium and 6 μg of C1130F 
construct resulted in 0.36 μg rVWF, predicting that in a co-transfection of 3 μg wt 
plus 3 μg mutant construct 1.08 μg ((1.80+0.36)/2) rVWF would be present in the 
medium, whereas 1.16 μg was actually observed (Fig. 3). In general, the secreted 
and intracellular amount of rVWF in the co-transfections, calculated from the 
3 μg or 6 μg transfections of wt or mutant only, is in good agreement with the 
observed values. Interestingly, a mild decrease in the highest molecular weight 
multimers and a concomitant increase of the low molecular weight multimers, 
especially the dimer and tetramer, was observed. The multimeric pattern of the 
Fig. 4, co-transfections of wt and mutant pSVHVWF-C1149R showing the effect 
of increasing amounts of C1149R on VWF secretion and multimer pattern. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 
pooled plasma (NP) was used. Equal amounts of VWF were used in each lane, except 
for the transfection, where only mutant construct was expressed. The expression in 
medium was too low to apply an equal amount. 
VWF: dimerization and multimerization defects 
 
47 
1:1 ratio co-transfection ("heterozygosity") was nearly normal and corresponds to 




The results of the co-transfection of wt with pSVHVWF-C2671Y shown in Fig. 5 
were similar to those obtained for the C1130F and C1149R constructs, except that 
the dose-dependent decrease of rVWF secreted in the medium and the increase of 
rVWF kept intracellularly were milder and that the multimeric pattern was 
normal in all co-transfections. 
Fig. 5, co-transfections of wt and mutant pSVHVWF-C2671Y showing the effect 
of increasing amounts of C2671Y on VWF secretion and multimer pattern. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 







C2739Y and C2754W VWF 
C2739Y and C2754W showed a lower total amount of rVWF produced in the 
co-transfections compared to the corresponding wt-only transfections (Figs. 6-7). 
The total rVWF amount stayed at approximately 1.26 μg for C2739Y, while it rose 
slightly in co-transfections of C2754W as more construct was added. Titration of 
wt with C2739Y or C2754W caused a dose-dependent decrease of the rVWF 
secretion in the medium compared to wt transfections. The decrease of 
rVWF-C2739Y was not accompanied by the expected concomitant rise of the 
Fig. 6, co-transfections of wt and mutant pSVHVWF-C2739Y showing the effect 
of increasing amounts of C2739Y on VWF secretion and multimer pattern. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 
pooled plasma (NP) was used. Equal amounts of VWF were used in each lane, except 
for the transfection, where only mutant construct was expressed. The expression in 
medium was too low to apply an equal amount. Oligomers are indicated. 
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intracellular level, on the contrary the level decreased, while the intracellular 
level of rVWF-C2754W, remained mildly elevated in all co-transfections. The 
formation of multimers of secreted rVWF did not seem to be affected by the 
increasing ratio of mutant over wt in the co-transfection of C2739Y, whereas 
intervening odd-numbered multimers were formed throughout the whole 
spectrum of multimers for rVWF-C2754W. In the lysate of the co-transfected cells 
monomer and dimer forms of rVWF are the most pronounced entities, for both 
C2739Y and C2754W. The odd-numbered VWF multimer, a trimer, is noticeable, 
indicating addition of mutant monomers to otherwise normal dimers. 
Fig. 7, co-transfections of wt and mutant pSVHVWF-C2754W showing the effect 
of increasing amounts of C2754W on VWF secretion and multimer pattern. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 
pooled plasma (NP) was used. Equal amounts of VWF were used in each lane, except 
for the transfection, where only mutant construct was expressed. The expression in 






We have investigated the effect of the loss of cysteine residues, involved in either 
dimerization or multimerization, on the quantity and quality of the VWF 
produced. The two mutations in the D3 domain, C1130F and C1149R, were 
identified in type 1 VWD patients. Their phenotypes are characterized by a 
dominant inheritance pattern with high penetrance and VWF antigen levels 
between 0.10-0.15 IU/mL. We postulated that the strikingly low levels of VWF:Ag 
could be explained by the interaction of the mutant subunit with the normal 
subunit, resulting in retention of normal subunits in the ER and the Golgi, causing 
a dominant negative defect. We have previously reported that the mutation 
C1149R decreases the secretion of co-expressed normal VWF and causes 
intracellular retention and degradation of VWF (7,8). In this study we performed 
expression studies of both C1149R and C1130F. Similar results were obtained for 
both mutations (Figs. 2-4): impaired secretion (~20% of wt) and intracellular 
retention (~280% of wt) of rVWF. In the 1:1 ratio (wt:mutant) co-transfection, 
mimicking the heterozygous type 1 patients, secretion of VWF was 69% and 63% 
for C1130F and C1149R, respectively, and both co-transfections demonstrated 
dose-dependent intracellular retention of rVWF. We have demonstrated that the 
reduced secretion is caused by intracellular retention and not by reduced 
expression of the mutant construct. Both in the present and in the previous study 
of C1149R (7) we did not find the decrease of VWF that is observed in the plasma 
of heterozygous patients with C1130F or C1149R. The more pronounced decrease 
of plasma VWF in the patients could be explained by mechanisms not reflected by 
the 293T cell system, such as an increased clearance of mutant VWF by VWF 
cleaving protease and/or regulated secretion.  
Both C1130F and C1149R rVWF show abnormal multimeric patterns in 
co-transfections (Figs. 3-4), illustrating a dominant negative effect at the 
qualitative level. However, the quantitative results support an additive rather 
than a dominant negative model as the observed amounts of rVWF secreted or 
retained can be predicted by the summation of single transfections of wt or 
mutant constructs alone. Bodo et al. (8) showed proteosomal degradation of 
intracellularly retained C1149R in Fur4BHK cells with stable expression of C1149R. 
This degradation could explain the dominant negative effect of the mutation 
C1149R observed in patients. Our 293T cell system may not reflect this dominant 
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negative aspect due to the transient nature of the transfection and the collection 
of medium at a time when production of VWF was still linear. In the linear phase 
the contribution of intracellular degradation may be negligible. 
The intracellular retention and impaired multimerization of both C1130F and 
C1149R are probably due to disturbed protein folding. The decrease of secreted 
rVWF-C1149R was previously shown to not be due to the effect of the resulting 
unpaired cysteine 1169, which normally pairs with C1149. It was shown that 
expression of the double mutant C1149R + C1169S did not restore the defect of 
C1149R alone (8). Another argument for a conformational change is the fact that 
cysteine 1130 and 1149 are likely to form intrachain bonds (3) and are not directly 
involved in the intersubunit bonds required for multimerization. Dong et al. (21) 
demonstrated that even mutating the three cysteines (C1222, C1225, C1227) 
involved in the formation of intersubunit disulfide bonds did not influence 
assembly or secretion of VWF, indicating that the conformation of VWF as 
determined by intrachain bonds is more important for normal multimerization 
than the individual interchain bonds. Finally, C1130F and C1149R involve 
mutations to bulky or charged amino acids, predicting major effects on the 
conformation. 
We have also investigated mutated carboxy-terminal cysteines that may be 
involved in dimerization. Three mutated cysteine residues (C2671Y, C2739Y and 
C2754W), all described in type 3 VWD patients (one reported by us (11) and two by 
others (12,13)), were studied. Most mutations described in type 3 VWD are null 
alleles (22). We hypothesized that these mutated cysteines at the carboxy-
terminus could mimic null alleles when the mutated monomer is not able to 
dimerize, when it is retained and degraded in the ER and, when subsequently, 
only homodimers from the normal allele are routed to the Golgi and secreted. 
This would result in a level of about 50% normal VWF (in a heterozygous carrier of 
such a mutation), which is the same as in carriers of a null allele. In recombinant 
expression a striking difference in rVWF levels and multimer patterns was 
observed for C2671Y compared to the two other carboxy-terminal mutants. 
C2671Y showed completely normal dimerization and multimerization (Figs. 2 and 
5). The apparent lack of influence of C2671Y on dimerization may be explained by 
its location. C2671 lies within the 151 carboxy-terminal amino acids that have 
been demonstrated by Voorberg et al. (10) to be required, and sufficient, for 





However, only the carboxy-terminal 90 amino acids are homologous to the 
cystine knot (CK) family of proteins (23). Therefore, it is possible that only amino 
acids 2724-2813, excluding C2671, are essential for dimerization. The VWF:Ag level 
in the patient carrying the C2671Y mutation in compound heterozygosity with a 
complete VWF gene deletion, corresponding to homozygosity for C2671Y, is only 
2%, whereas the expression in medium of 293T cells is 40% of wt. This discrepancy 
can be explained by increased physiologic proteolysis of VWF C2671Y, that was 
demonstrated in this patient’s plasma (24), but which is lacking in the medium of 
the in vitro expression system. Our results suggest that the mutation C2671Y 
interferes with intracellular routing, has little or no influence on dimerization 
and is possibly more sensitive to proteolytic degradation in plasma. 
The missense mutations C2739Y and C2754W were shown to interfere with 
dimerization. Excess of mainly intracellular monomers and odd-numbered 
multimers was found for both mutations (Figs. 2 and 6-7). This indicates 
N-terminal pairing of mutant monomers in the Golgi. The pattern with 
odd-numbered multimers in the heterozygous transfection of C2754W was 
previously described by Schneppenheim et al. and demonstrated in plasma of a 
heterozygous carrier (13). Odd-numbered multimers were not observed in 
medium of C2739Y co-transfections. The difference in secreted multimers of 
C2739Y and C2754W may lie in the survival of the mutant monomers in the cell. It 
is unlikely that a missense mutation affects translation; we therefore assume that 
the mutant monomer is misfolded, is retained in the cell and cleared at a high rate 
as has previously been described (10). The linear increase in the total amount 
VWF in C2754W co-transfections compared to the fixed low value in C2739Y 
co-transfections indicate that the C2739Y mutation causes a more profound 
conformational change than the C2754W. This would explain the different rate of 
clearance and the impossibility for C2739Y to pass the ER and participate in 
multimerization in the Golgi, whereas C2754W may pass the ER. 
Both rVWF-C2739Y and rVWF-C2754W were retained in the cell and secreted 
at very low levels in medium, 1% and 8%, respectively (Fig. 2), which corresponds 
to a type 3 phenotype. Further, the co-transfection experiments of mutant and wt 
in a 1:1 ratio showed about 50% rVWF secretion for C2739Y and C2754W, which 
agrees with the phenotype of a heterozygous carrier of type 3 VWD. However, 
heterozygosity for mutations of some cysteine residues in the CK domain results 
in type 2A (formerly subtype IID) VWD. Expression studies have shown a similar 
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dimerization defect (13,25) as in the mutants in this study. This apparent 
phenotypic discrepancy may be explained by differences in the involvement of 
cysteines in either intrachain or interchain disulfide bonds. All mutations that 
have been described in association with a type 3 phenotype, C2739Y (12), C2754W 
(13), C2804Y (14) and C2806R (15) are involved in intrachain disulfide bonds (23), 
whereas the mutations associated with a 2A(IID) phenotype involve interchain 
disulfide bonds: C2771Y (25), C2771S (25) and C2773R (13,26). We hypothesize that 
the loss of a cysteine involved in an intrachain disulfide bond considerably 
disturbs the conformation of the VWF subunit, leading to hampered dimerization 
and rapid degradation in the ER. The amount of abnormal monomer contributing 
to the total amount of VWF would be small and would not cause a dominant 
negative effect. This would result in a quantitative defect with little influence on 
multimeric structure, i.e., a type 3 phenotype in homozygotes and only 50% 
reduction of VWF in heterozygotes, mimicking the effect of null alleles. On the 
contrary, the mutations interfering with interchain bonds do not disrupt the 
conformation of the monomer, but do reduce the covalent dimerization of the 
subunit (23). As the conformation of the monomer is not dramatically affected, it 
is possible that a higher fraction of monomers escape degradation in the ER and is 
routed to the Golgi. Since the proportion of mutant monomer to normal monomer 
is higher in this case, the multimerization will be significantly influenced by 
N-terminal disulfide bonding of the excess mutant monomers resulting in a type 
2A(IID) VWD multimer pattern. 
In conclusion, we have shown that the cysteine mutations investigated in 
this study cause quantitative VWF deficiency although the effect is not as strong 
as that observed in patients. The discrepancy in VWF levels of C1130F, C1149R and 
C2671Y observed in vitro versus in vivo may be explained by physiological factors 
such as heightened clearance. The loss of cysteines 2739 and 2754 corresponds 
with the type 3 VWD phenotype and the apparent lack of influence of the C2671Y 
mutation on dimerization is most likely due to its location just outside the 
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Intracellular retention of von 
Willebrand factor C2671Y is due to 
the loss of the disulfide bond and not 
to the introduction of the bulky side 
chain of the tyrosine residue 
 









The replacement of cysteine 2671 by tyrosine, C2671Y, in von Willebrand factor 
(VWF) was previously identified in a patient with type 3 von Willebrand disease 
(VWD). This naturally occurring mutation was transiently expressed in 293T cells. 
C2671Y was compared with the alanine variant, C2671A, with respect to secretion, 
retention and multimerization. We assessed whether the retention of the mutant 
protein is caused by loss of the cysteine and its disulfide bond or is the result of a 
combined effect of the lost disulfide bond and the introduced bulky side chain of 
the tyrosine residue. Expression of the C2671A and C2671Y constructs resulted in 
slightly higher levels of recombinant VWF (rVWF) C2671A than of rVWF-C2671Y 
in the conditioned media of transfected cells. Intracellular levels of rVWF-C2671Y 
were slightly higher than observed for rVWF-C2671A. Expression of wt, C2671A 
and C2671Y rVWF resulted in normal multimerization of rVWF both in single 
transfections and in co-transfection experiments. These results indicate that 
retention of VWF-C2671Y is predominantly caused by the loss of the cysteine 
residue and the corresponding disulfide bridge and not by the introduction of the 





In a previous study (1), mutations of cysteine residues located in both the 
multimerization and dimerization area of von Willebrand factor (VWF) were 
studied. Mutations of cysteines C1130, C1149, C2671, C2739 and C2754 were all 
identified in patients with a predominantly quantitative defect of VWF (2-5). 
Interestingly, examination of the human VWF database (http://www.sheffield. 
ac.uk/vwf) revealed that most mutated cysteines in VWF were altered to a bulky 
aromatic or charged amino acid residue. Of the 27 cysteine mutations reported, 
one was a stop codon, four were altered to serine or glycine and as many as 22 
represented alterations to tryptophane, tyrosine, phenylalanine or arginine. The 
observation that cysteine residues were mutated to bulky or charged amino acids 
in 81% of the cases made us hypothesize that the change to such an amino acid 
may have additional effects on the conformation of the VWF subunit and thus 
influence the biosynthesis and secretion of VWF and result in a more severe 
phenotype. 
To investigate this hypothesis we compared the recombinant expression of 
the naturally occurring C2671Y mutation with the C2671A mutation. If the side 
chain of the tyrosine residue would introduce disadvantageous conformational 
changes in the VWF subunit, then the secretion levels of VWF-C2671A are 
anticipated to be less affected than those of VWF-C2671Y. 
 
Materials and Methods 
Plasmid construction 
Construction of plasmids pSVHVWF encoding VWF-wt and VWF-C2671Y was 
described previously (1). The C2671A VWF mutation was introduced in the 
pSVHVWF plasmid containing the full-length cDNA of wt-VWF. Oligonucleotides 1 
and 2 (Table I) were used in combination with the QuikChange® XL site-directed 
mutagenesis kit from Stratagene (La Jolla, CA, USA) to introduce the C2671A 
mutation in pSVHVWF using the following cycling conditions: (1x 95°C 60 s, 18x 
(95°C 50 s, 60°C 50 s and 68°C 24 minutes), 1x 68°C 7 minutes). The presence of the 
mutation was confirmed by restriction digestion of plasmid DNA with HaeII. 
Subsequently, pSVHVWF-C2671A DNA was directly sequenced using the 
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CEQ 2000™ Dye Terminator Cycle Sequencing Kit (Beckman Coulter, Fullerton, CA, 
USA) in combination with oligonucleotides 3 and 4 (Table I). The mutant 
PshAI-EcoRV C2671A VWF fragment replaced the wt fragment in pSVHVWF, 
creating pSVHVWF-C2671A. The constructs were transformed and propagated in 
E. coli DH5α. DNA used in transient transfection experiments was purified with the 
plasmid maxi kit from Qiagen (Hilden, Germany) and the preparations used were 
screened by restriction with HaeII as described. 
 
Expression of recombinant VWF 
Single transfections of wt and mutant pSVHVWF-C2671A and pSVHVWF-C2671Y 
plasmids and co-transfection of wt and pSVHVWF-C2671A constructs were 
performed according to the calcium phosphate precipitation method in 293T 
human kidney cells. The transfections and the collection of conditioned medium 
and cell lysate and subsequent quantitative and qualitative analysis were as 




The effect of the C2671A mutation on dimerization, multimerization and on levels 
of VWF in conditioned medium of 293T cells was studied in transient single 
Table I: Oligonucleotides for mutagenesis and sequencing 
Oligonucleotide Sequence* Position† Purpose§ 
# Direction (5' to 3')   
1 Forward CGCTCCAGGATGGCgcTGATACTCACTTCTGC 8267-8298 Mutagenesis 
2 Reverse GCAGAAGTGAGTATCAgcGCCATCCTGGAGCG 8298-8267 Mutagenesis 
3 Forward CACCGACATGGAGGATGCCG 7629-7648 Sequencing 
4 Reverse GCACATCGTTGATGTCAATGG 8572-8552 Sequencing 
*Nucleotide substitutions indicated in lower case, the additional HaeII restriction site 
introduced in pSVHVWF-C2671A is underlined. †Nts in pSVHVWF (1). §Mutagenesis, 





transfections and co-transfections of wt and mutant constructs. Three 
independent single transfections including duplicate transfections of each 
construct were performed. The average secretion of recombinant VWF (rVWF) in 
conditioned medium was 49% and 39% of rVWF-wt for rVWF-C2671A and 
rVWF-C2671Y, respectively (Fig. 1). The intracellular VWF levels were 178% for 
rVWF-C2671A and 194% for rVWF-C2671Y compared to rVWF-wt. Total VWF, i.e., 
the sum of VWF secreted in medium and VWF in the cell lysate, were 2.4 μg, 2.2 μg 
and 2.2 μg for rVWF-wt, rVWF-C2671A and rVWF-C2671Y VWF, respectively. This 
indicated that the reduced levels of mutant VWF found in the conditioned media 
were not caused by a lower production of the mutant protein. The relative 
amounts of rVWF-C2671Y secreted and retained were in accordance with results 
 
Fig. 1, single transfections of wt and mutant pSVHVWF constructs in 293T cells. 
The VWF production in medium (left panel) and lysate (right panel) is expressed 
relative to the amount of wt VWF protein. One hundred percent of wt VWF 
corresponds to 0.24-0.34 µg/mL in conditioned medium (5 mL) and 0.95-1.1 µg/mL in 
cell lysate (0.8 mL). Mean and standard deviation are based on six measurements 
(three independent experiments with two transfections in each experiment). The 
corresponding multimeric patterns are shown in the lower panel. The construct names 
are indicated below each lane. 293T corresponds to untransfected 293T cells. Normal 
plasma (NP) was used as reference. 
C2671A VWF versus C2671Y VWF 
 
63 
obtained previously (Chapter 2a) (1). Although the difference in secretion 
between rVWF-C2671A and rVWF-C2671Y was only small it was statistically 
significant (p<0.005, two-tailed students t-test). However, the intracellular levels 
of rVWF-C2671A and rVWF-C2671Y were not significantly different (p=0.5, 
two-tailed students t-test). Normal multimerization of VWF was observed for both 
rVWF-C2671A and rVWF-C2671Y (Fig. 1). 
 
Co-transfections 
In co-transfections, 3 μg wt construct was supplemented with 1.5, 3, or 6 μg of 
mutant or wt construct. Previously, we have shown that addition of up to 9 μg of 
Fig. 2, co-transfections of wt and mutant C2671A pSVHVWF constructs. The 
VWF production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of wt-VWF of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars as is the amount (µg) of VWF produced in 
either medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. As reference, normal 




DNA leads to a linear increase in VWF production in this cell system (1). The total 
amount of VWF produced in co-transfections of C2671A and wt constructs was 
approximately equal to that found in the corresponding wt transfections (Fig. 2). 
A relative decrease from 98% to 71% of secreted rVWF, and a slight increase from 
122% to 133% of retained rVWF was detected as the amount of C2671A plasmid 
was increased from 1.5 μg to 6 μg. As observed in the single transfections, the 
multimerization of rVWF-C2671A appeared normal and rVWF-C2671A did not 
seem to impair the multimerization in co-transfections (Figs. 1-2). These results 
were similar to those obtained in co-transfections of wt and C2671Y construct ((1), 
see Fig. 5, Chapter 2a). 
 
Discussion 
We have previously identified the C2671Y VWF mutation in a patient with type 3 
VWD (3). The patient was found to be compound heterozygous for the C2671Y 
mutation and a deletion of the other allele. In the present study we examined 
whether the introduction of a residue with an aromatic side chain like tyrosine 
would have a disadvantageous effect on the level of recombinant VWF secreted 
additional to the one created by the loss of the cysteine bond. Therefore, we 
compared the expression of rVWF-C2671Y, rVWF-C2671A and rVWF-wt in 293T 
cells. The total VWF production, i.e., VWF in medium and lysate, was similar for 
the rVWF-C2671A and rVWF-C2671Y variants (Fig. 1). The alanine variant seemed 
to be secreted into the medium slightly better and less retained intracellularly. 
However, the difference in retention was not statistically significant. 
Furthermore, the levels of secreted VWF in co-transfections of wt and C2671A 
VWF constructs were similar to those in the co-transfections of wt and C2671Y 
VWF plasmids (Fig. 2 and Chapter 2a or reference (1)). 
On the basis of these results, we conclude that the retention of VWF-C2671Y 
is primarily caused by the loss of the cysteine and its disulfide bond, and that the 
contribution of the size of the introduced aromatic side chain is only minimal. On 
the one hand, we observed that the number of cysteines mutated to a serine or a 
stop codon in patients with VWD is clearly lower than the expected number, 
suggesting that these alterations may not always lead to disease (Table II). On the 
other hand, the number of cysteines substituted by phenylalanine, arginine and 
tryptophane observed in patients is higher than expected, which suggests that 
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these large residues more often cause VWD. The virtual absence of smaller amino 
acids at these positions supports this hypothesis. 
It is not surprising that only one mutation to a stop codon has been reported 
since it would result in a null allele, which in a heterozygous carrier would result 
in only mildly reduced VWF:Ag levels. To result in VWD, an additional mutation 
would be required. Likewise, no silent mutations of cysteines are reported in the 
database. Finally, it may be that the effect of the mutation is also dependent on 
the position and function of the cysteine residue in the VWF protein. It would 
therefore be interesting to compare phenylalanine, arginine and tryptophane 
versus serine and glycine at the positions of other mutated cysteines in VWF. 
 
Table II: Distribution of mutated cysteines in VWF 







Small Ser AGY/TCN Transversion 19.3 2 5.2 
Small Gly GGN Transversion 9.7 2 2.6 
Bulky Phe TTY Transversion 9.7 6 2.6 
Bulky Trp TGG Transversion 9.7 4 2.6 
Bulky Arg CGN Transition 21.0 8 5.7 
Bulky Tyr TAY Transition 21.0 4 5.7 
Nonsense Stop TGA Transversion 9.7 1 2.6 
Total    100.0 27 27.0 
*Possible single nucleotide changes from a cysteine-encoding TGC- or TGT-codon. The altered 
nucleotide is underlined. Note that there are two changes that lead to a serine codon. 
Y = C or T. N = any nucleotide. †Distribution based on the alteration of the first, second or third 
position of the cysteine codons and a transition to transversion ratio of 2.17 for 
nonsynonymous codon changes according to Freudenberg-Hua et al. (6). §Number of different 
cysteine positions altered. Data were compiled from http://www.sheffield.ac.uk/vwf. 
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Von Willebrand disease (VWD) is a bleeding disorder caused by the decrease of 
functional von Willebrand factor (VWF). Low levels of VWF can result from 
decreased synthesis, impaired secretion, increased clearance or combinations 
thereof. Several mutations lead to impaired synthesis or secretion of VWF, 
however, little is known about the survival of VWF in the circulation. To evaluate 
the effect of several VWF mutations on VWF clearance the effect of three cysteine 
mutations (C1130F, C1149R or C2671Y) on the in vivo survival of VWF was studied 
in patients carrying these mutations and in a VWF-deficient mice model. 
In patients carrying these mutations we observed increased VWF-
propeptide/mature VWF ratios and rapid disappearance of VWF from the 
circulation after desmopressin treatment. Detailed analysis of in vivo clearance of 
recombinant VWF in a VWF-deficient mice model revealed a four-fold increased 
clearance rate of the mutants. The mutations C1130F, C1149R and C2671Y are each 
associated with reduced survival of VWF in the circulation. Detailed analysis of 
recombinant mutant VWF demonstrated that increased clearance was not due to 
increased proteolysis by ADAMTS13. We did not identify functional or structural 
characteristics that the mutant proteins have in common and could be associated 
with the phenomenon of increased clearance. In conclusion, cysteine mutations in 
VWF may result in reduced in vivo survival. The observation that various 
mutations are associated with increased in vivo clearance may have major 
implications for the therapeutic strategies that rely on the rise of endogenous 





Von Willebrand factor (VWF) is a plasma glycoprotein that plays a dual role in 
haemostasis. Firstly, VWF forms a complex with coagulation factor VIII (FVIII), 
which is required for FVIII survival in vivo. Secondly, VWF contributes to platelet 
adhesion and aggregation by acting as a molecular bridge between subendothelial 
collagen and platelets (reviewed in (1)). 
VWF is produced in megakaryocytes and endothelial cells, where it is 
subjected to extensive posttranslational modifications, including proteolytic 
separation of the precursor molecule in VWF-propeptide and mature VWF. VWF 
maturation involves C-terminal dimerization and VWF-propeptide dependent 
N-terminal multimerization via the formation of covalent intermolecular cystine 
bonds (1). The ability of VWF to support platelet adhesion and aggregation 
increases with multimer size (1). In the circulation, multimer size is controlled by 
several mechanisms, including proteolytic cleavage by ADAMTS13 (2,3). VWF is 
also subjected to N- and O-linked glycosylation and is one of the rare plasma 
proteins that carry the blood group antigens A, B and H (4). The VWF 
glycosylation profile is one of the determinants of VWF survival in the circulation 
(5,6). Besides altered glycosylation, amino acid substitutions in VWF may also 
affect clearance. Recently, we have used a mouse-model to demonstrate that the 
mutation R1205H leads to a strongly reduced survival of VWF in the circulation 
(7). 
Defects in the VWF gene result in a bleeding disorder (von Willebrand 
disease, VWD) with variable penetrance. VWD can be categorized in qualitative 
VWF defects (type 2) and quantitative VWF deficiency (type 1 and type 3; partial 
and virtually complete deficiency, respectively) (1). Most mutations in the human 
mutation database that are associated with the quantitative deficiencies originate 
from null alleles (gene deletions, stop codons, frame shifts, and splice mutations), 
but missense mutations have also been reported. Some of these mutations lead to 
replacement of cysteine residues, like C1130F, C1149R and C2671Y (8,9). Mutations 
C1130F and C1149R are both located in the VWF D3 domain and are recognized as 
dominant negative mutations (9,10). Patients heterozygous for C1130F and C1149R 
display a pronounced quantitative VWF deficiency, a prolonged bleeding time and 
a history of moderate bleeding (9,11,12). Mutation C2671Y is located towards the 
carboxy-terminus of the molecule in the connective region between the C2 and 
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CK domains. The mutation has been reported for a single patient who is 
compound heterozygous for this mutation and a gene deletion. The patient 
displays a type 3 phenotype with VWF antigen (VWF:Ag) levels of 0.02-0.04 U/mL, 
and part of the residual circulating VWF protein consists of proteolyzed products 
(8,13). 
Analysis of recombinant variants of C1130F and C1149R VWF revealed that 
these mutants lacked high molecular weight multimers, which defect could be 
corrected upon co-expression with recombinant wild-type VWF (rVWF-wt). In 
contrast, rVWF-C2671Y showed a normal multimerization pattern. All three 
mutations resulted in reduced secretion of VWF due to intracellular retention, 
and, at least for rVWF-C1149R, proteosomal degradation (9,10,12). However, the 
plasma VWF:Ag levels found in the patients were much lower than the VWF levels 
observed in the in vitro expression experiments (12). This indicates that the 
intracellular retention and degradation of the mutants only partly explain the low 
VWF levels in the patients. In the present study we explored the possibility that 
modified clearance also contributes to the reduced VWF levels in these patients. 
By investigating the behaviour of endogenous VWF upon desmopressin treatment 
of patients as well as the survival of recombinant VWF mutants in an 
experimental model employing VWF-deficient mice, we have indeed obtained 
evidence that increased clearance contributes to the reduced VWF levels in vivo. 
 
Materials and methods 
 Patients, mutations and phenotypic tests 
The C1130F and C1149R mutations were originally identified in patients classified 
as type 1 VWD, characterized by very low VWF:Ag levels (0.10–0.15 IU/mL) (9). 
The C2671Y mutation was found in a type 3 VWD patient, compound heterozygous 
for this mutation and a deletion of the other allele (8). Plasma was collected on 
several occasions from seven patients and two unaffected family members 
(Table I). An infusion with 1-deamino-8-D-arginine vasopressin (DDAVP; 0.3 μg 
DDAVP/kg body weight) was performed after informed consent. Blood samples 
were analyzed for VWF:Ag by an immunosorbent assay, VWF ristocetin cofactor 
(VWF:RCo) activity by aggregometry using fixed human platelets and FVIII 




VWF-propeptide antigen were analyzed in an immunosorbent assay as described 
(14,15). A plasma pool containing 6.3 nM VWF-propeptide and 50 nM VWF 
(monomer concentration) was used as a standard. 
 
Mice 
The VWF-deficient (16) and wild-type mice were on a C57BL/6J background and 
were between 8 and 12 weeks old. Housing and experiments were done as 




Recombinant Glycoprotein Ibα (GpIbα, residues 1-290) was prepared as described 
(17). The GpIbα antibody (2D4) was a gift of H. Deckmyn (Kortrijk, Belgium). 
Botrocetin was from Kordia (Leiden, the Netherlands). Purified recombinant 
Table I: Patient characteristics 










C1130F/wt C proband 0.19 0.14 <0.20 O 
 C sister 0.2-0.25 0.13-0.16 <0.20 O 
 B proband 0.45 0.13-0.21 <0.20 A 
C1149R/wt III-4 0.18-0.21 0.10-0.21 <0.20 A 
 IV-1 0.22-0.29 0.11-0.22 <0.20 A 
 IV-2 0.35-0.74 0.15-0.35 <0.20 O 
 III-5† 1.17 0.83-0.91 0.93 O 
 IV-3† 1.09 0.86-1.33 0.91 A 
C2671Y/del A III-2 0.17 0.10 <0.20 O 
Normal 
range 
 0.5-2 0.4-2 0.5-2  
*Patients and family members are indicated according to the original articles (8,9,11). 
†Unaffected family members. FVIII:C, FVIII activity; VWF:Ag, VWF antigen; VWF:RCo, VWF 
ristocetin cofactor activity. 
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VWF-propeptide was prepared as described (15). Recombinant B-domain deleted 
FVIII (Refacto) was from Wyeth. Human collagen type III (catalogue number 
C-4407) and bovine albumin (fraction V) were from Sigma. Human albumin 
(fraction V) was from MP Biochemicals (Irvine, CA, USA). Polyclonal antibodies 
(unlabeled and peroxidase-conjugated) against VWF were from Dako (Glostrup, 
Denmark). 
 
Plasmids and recombinant expression of VWF 
All plasmids were constructed using conventional techniques and all constructs 
were sequenced before transfection. Plasmids pSVHVWF encoding rVWF-wt, 
rVWF-C1130F, rVWF-C1149R and rVWF-C2671Y were transiently expressed in 
293T human kidney cells (12). These recombinant variants were used to analyze 
ADAMTS13-mediated proteolysis. Plasmids pNUT-VWF encoding rVWF-wt, 
rVWF-C1130F, rVWF-C1149R and rVWF-C2671Y were stably expressed in baby 
hamster kidney cells overexpressing furin for proper removal of the 
VWF-propeptide (7,18,19). cDNA encoding VWF-wt was subcloned into pcDNA6 
for co-transfection to rVWF-C1149R-expression cells, allowing selection using 
blasticidin to establish stable cell-lines expressing rVWF-wt and rVWF-C1149R 
heterozygously. All recombinant variants were purified from conditioned serum 
free medium, and used in the various functional assays and to determine VWF 
clearance in mice. 
 
ADAMTS13-mediated proteolysis 
The pcDNA3.1-ADAMTS13 V5/hisC expression vector (kindly provided by B.M. 
Luken and J. Voorberg, CLB research at Sanquin, Amsterdam, the Netherlands) 
was used for transient expression of recombinant ADAMTS13. Conditioned 
medium was collected and Pefabloc SC (Roche Diagnostics, Mannheim, Germany) 
was added to a final concentration of 1 mM. Medium was concentrated ~10 times 
by centrifugation in 5 mM Tris (pH 8.0) using Macrosep concentrators (cut-off 
value 100 kDa; Pall Gellman Laboratory, Ann Harbor, USA). ADAMTS13 protease 
activity was determined using previously described methods and conditions 
(20,21). The sensitivity of a fixed concentration of mutant, co-transfected or wt 




12.5 mM BaCl2 to initiate the reaction. The final concentration of urea in the 
reaction was 0, 0.1, 0.5, 1.0 or 1.5 M. Aliquots were taken after 0, 8 and 24 h 
incubation at 37°C and the reaction was stopped with EDTA. Subsequently, the 
VWF multimeric structure was analyzed on denaturing, non-reducing agarose gels 
(1.5% (w/v)) (12,22). In all tests the same batch of concentrated ADAMTS13 was 
used. 
 
Clearance of purified recombinant VWF in mice 
Clearance of recombinant wt and mutant VWF has been analyzed as described 
(7,16). Three to six mice were used for each time-point, and each mouse was bled 
only once. Human VWF:Ag levels were quantified as described (14). 
 
GpIbα binding 
Monoclonal anti-GpIbα antibody 2D4 was immobilized in microtiter-wells (Costar, 
Cambridge MA, USA) in 50 mM NaHCO3 (1.0 μg/mL, overnight at 4°C), which were 
then blocked for 1h at 37°C with PBS/3% (w/v) bovine albumin/0.1% (v/v) Tween- 
20). Recombinant GpIbα was added (0.1 μg/mL for 2 h at 37°C) and subsequently 
increasing concentrations of VWF (0-4 nM) were applied in the presence of 
botrocetin (2 μg/mL) and incubated for 2 h at 37°C. After washing, wells were 
incubated with peroxidase-labeled polyclonal anti-VWF antibodies (1.3 μg/mL for 
1 h at 37°C), and bound VWF was detected by measuring peroxidase activity using 
O-phenylenediamine as a substrate. 
 
αIIB β3-dependent platelet adhesion to immobilized VWF 
Perfusion with platelets (shear rate 1600 s-1) over VWF-coated cover slips was 
performed as described elsewhere (23). The amount of platelet-adhesion was 
evaluated using computer-assisted analysis with OPTIMAS-6.0 software 
(Dutch-Vision-Systems, Breda, the Netherlands), and was expressed as the 
percentage of surface-coverage. Perfusions were performed 6-9 times for all 
variants. 
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Surface Plasmon Resonance analysis 
Several binding assays were performed employing a Biacore2000 system (Biacore 
AB, Uppsala, Sweden). Binding of VWF-propeptide and FVIII to immobilized VWF 
or its mutants was investigated as described (7), except that recombinant 
B-domain deleted FVIII (Refacto) was used instead of FVIII light chain. Binding of 
VWF or its derivatives to immobilized collagen type III was performed as 
described (14). 
 
Data analysis and statistics 
Analysis of protein-interaction assays and clearance data obtained from mouse 
experiments was performed using the GraphPad Prism program (GraphPad Prism 
version 4.0 for Windows, GraphPad Software, San Diego, CA, USA) as described (7). 
Clearance data obtained from the patients, after subtraction of the basal VWF and 
VWF-propeptide level from the post-DDAVP values, were fitted to the 
monoexponential equation Ct = Ae-αt to obtain α. Ct refers to the plasma 
concentration of VWF or VWF-propeptide at time-point t after DDAVP infusion, 
and the apparent half-life was calculated from the equation t½ = ln 2/α. Statistical 
analyses were performed by the Student’s unpaired t-test using the GraphPad 
InStat program (GraphPad InStat version 3.00 for Windows). 
 
Results 
Increased VWF-propeptide/mature VWF ratio 
VWF is secreted simultaneously with its propeptide at equimolar concentrations 
and they circulate at a distinct ratio (15,24). The patients in this study display 
VWF:Ag levels that are well below the normal range (Table I). In contrast, the 
VWF-propeptide levels were less reduced, resulting in an increased ratio of 
VWF-propeptide over VWF:Ag (Fig. 1). These ratios were increased three-fold for 
patients with the mutations C1130F and C1149R compared to the normal 
population. The ratio was also increased in the compound heterozygous patient 
(C2671Y/deletion) (Fig. 1). These data suggest a reduced half-life of VWF, or, 





Increased clearance of VWF upon DDAVP treatment 
To test whether the modified ratios result from a change in half-life of 
VWF-propeptide or mature VWF, plasma levels of VWF and VWF-propeptide were 
monitored at different time-points after DDAVP infusion. Healthy subjects and 
patients showed a rapid increase of the VWF-propeptide level, which was followed 
by a monophasic decay (Fig. 2A). The half-life of VWF-propeptide in patients with 
C1130F or C1149R was similar to healthy subjects, whereas the half-life of 
VWF-propeptide in the patient with C2671Y was somewhat longer (Fig. 2A, 
Table II). VWF showed a similar rapid increase followed by a monophasic decay 
(Fig. 2B). In the patient group, VWF was cleared much quicker than in the group 
of healthy subjects. Indeed, the estimated half-life of VWF in the patients with 
mutations C1130F, C1149R and C2671Y was reduced four to five-fold (Fig. 2B, 
Table II). It should be noted that the estimated half-lives were based on a limited 
number of time points, which prevents accurate calculation of the half-lives. 
 
Fig. 1, VWF-propeptide/VWF ratio in VWD patients. The average ratio of 
VWF-propeptide over mature VWF for normal controls (N1), unaffected family 
members from the family with the C1149R mutation (N2), and patients harbouring the 
C1130F, C1149R or C2671Y/del mutation at basal level are depicted. The number of 
measurements (n) is indicated, with the number of patients in brackets. Differences 
between groups were tested with the unpaired two-tailed t-test. Data represent 
mean ± standard deviation, and data of N1 were obtained in a previous study (24). ns, 
not significant (p>0.05). 
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Nevertheless, these data strongly indicate that the mutations C1130F, C1149R and 
C2671Y are associated with an increased clearance of mature VWF. 
 
Mutations at C1130, C1149 and C2671 leave ADAMTS13-dependent proteolysis unaffected 
Rapid clearance could be due to increased susceptibility of VWF mutants to 
degradation by ADAMTS13. The susceptibility of the recombinant mutants for 
ADAMTS13 was therefore assessed in degradation assays. Representative results 
from the protease assay of rVWF-C1130F and rVWF-C2671Y are shown in Fig. 3. No 
or little degradation was detected in the absence of urea. However, the presence 
 
Fig. 2, survival of endogenous VWF-propeptide and VWF after DDAVP 
administration. Blood was collected before and after DDAVP infusion (0.3 µg/kg body 
weight). Samples were analyzed for VWF-propeptide (A) and VWF (B) levels. Shown 
are the mean ± standard deviation for controls (n=9) and data from single experiments 
in patients. Data of the normal controls were obtained in a previous study (24). The 
apparent half-lives are listed in Table II. 
 
Table II: Apparent half-lives of VWF-propeptide and VWF after DDAVP 
treatment 
VWF t½ VWF-propeptide (h) t½ VWF (h) Blood group 
Normal 2.3 7.0  
C1130F 3.2 1.6 O 
C1149R 2.6 1.5 A 




of 1.0 M urea resulted in a gradual disappearance of the higher multimers (Fig. 3). 
Due to impaired multimerization of rVWF-C1130F and rVWF-C1149R, the 
sensitivity for ADAMTS13 could only be interpreted for the respective 
co-transfections with wt VWF, which are also more representative for the 
situation in the heterozygous patients (Fig. 3). At all urea concentrations and at all 
incubation times tested, the VWF mutants were indistinguishable from wt VWF 
and no evidence was found that the accelerated disappearance from the 
 
Fig. 3, ADAMTS13-mediated proteolysis of recombinant wild-type and mutant 
VWF. rVWF-C1130F (A), rVWF-C2671Y (B), rVWF-wt (wt) alone or VWF obtained 
from co-transfections (Co-tf) were incubated with recombinant ADAMTS13 for 0, 8 or 
24 h (t) in the absence or presence of 0.1, 0.5, 1.0, 1.5 M urea. The results from 0 and 
1.0 M urea are depicted. The degree of proteolysis was assayed on SDS-agarose gel 
electrophoresis under non-reducing conditions. The results for rVWF-C1130F are 
representative for rVWF-C1149R (data not shown). 
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circulation is caused by an elevated susceptibility towards ADAMTS13-mediated 
cleavage. 
 
Increased clearance of VWF mutants in VWF-deficient mice 
The clearance of mutant VWF was studied in a murine model in which VWF 
clearance is independent of ADAMTS13-mediated proteolysis and independent of 
the extent of VWF multimerization (7). VWF mutants produced by stable cell-lines 
were purified from conditioned medium. Multimer analysis revealed a normal 
multimeric pattern for rVWF-C2671Y. rVWF-C1130F and rVWF-C1149R consisted 
mainly of low molecular weight multimers, whereas co-expression of 
rVWF-C1149R with rVWF-wt resulted in the reappearance of higher multimers. 
These patterns are similar to that of the mutants produced by transiently 
transfected cells (Fig. 3 and reference (12)). Purified proteins were injected 
intravenously in VWF-deficient mice and residual plasma levels were measured. 
The mutants and wt VWF displayed a similar recovery after injection (Table III). In 
contrast, all four mutants were cleared from the circulation more rapidly than wt 
VWF (Table III, Fig. 4). In the murine system, wt VWF disappears from plasma in a 
biphasic manner, characterized by a rapid initial phase and a slow secondary 












wt* 79 ± 14  2.8 ± 0.7  12.6 ± 0.9  3.0 ± 0.9  
D2509G* 82 ± 5 (p>0.05) 2.3 ± 0.5 (p>0.05) 12.0 ± 2.2 (p>0.05) 2.2 ± 0.2 (p>0.05) 
C1130F 72 ± 6 (p>0.05) 0.7 ± 0.2 (p=0.007) 6.0 ± 1.4 (p=0.002) 1.1 ± 0.5 (p=0.032) 
C1149R 67 ± 10 (p>0.05) 0.8 ± 0.4 (p=0.011) 7.5 ± 2.5 (p=0.028) 1.1 ± 0.5 (p=0.032) 
wt/C1149R 75 ± 9 (p>0.05) 0.4 ± 0.1 (p=0.0042) 5.5 ± 0.4 (p=0.0002) 0.7 ± 0.1 (p=0.012) 
R1205H* 97 ± 8 (p>0.05) 0.3 ± 0.1 (p=0.004) 7.6 ± 0.2 (p=0.0007) 0.3 ± 0.03 (p=0.007) 
C2671Y 63 ± 8 (p>0.05) 0.7 ± 0.1 (p=0.006) 8.9 ± 1.5 (p=0.022) 0.7 ± 0.2 (p=0.012) 
*Data were obtained during a previous study (7). rVWF-wt is reference for comparisons. 
rVWF-D2509G and rVWF-R1205H are shown to illustrate the normal and decreased half-life 




phase (7). As for wt VWF, the mutants disappeared in a biphasic manner, but data 
analysis revealed that the initial rapid phase (t½α), the slow secondary phase (t½β) 
and mean residence time were significantly reduced compared with the values 
obtained for wt VWF (Table III). Thus, the mutations C1130F, C1149R and C2671Y 
per se are associated with accelerated clearance of VWF. 
 
 
Fig. 4, in vivo survival of recombinant VWF mutants. VWF-deficient mice were 
injected intravenously with purified rVWF-wt, rVWF-C1130F (A), rVWF-C1149R (B), 
rVWF-wt/C1149R (B) or rVWF-C2671Y (C) at a concentration of 5 µg/mouse. Plotted 
is the residual VWF:Ag in plasma relative to the amount injected versus time after 
injection. For clarity, only data between 3 min and 4 h are shown. Data for rVWF-wt 
were obtained in a previous study, and are shown for comparison. Pharmacokinetic 
parameters derived from the complete data set (from 3 min to 24 h) are summarized in 
Table III. Data represent the mean ± standard deviation of 3-6 mice for each 
time-point. 
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Functional characterization of rVWF-C1130F, rVWF-C1149R and rVWF-C2671Y 
Because the accelerated clearance of the mutant VWF is due to the mutations per 
se, we examined whether the mutants have functional or structural 
characteristics in common that point to a region in VWF responsible for the 
increased clearance. The results of a number of functional parameters (i.e., FVIII-, 
GpIbα- and collagen-binding, platelet-adhesion under flow-conditions) are 
summarized in Table IV. Briefly, mutant rVWF-C2671Y was similar to rVWF-wt in 
all assays tested. Mutant rVWF-C1130F displayed normal GpIbα-binding and 
platelet-adhesion capacity. Furthermore, FVIII-binding was reduced five-fold for 
this mutant, while collagen-binding was reduced to a level similar to a dimeric 
control protein. Mutant rVWF-C1149R was most severely affected; apart from 
collagen-binding that was reduced to the level of the dimeric control, all other 
functions were considerably reduced compared to the control proteins. 
In view of the multimerization defects of rVWF-C1130F and rVWF-C1149R, 
we also tested the interaction with the VWF-propeptide. This interaction 
mediates intracellular multimerization and targeting of mature VWF to the 
storage organelles and occurs under slightly acidic conditions. The interaction 
between VWF and VWF-propeptide was investigated at various pHs (Fig. 5). For 
rVWF-wt a pH-dependent increase in affinity was observed with lower affinity at 
higher pH (pH 7.4, KD, app = 1.0 ± 0.1 μM and pH 5.2, KD, app = 0.08 ± 0.02 μM). A similar 
pattern was found for rVWF-C2671Y. However, binding of VWF-propeptide was 
Table IV: Functional analysis of recombinant VWF mutants 












wt 1.2 ± 0.2  9.4 ± 0.6 0.51 ± 0.04 77.3 ± 6.3 
C1130F 1.0 ± 0.1  47.4 ± 1.0 2.3 ± 0.1 80.9 ± 8.8 
C1149R 3.9 ± 1.1  53.4 ± 1.4 10.6 ± 0.4 49.4 ± 16.1 
C2671Y 1.0 ± 0.2  8.3 ± 0.6 0.33 ± 0.02 79.2 ± 9.8 
Dimeric control* nd 67.5 ± 1.2 0.38 ± 0.06 70.5 ± 6.4 
*Dimeric control was: rVWF-(D’-A3) for collagen binding, rVWF-(A1-CK) for 
platelet-adhesion and rVWF-(D’-D3) for FVIII binding. All dimeric controls have been 




markedly reduced for mutants rVWF-C1130F and rVWF-C1149R (KD, app > 2 μM at 
all pHs tested). Again, rVWF-C1149R was less efficient compared with 
rVWF-C1130F. These data indicate that mutations within the D’-D3 domains are 
not only associated with increased clearance, but also may lead to suboptimal 
interactions with ligands that bind to this particular region of the VWF molecule. 
 
Fig. 5, binding of VWF-propeptide to immobilized VWF. rVWF-wt, rVWF-C1130F, 
rVWF-C1149R, and rVWF-C2671Y immobilized onto a CM5 sensor-chip (10-12 
fmol/mm2) were incubated with various concentrations of purified VWF-propeptide 
(0-1.0 µM). Incubations were performed in 125 mM NaCl, 25 mM HEPES (pH 7.4 (A) 
or pH 6.8 (B)), 125 mM NaCl, 25 mM (CH3)2AsO2Na (pH 5.8 (C) or pH 5.2 (D)) at a 
flow rate of 10 µl/min for 4 min at 25°C. Response at equilibrium (indicated as mol 
VWF-propeptide/mol VWF) is plotted against concentration of VWF-propeptide. Note 
the different scales of the Y-axes. Data represent the mean of duplicate experiments 
(range less than 10 %). 




Circulating levels of VWF need strict regulation, as levels that are too low are 
associated with an increased bleeding tendency (1), whereas levels that are too 
high predispose to an increased risk of cardiovascular mortality (25). Low levels of 
VWF can result from decreased synthesis, impaired secretion, increased clearance 
or combinations thereof. Several mutations lead to impaired synthesis or 
secretion of VWF, however, little is known about the relationship between amino 
acid variations in VWF and its survival in the circulation. In the present study we 
evaluated the effect of three VWD-associated mutations on the survival of VWF. 
These mutations were selected on basis of discrepancies between VWF levels 
measured in in vitro expression experiments and the relatively lower actual 
antigen values in the patients' plasmas (9,10,12). Such discrepancies may indicate 
the presence of mechanisms other than synthesis and secretion that contribute to 
the low VWF levels. 
We have obtained several lines of evidence of increased clearance of mutant 
C1130F, C1149R and C2671Y VWF. Firstly we analyzed in the patients the 
VWF-propeptide/VWF:Ag ratio, which is the resultant of a dissimilar survival of 
these proteins in the circulation (15,24). The VWF:Ag levels were much more 
reduced than the VWF-propeptide levels, resulting in ratios that were increased 
up to three-fold compared with normal individuals or unaffected family members 
(Fig. 1). Secondly, VWF disappeared from the circulation four to five-fold more 
rapidly in the patients upon DDAVP treatment (Fig. 2B). Thirdly, we performed 
detailed analysis of in vivo clearance of recombinant VWF in a model employing 
VWF-deficient mice (7). Both the initial and secondary phase of the clearance of 
rVWF-C1130F, rVWF-C1149R and rVWF-C2671Y were accelerated (Fig. 4), which 
was reflected by a mean residence time that was reduced four-fold (Table III). 
Thus, the mutations C1130F, C1149R and C2671Y are each associated with a 
reduced survival of VWF in the circulation. Because also the heterozygous 
rVWF-wt/C1149R mimicked the increased clearance of the protein in the patients, 
it seems that at least some of these mutations may have a predominant effect on 
the clearance of the mutated protein. Furthermore, we have recently shown that 
also mutation R1205H results in increased clearance of VWF (7). A preliminary 
report has recently described a mutation S2179F in the VWF D4 domain, which 




mutations in VWF predispose to increased clearance. Indeed, a decreased survival 
of VWF upon DDAVP treatment in a cohort of VWD type 1 patients has recently 
been reported (27). 
This conclusion is of importance with respect to treatment of VWD patients. 
The goal of treatment is to correct the deficiency of VWF and FVIII, either by 
transfusion with plasma-derived FVIII/VWF concentrates or DDAVP 
administration. The latter leads to the release of endogenous VWF from storage 
organelles, which are associated with a three to five-fold increase of VWF levels. 
However, if due to a mutation the survival of endogenous VWF is reduced, the 
initial response to DDAVP may be normal, but the effect is only short-lasting 
because the endogenous VWF is cleared rapidly. In some of these patients it may 
be more appropriate to treat with FVIII/VWF concentrates. As also put forward by 
Brown et al. (27), the clinical practice to judge the effectiveness of DDAVP 
treatment by the initial rise of VWF may be insufficient for several patients as it 
does not take clearance into account. Therefore we suggest that, after a DDAVP 
test-infusion, VWF:Ag is monitored over a sufficient length of time and we 
propose the implementation of the VWF-propeptide/VWF:Ag ratio in the 
diagnosis of VWD. 
The question remains why the various mutations are associated with 
increased clearance of the VWF protein. It has recently been shown that the 
presence of a Tyr to Cys polymorphism at position 1584 results in increased 
susceptibility to the VWF-cleaving protease ADAMTS13 (28). As the patient 
harbouring the C2671Y mutation displays relatively high plasma levels of VWF 
degradation products (13), we tested whether increased clearance could result 
from an increased susceptibility to the ADAMTS13 protease. However, we did not 
find evidence of increased proteolysis (Fig. 3). Moreover, normal proteolysis was 
also reported for VWF/R1205H (29), another mutant that displays increased 
clearance (7). Final evidence that the increased clearance of the various mutants 
is independent of ADAMTS13 was provided by the rapid clearance in the mouse 
model, as murine ADAMTS13 does not recognize human VWF. It should be noted 
that our study has not examined the potential role of thrombospondin-1, a plasma 
depolymerase that is able to modulate VWF multimer size (30). 
Increased clearance may also be due to disturbed structural integrity of the 
mutant proteins, rendering them susceptible to quality control mechanisms that 
remove anomalous proteins from the circulation. We have tried to identify 
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whether the mutant proteins have functional or structural characteristics in 
common that may be associated with the phenomenon of increased clearance. 
Several parameters were examined, but none of these functional tests pointed to a 
particular region within the VWF molecule that seems to be consistently 
associated with abnormal clearance. Mutant rVWF-C2671Y was normal for all 
functions, indicating that this mutation results in local changes within the 
molecule only. This could suggest that this part of VWF contributes to 
interactions with clearance receptors. All other mutations that we tested so far, 
i.e., rVWF-C1130F, rVWF-C1149R and rVWF-R1205H, are located within a relatively 
short stretch in the D3 domain. However, the impact of these mutations on VWF 
function differs considerably. Whereas mutant rVWF-R1205H has normal 
interaction with FVIII (7), both rVWF-C1130F and rVWF-C1149R display impaired 
FVIII binding (Table IV). Mutations C1130F and C1149R further resulted in a lack 
of proper multimerization (Fig. 3, reference (12)), which was not seen with 
rVWF-R1205H (7). A combined effect on FVIII binding and multimerization has 
been described for several other mutations, and seems to be related to a local 
distortion of the secondary structure (31). Incomplete multimerization is a 
consequence of a suboptimal interaction with the VWF-propeptide, which is 
involved in intracellular multimerization of VWF (32,33). Indeed, mutants 
rVWF-C1130F and rVWF-C1149R displayed defective binding of the 
VWF-propeptide (Fig. 5). Thus, the lack of multimerization observed for these 
mutants can readily be explained by an almost complete absence of 
VWF-propeptide binding.  
In conclusion, our study shows that certain amino acid changes within the 
VWF molecule are associated with increased clearance. This may have major 
implications for the therapeutic strategies that rely on the temporary rise of 
endogenous VWF after DDAVP administration. New therapeutic approaches based 
on the inhibition of VWF clearance could be developed as an adjuvant to optimize 
treatment of these patients. However, more insights into the molecular 
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The missense mutation of cysteine 2362 to a phenylalanine in von Willebrand 
factor (VWF) has been detected in several Italian families with autosomal 
recessive, severe von Willebrand disease. We investigated how this amino acid 
change in VWF may lead to a predominantly quantitative defect. This mutation 
was studied in vitro by transient expression of the full-length mutant VWF-C2362F 
protein and in vivo by analysis of plasma VWF after infusion of 1-deamino-
8-D-arginine vasopressin in a patient homozygous for this mutation. Single 
transfections of pSVHVWF-C2362F and co-transfections of mutant and wild-type 
constructs resulted in 8% and 50% VWF antigen, respectively, in conditioned 
medium. These reduced levels are in accordance with observations in 
homozygous and heterozygous carriers of the mutation. In addition, VWF-C2362F 
was retained intracellularly. Similar results were obtained for VWF-C2362A. After 
infusion of 1-deamino-8-D-arginine vasopressin in a patient homozygous for the 
C2362F mutation, a two-fold decrease in half-life of plasma VWF-C2362F was 
observed. This was not explained by increased susceptibility of recombinant 
VWF-C2362F to ADAMTS13. It was concluded that VWF-C2362F causes reduced 
VWF plasma levels due to impaired secretion and intracellular retention. 
Furthermore, it is the loss of cysteine 2362 rather than the introduction of the 





Von Willebrand factor (VWF) is a high molecular weight (HMW) multimeric 
glycoprotein (0.5-10x106 Da) with adhesive properties. In the circulation, VWF 
mediates adhesion of platelets to the vessel wall and platelet-platelet aggregation 
at the site of injury. VWF also functions as a carrier of factor VIII (FVIII). VWF and 
FVIII form a non-covalent complex, which prolongs the half-life of FVIII in the 
circulation reviewed in (1,2). 
Von Willebrand disease (VWD) is the most common inherited bleeding 
disorder. It is caused by dysfunction or deficiency of VWF. VWD is divided into 
qualitative (type 2) and quantitative (types 1 and 3) VWF defects (3). The 
molecular basis of most of the qualitative VWD variants have been identified (4). 
However, the identification of mutations causing quantitative VWD has been 
more difficult due to the occurrence of such mutations throughout the whole 
VWF gene. 
Type 3 VWD is characterized by virtually complete deficiency of VWF, 
autosomal recessive inheritance, and moderate to severe bleeding symptoms. 
Heterozygous carriers of type 3 mutations have about 50% VWF antigen (VWF:Ag) 
and usually only mild or no bleeding symptoms. In addition to the many 
mutations that result in a null allele, a few missense mutations have also been 
identified in type 3 VWD (5). Compound heterozygosity and homozygosity for 
missense mutations of cysteine residues 2739, 2754, 2804 and 2806 have been 
described in type 3 VWD (6-9). All these mutations are located in the 
carboxy-terminal cystine knot (CK) domain. Another mutation of a cysteine 
residue that causes a major quantitative deficiency is the C2362F mutation, which 
is found in several Italian patients with autosomal recessive severe VWD (10). 
Cysteine 2362 is particularly interesting as it is located in a region of VWF of 
which the function is yet unknown. The location of C2362 outside the 
amino-terminal region and the CK domain, involved in the multimerization and 
dimerization of VWF, respectively, excludes its participation in an interchain 
disulfide bond. 
The present study investigated the effect of the C2362F mutation on the 
quantity and quality of the VWF produced. It was hypothesized that the 
quantitative defect observed in patients homozygous for the C2362F mutation is 
the result of intracellular retention and rapid degradation of a VWF subunit which 
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is misfolded due to the loss of an intrachain disulfide bond. To evaluate whether 
the replacement of a cysteine by the more bulky and hydrophobic phenylalanine 
residue may additionally compromise the conformation of the mutant subunit, 
both C2362F and the C2362A, were studied. In addition, we assessed aspects of 
clearance of C2362F by the in vivo survival of plasma VWF-C2362F after infusion of 
1-deamino-8-D-arginine vasopressin (DDAVP) and by studying the in vitro 
susceptibility of recombinant VWF (rVWF)-C2362F to proteolysis by the 
VWF-cleaving protease ADAMTS13. 
 
Materials and methods 
Patients and mutations 
The C2362F mutation was previously found in autosomal recessive severe VWD 
patients, characterized by very low levels of VWF:Ag (0.02-0.07 IU/mL) and a 
moderate to severe bleeding tendency (10,11). Two patients were studied. One 
patient was homozygous for the C2362F mutation (patient M III-2 in reference 
(10)). The other patient was compound heterozygous for the C2362F mutation in 
combination with a C to A substitution at position 11/24 in the consensus 
sequence of the 3' splice site of intron 13, which leads to skipping of exon 14 and a 
premature stop codon (patient III-2 in reference (12)). A third subject was 
heterozygous for the C2362F mutation and had mildly decreased FVIII activity 
(FVIII:C), VWF:Ag and VWF ristocetin cofactor (VWF:RCo) activity, but a normal 
bleeding time (subject II-5 in reference (12)). All three patients were identified in 
the Veneto region in northern Italy and the allele carrying the C2362F mutation is 
identical for five additional polymorphic markers in all patients suggesting the 
presence of a founder allele (10,12). The patients' characteristics are presented in 
Table I. 
 
DDAVP infusion and VWF parameters 
The patient homozygous for the C2362F mutation was infused with DDAVP 
(dosage 0.3 μg DDAVP/kg body weight) after informed consent. Blood was drawn 
before and 1, 2 and 4 hours after starting the DDAVP infusion. The patient's 
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assay (ELISA) method, for VWF:RCo activity by aggregometry using formalin-fixed 
human platelets and for FVIII coagulant activity (FVIII:C) by a one-stage clotting 
assay on an automated coagulometer. The concentration of VWF-propeptide was 
analyzed in an immunosorbent assay as described previously (18). A pooled 
normal plasma containing 6.3 nM VWF-propeptide and 50 nM VWF (based on 
concentration of VWF monomers) was used as a standard. After subtraction of the 
basal VWF and VWF-propeptide levels from the post-DDAVP values, the data were 
fitted to the monoexponential equation Ct = Ae-αt to obtain α. Ct refers to the 
plasma concentration of VWF or VWF-propeptide at time-point t after DDAVP 
infusion, and the apparent half-life was calculated from the equation t½ = ln 2/α. 
 
Plasmid construction 
Construction of plasmid pSVHVWF encoding rVWF-wild type (wt) was described 
before (19). The C2362F and C2362A VWF mutations were introduced in the 
pSVHVWF plasmid containing the full-length cDNA of wt VWF. First, the wt 
HindIII-MunI fragment of pSVHVWF was subcloned in pSE280 (Invitrogen, 
Groningen, the Netherlands), creating pSE280-HindIII-MunI-wt. Then oligo-
nucleotides 1 and 2 or oligonucleotides 3 and 4 (Table II) and pSE280-
HindIII-MunI-wt were used in combination with the QuikChange® XL site-directed 
mutagenesis kit from Stratagene (La Jolla, CA, USA) to introduce the C2362F or 
C2362A mutation using the following cycling conditions: denaturation at 95°C for 
1 minute, and 18 cycles of denaturation at 95°C for 50 seconds, annealing at 60°C 
Table II. Oligonucleotides for mutagenesis and sequencing 
Oligonucleotide Direction Sequence* Complementarity Purpose§
# (5' to 3')  (to pSVHVWF)†  
1 Forward CCAACTTCACCTGCGCaTtCAGGAAGGAGGAGTGC 7337-7371 Mut 
2 Reverse GCACTCCTCCTTCCTGaAtGCGCAGGTGAAGTTGG 7371-7337 Mut 
3 Forward CCAACTTCACCTGCGCCgcCAGGAAGGAGGAGTGC 7337-7371 Mut 
4 Reverse GCACTCCTCCTTCCTGgcGGCGCAGGTGAAGTTGG 7371-7337 Mut 
5 Forward GCATTGGTGAGGATGGAGTCC 7040-7060 Seq 
6 Reverse GCAGATGGCAGGCACCTTCC 7763-7744 Seq 
*Nucleotide substitution indicated in lower case, the additional NsbI (tgcgca) or TauI (gc c/g gc) 
restriction site introduced in pSVHVWF-C2362F and pSVHVWF-C2362A, respectively, are 




for 50 seconds and extension at 68°C for 24 minutes followed by final extension at 
68°C for 7 minutes. The presence of the C2362F or C2362A mutation was 
monitored by restriction enzyme digestion of plasmid DNA with NsbI (MBI 
Fermentas, St. Leon-Rot, Germany) or TauI (MBI Fermentas), respectively. 
pSE280-HindIII-MunI-C2362F or pSE280-HindIII-MunI-C2362A were subsequently 
sequenced using CEQ 2000 Dye Terminator Cycle Sequencing (Beckman Coulter, 
Fullerton, CA, USA) and oligonucleotides 5 and 6 (Table II). The PshAI-BglII 
fragment containing only the C2362F or C2362A mutation was transferred to 
pSE280-HindIII-MunI-wt with compatible sites, creating pSE280-HindIII-
MunI-C2362F or pSE280-HindIII-MunI-C2362A. Colonies containing either the 
C2362F or the C2362A plasmid were selected by restriction digestion of plasmid 
DNA with NsbI or TauI. The mutant HindIII-MunI fragments were exchanged with 
the corresponding wt fragment in pSVHVWF creating pSVHVWF-C2362F and 
pSVHVWF-C2362A. All constructs were transformed and propagated in E. coli 
DH5α. DNA used in transient transfection experiments was purified with the 
plasmid maxi kit from Qiagen (Hilden, Germany) and the preparations used were 
screened by restriction digestion with NsbI or TauI. 
 
Expression of recombinant VWF 
Using the calcium phosphate precipitation method, 293T human kidney cells were 
cultured in T75 flasks and transiently transfected with a total of 27 μg plasmid 
DNA per flask (20). Cells were transfected with wt and pSVHVWF-C2362F (mutant) 
constructs alone or in combination to mimic the homozygous or heterozygous 
state in the patients. All transfections were performed essentially as previously 
described (19). 
 
ADAMTS13-mediated proteolysis of VWF 
Recombinant ADAMTS13 (rADAMTS13) was produced by transient transfection of 
the pcDNA3.1-ADAMTS13 V5/hisC expression vector (kindly provided by B.M. 
Luken and J. Voorberg, CLB research at Sanquin, Amsterdam, the Netherlands) in 
293T human kidney cells. Conditioned media containing either recombinant VWF 
(rVWF) or rADAMTS13 were supplemented with Pefabloc SC (Roche Diagnostics, 
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Mannheim, Germany) to a final concentration of 1 mM and concentrated 
approximately 10 times by centrifugation in 5 mM Tris (pH 8.0) using Macrosep 
concentrators (cut-off value 100 kDa; Pall Gelman Laboratory, Ann Harbor, MI, 
USA). Protease activity of rADAMTS13 aliquots was determined with the 
immunoblotting method of Böhm and co-workers (21) using ADAMTS13 in pooled 
normal plasma as a standard. The sensitivity for the ADAMTS13 protease activity 
of rVWF: C2362F, wt/C2362F and wt, was assessed at a fixed concentration of the 
recombinant substrates and a 1:20 dilution of ADAMTS13 in 5 mM Tris pH 8.0. This 
dilution of rADAMTS13 protease showed approximately the same proteolytic 
activity as ADAMTS13 in normal pooled plasma. To mimic proteolysis of VWF 
during normal activity of ADAMTS13 this fixed amount of rADAMTS13 was used in 
the assay. The final concentration of urea in the reaction mixture was 0, 0.1, 0.5, 
1.0 or 1.5 M. After 0, 8 and 24 h incubation at 37°C, aliquots were taken and the 
reaction was stopped by the addition of EDTA. Subsequently, the VWF multimeric 
distribution was analyzed. In all tests the same batch of concentrated rADAMTS13 
was used. 
 
Quantitative and qualitative analysis of VWF 
In conditioned medium and cell lysate VWF:Ag was measured by ELISA (19) and 
the distribution of VWF multimers was assessed by nonreducing sodium dodecyl 
sulfate (SDS)-agarose gel electrophoresis on 1.5% gels essentially according to the 
protocol of Raines et al. (22). The subunit size of reduced recombinant or plasma 
VWF was analyzed on denaturing 5% SDS-polyacrylamide gel electrophoresis 
(PAGE) or on 3% MetaPhor® gels (BMA, Rockland, ME, USA). VWF was transferred 
to 0.45-μm Immobilon™-P polyvinylidene difluoride membrane (Millipore, 
Bedford, MA, USA) by semi-dry blotting for SDS-PAGE gels and by capillary 
transfer for MetaPhor® gels. VWF was detected using the polyclonal anti-human 
VWF A082 antibody (Dako, Glostrup, Denmark) in combination with the 
peroxidase rabbit immunoglobulin-G ABC kit from Vectastain (PK-4001; Vector 
Laboratories, Burlingame, CA, USA). VWF was visualized with SuperSignal® West 
Pico chemoluminescent substrate kit from PIERCE (Perbio Science Nederland, 
Etten-Leur, the Netherlands) and/or precipitation colouring with 






The characteristics of one homozygous patient, one compound heterozygous 
patient, and one heterozygous carrier of the VWF mutation C2362F are listed in 
Table I. The data from the heterozygous carrier indicates a mainly quantitative 
defect with normal platelet dependent function of VWF (normal 
VWF:RCo/VWF:Ag and collagen binding activity (VWF:CB)/VWF:Ag ratios). The 
low levels of VWF-C2362F observed in the autosomal recessive severe VWD 
patients may be explained by several factors, e.g., decreased synthesis of VWF, 
decreased secretion of VWF, or increased turn-over of mutant VWF due to 
conformational changes leading to elevated receptor-mediated clearance or 
increased susceptibility towards its natural protease, ADAMTS13. VWF and its 
propeptide are secreted in equimolar amounts and in steady state the 
VWF-propeptide and the mature VWF circulate at a distinct ratio. This was used 
to asses whether mutant VWF was cleared more rapidly than normal VWF. Under 
non-stimulated conditions the VWF-propeptide/VWF ratios for the homozygous, 
compound heterozygous and heterozygous subjects were, 0.07, 0.16 and 0.21, 
respectively, which was within the normal range (Table I) and did not indicate 
increased turn-over of VWF. In addition, in vivo clearance of VWF-C2362F was 
studied by determining the half-life of VWF as well as VWF-propeptide after 
infusion of DDAVP in a subject homozygous for the C2362F mutation. This 
resulted in a rapid six-fold increase in the level of VWF-propeptide compared 
with the basal level, while only a mild transient rise of VWF:Ag and a minimal rise 
in VWF:RCo occurred (Fig. 1 and Table I). FVIII:C activity increased 1.5-fold and 
remained >0.50 IU/mL for 4 hours. The half-life of VWF-C2362F was estimated at 
3.6 h (Fig. 1A) indicating a two-fold decrease in its survival compared to normal 
VWF, while the half-life of 3.1 h for the VWF-propeptide remained normal. 
Although the level of VWF-C2362F was low in the homozygous subject, the mutant 
protein was detectable and could form both dimers and multimers (Fig. 1B). 
However, the VWF multimer analysis of plasma before and after DDAVP infusion 
also showed a remarkably high intensity smear of VWF. The smear in VWF 
multimers may indicate increased susceptibility of VWF-C2362F to proteolytic 
degradation, however mutations of cysteine residues have also been implicated in 
a multimer pattern with smear (23). 
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Expression of recombinant VWF 
Single transfections 
The level and quality of rVWF-C2362F and rVWF-C2362A produced in both media 
and cell lysate were compared with that of rVWF-wt. Three independent 
experiments with duplicate single transfections of mutant and wt VWF constructs 
were performed . The VWF:Ag level of mutant rVWF-C2362F and rVWF-C2362A in 
conditioned medium was 8% and 12%, respectively, compared with that of 
rVWF-wt (Fig. 2). In cell lysates the levels of rVWF-C2362F and rVWF-C2362A were 
275% and 308%, respectively, compared with those of rVWF-wt. The low level of 
secreted rVWF-C2362F is in accordance with the phenotype of the patient 
homozygous for this mutation (Table I) (10,12). The total production of rVWF (i.e., 
the sum of rVWF in medium and lysate) was on average 2.4, 2.7 and 2.4 μg for 
rVWF: C2362F, C2362A and wt, respectively. Together, these data indicate normal 
production, but strong intracellular retention of rVWF-C2362F and rVWF-C2362A. 
The low levels of platelet VWF:Ag in the patients (Table I) suggests rapid 
intracellular degradation in vivo of the mutant protein. Mutant rVWF are secreted 
 
Fig. 1, FVIII:C, VWF:Ag and VWF-propeptide response after administration of 
DDAVP. Blood was collected before and after DDAVP infusion (0.3 µg/kg body 
weight) in the patient homozygous for the C2362F mutation (A). VWF multimer 
analysis (B) on 1.5% nonreducing SDS-agarose gel of plasma of the patient before 
and after DDAVP infusion (t = 0, 1, 2 and 4 hrs) compared with pooled normal plasma 




mainly as dimers and tetramers although higher molecular weight forms were 
present at a low level. Homodimers of rVWF-C2362F and rVWF-C2362A showed an 
increased electrophoretic mobility compared to rVWF-wt (Fig. 2). 
 
Co-transfections 
To study a possible dominant negative effect of the loss of cysteine 2362 on the 
dimerization and multimerization of normal VWF we performed co-transfections 
with a basal level of 3 μg wt construct, to which 1.5, 3, or 6 μg of mutant VWF 
construct or wt VWF construct was added. It was previously shown that in this 
 
Fig. 2, single transfections of wt and mutant pSVHVWF constructs in 293T cells. 
The VWF production in medium (left panel) and lysate (right panel) is expressed 
relative to the amount of rVWF-wt protein. One hundred percent of rVWF-wt 
corresponds to 0.24-0.34 µg/mL in conditioned medium (5 mL) and 0.95-1.1 µg/mL in 
cell lysate (0.8 mL). Mean and standard deviation are based on six measurements 
(three independent experiments with two transfections in each experiment). The 
corresponding multimeric patterns are shown in the lower panel. The construct names 
are indicated below each lane. 293T corresponds to untransfected 293T cells. Pooled 
normal plasma (NP) was used as reference. 
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experimental cell system the total amount of VWF produced in wt transfections 
increases linearly with the amount of DNA in the transfection and that the system 
is not overloaded by 9 μg of DNA (19). The results of these transfections are shown 
in Fig. 3. The total amount of rVWF produced was approximately the same in all 
co-transfections as in the corresponding wt transfections for both 
pSVHVWF-C2362F and pSVHVWF-C2362A. Increasing the amount of mutant 
construct included in the co-transfection resulted in a linear decrease of rVWF 
secreted in the medium. There was no indication of a dominant negative effect, 
given that a 50% reduction of rVWF secretion was observed in the 1:1 
 
Fig. 3, co-transfections of wt and C2362F pSVHVWF constructs. The VWF 
production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to the amount of rVWF-wt of the corresponding wt 
transfection (black bars). The amount of wt and mutant (mut) construct added in each 
transfection is indicated below the bars, as is the amount (µg) of rVWF produced in 
either medium or lysate. The amount of wt and mutant (mut) constructs in the 
corresponding transfections are indicated below the multimer blots. As reference, 
pooled normal plasma (NP) was used. Equal amounts of VWF were applied in each 
lane, except for the transfection in which only mutant construct was expressed as the 




co-transfection of wt and mutant (Fig. 3). Also, the multimer pattern gave no 
indication for a dominant negative effect (Fig. 3). However, a clear difference in 
the electrophoretic mobility of VWF dimers was observed between wt and mutant 
VWF. A double band was detected in conditioned medium of the co-transfections, 
as well as in a heterozygous patient's plasma (Figs. 3 and 4A). Titration of wt 
construct with an increasing quantity of mutant construct resulted in an 
increasing intensity of the lower band while the upper band faded (Fig. 3). 
Although best visualized for dimers this was also seen for multimers. The upper 
band probably corresponds to homodimeric rVWF-wt, while the lower band 
corresponds to heterodimers of mutant and wt rVWF. The band of homodimeric 
rVWF-C2362F runs even faster (Fig. 3 left panel, right lane with mutant construct 
only). In the lysate three bands of dimeric rVWF were detected in close proximity 
of each other, which probably correspond to homodimeric wt, heterodimeric and 
homodimeric C2362F, respectively (Fig. 3, right panel). The same results were 
obtained in co-transfections of wt and the C2362A construct (data not shown). 
 
VWF subunit size 
Fig. 4A shows the increased electrophoretic mobility of both plasma and 
recombinant C2362F VWF as compared to normal plasma and recombinant wt 
VWF. The "heterozygous" wt/C2362F samples (both plasma and recombinant) 
show an intermediate VWF multimer pattern. These differences in 
electrophoretic mobility could be due to an altered conformation of the mutant 
protein or due to differences in the subunit size. The subunit size of VWF was 
analyzed on denaturing gels, after reduction of rVWF, and no difference in 
subunit size between wt, wt/C2362F or C2362F was observed in conditioned 
medium (Fig. 4B, left panel). The intracellular proVWF subunits were of equal size 
for both rVWF-wt and rVWF-C2362F. In addition, no difference in VWF subunit 
size was detected when rVWF was compared with VWF in patient plasma (Fig. 4B, 
right panel). Analysis of reduced rVWF in lysate did, however, show a distinct 
difference in processing of rVWF-C2362F and rVWF-wt (Fig. 4B, left panel). Both 
mature and proVWF were detected in lysate of wt transfections, but only proVWF 
was found in the lysates of cells transfected with the pSVHVWF-C2362F construct. 
This indicates that the majority of mutant rVWF-C2362F is not processed to 
mature VWF but is retained in the cell. As the subunit size of VWF-C2362F is 
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identical to normal VWF, the difference in electrophoretic mobility of homo- and 
heterodimers of VWF is probably best explained by an alternative conformation 
of the mutant subunit (Figs. 1B-4A). 
 
 
Fig. 4, multimer and subunit size of rVWF-wt and rVWF-C2362F. Non-reduced 
rVWF-wt (wt), rVWF-C2362F (C2362F), rVWF-wt/C2362F (wt & C2362F) and plasma 
of patients homozygous and heterozygous for the C2362F mutation were analyzed on 
SDS-agarose (1.5%) gel (A), and reduced VWF on SDS-PAGE (5%) gels (B, left) or 
on denaturing 3% MetaPhor gel (B, right) and immunoblotted with anti-VWF IgG. 
Patient plasma and recombinant mutant show faster migrating dimers and multimers 
(A, inset), but identical subunit size compared to normal VWF after reduction (B). M, 
medium; L, lysate; P, plasma; NP, pooled normal plasma; HMW VWF, purified high 




ADAMTS13 proteolysis assay 
After administration of DDAVP the half-life of mutant VWF-C2362F was found to 
be reduced (Fig. 1A). It has previously been shown by Castaman et al. (24) that 
plasma of patients homozygous for the C2362F mutation contains increased levels 
of degraded VWF. To investigate whether the reduced half-life of VWF-C2362F 
 
Fig. 5, ADAMTS13-mediated proteolysis of rVWF-wt and rVWF-C2362F. 
Recombinant VWF from single transfections of pSVHVWF-C2362F (C2362F), 
co-transfections (wt & C2362F) and single transfections of wt construct (wt) were 
incubated with recombinant ADAMTS13 for 0, 8 or 24 h (t) in the absence or presence 
of 0.1, 0.5, 1.0, 1.5 M urea (0.5 M urea not shown). The degree of proteolysis was 
assayed on SDS-agarose gel electrophoresis under non-reducing conditions. 
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was due to increased proteolysis of mutant VWF by ADAMTS13, proteolysis 
mediated by ADAMTS13 was studied in an in vitro assay. No or little degradation 
was detected in the absence or in the presence of 0.1 M urea (Fig. 5A). However, at 
1.0 M or 1.5 M urea a gradual disappearance of the HMW multimers and the 
formation of the typical protease-dependent triplet structure was observed 
(Fig. 5B). Comparison of rVWF: wt, wt/C2362F and C2362F did not reveal any 
difference in the sensitivity of the rVWF substrates to cleavage by ADAMTS13. 
 
Discussion 
In patients with type 3 VWD, identification of the underlying mutations has been 
laborious since their location is not restricted to a certain region of the large VWF 
gene. The mutations that have been described mainly result in null alleles (5). 
However, some missense mutations of cysteines at the C-terminal region of VWF 
have been identified in type 3 VWD patients (6-9). We and others have previously 
studied mutated cysteines in the CK domain of VWF and have shown that 
mutation of cysteines involved in intrachain bonds result in a mainly quantitative 
VWF defect, while mutation of cysteines involved in interchain bonds result in a 
qualitative type 2A (subtype IID) VWF defect (Chapter 5) (7,19,25). The 
quantitative deficiency observed in the type 3 phenotype may be caused by the 
disruption of VWF monomer structure when an intrachain bond is lost, which 
subsequently leads to pronounced intracellular retention and has no dominant 
negative effect. On the contrary, the loss of an interchain bonds interferes with 
subsequent dimerization and multimerization and thus results in a dominant 
negative defect which corresponds with the type 2A(IID) phenotype. The present 
study, however, investigated the effects of a mutation of a cysteine (C2362F) 
located outside the CK domain. This location predicts the cysteine to be involved 
in an intrachain bond and, to date, no specific function has been assigned to this 
region of VWF. The C2362F mutation is found in patients with a severe 
quantitative VWF defect. Based on this severe quantitative autosomal recessive 
VWD phenotype and our previous studies (19), it was hypothesized that this 
mutation also would result in intracellular retention without a dominant negative 
effect. Patient data indicated a severe VWF deficiency in homozygous (C2362F) 
and compound heterozygous (C2362F/null allele) patients, whereas VWF was 




carriers of the C2362F mutation (Table I). Expression of recombinant VWF-C2362F 
showed normal production, but nearly complete intracellular retention (Fig. 2). 
No sign of a dominant negative effect was found in co-transfections, indicating 
that the ultimate effects of the C2362F mutation are similar to those of a null allele 
(Fig. 3). Expression of the alternate mutant C2362A gave similar results indicating 
that monomer conformation of VWF is affected by the loss of the cysteine rather 
than by the introduction of phenylalanine. The processing of intracellularly 
retained rVWF-C2362F is severely hampered as only proVWF is present in lysate 
(Fig. 4B, left panel). This was in agreement with the low VWF-propeptide levels 
observed in patients plasma (Table I), which indicates that there is no selective 
retention of mature VWF, but retention of VWF-propeptide as well (probably as 
unprocessed proVWF). In addition, the low platelet VWF:Ag observed in the 
patients (Table I) indicates intracellular degradation. The abnormal 
electrophoretic mobility observed for both the phenylalanine and the alanine 
mutant is probably due to a conformational change as the subunit size of reduced 
VWF-C2362F was identical to that of rVWF-wt (Fig. 4). The presence of a smear in 
the plasma VWF multimer pattern of the patient homozygous for VWF-C2362F 
(Fig. 1B), the absence of this smear in the multimer pattern of rVWF-C2362F, the 
previous finding of increased concentrations of proteolytic fragments of 
VWF-C2362F in patient's plasma (24), as well as the reduced half-life of 
VWF-C2362F after DDAVP infusion (Fig. 1A), may all result from increased 
degradation of VWF-C2362F in plasma, elevated receptor-mediated clearance of 
mutant VWF, or a combination thereof. The increased presence of proteolytic 
fragments in patients plasma observed by Castaman and co-workers is however 
not explained by an increased sensitivity of the mutant protein to proteolysis by 
rADAMTS13 (Fig. 5). Additional proteases, which were not present in our 
ADAMTS13 preparation, in combination with ADAMTS13 may be responsible for 
the observed proteolysis. However, considering the very low secretion of 
rVWF-C2362F, the contribution of in vivo degradation of VWF-C2362F in plasma to 
the overall reduction of VWF in the homozygous patients seems to be limited. To 
conclude, this study has shown that the C2362F mutation causes a severe 
quantitative defect. We have demonstrated that the autosomal recessive severe 
VWD phenotype is the result of impaired secretion due to strong intracellular 
retention of unprocessed mutant proVWF subunits, which is caused by the loss of 
an intrachain bond and not by the introduction of an bulky amino acid side chain. 
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Von Willebrand factor (VWF) contains a large number of cysteine residues, which 
all participate in the formation of disulfide bonds. Mutations of cysteine residues 
in the cystine knot (CK) domain of VWF resulting in dimerization defects have 
been identified in both qualitative type 2A (former subtype IID, 2A(IID)) and 
quantitative type 3 von Willebrand disease (VWD). We hypothesized that this 
difference in phenotype is related to whether the mutated cysteine residue is 
involved in either interchain or intrachain disulfide bond formation. To test this 
hypothesis we studied three mutations in the CK domain of VWF. We compared 
the effects of the novel C2773S mutation, which was identified in a family with 
type 2A(IID) VWD, with those of the C2739Y and C2754W mutations, which were 
previously identified in patients with type 3 VWD. The effect of these mutations 
on dimerization and multimerization of VWF was studied by transient expression 
in 293T cells. Co-transfection of wild-type (wt) and C2773S VWF constructs 
reproduced the plasma phenotype of heterozygous type 2A(IID) patients, with 
normal to high levels of VWF antigen (VWF:Ag), absence of high molecular weight 
multimers, and the presence of intervening bands between the normal multimers. 
In contrast, single transfections of C2739Y or C2754W, resulted in a quantitative 
VWF defect with low VWF:Ag levels, and a 50% reduction of VWF:Ag in 
co-transfections of wt and mutant constructs and only a minor effect on VWF 
multimerization. We showed preferential N-terminal dimerization of VWF-C2773S 
and both C- and N-terminal dimerization of VWF-C2754W. Our data suggest that 
loss of a single disulfide bond in the CK domain of VWF will lead to a recessive, 
quantitative VWF deficiency if an intrachain disulfide bond is involved, and to a 






Von Willebrand factor (VWF) is a high molecular weight (HMW) plasma 
glycoprotein with two vital functions. At the site of vascular injury, VWF mediates 
the adhesion of platelets to the vessel wall and initiates the formation of a platelet 
plug by aggregation of platelets. In addition, VWF is indirectly involved in 
secondary hemostasis as the carrier protein of coagulation factor VIII (FVIII) with 
which it forms a non-covalent complex. The function of VWF depends on the 
proper formation of HMW multimers, which range from 0.5 to 10 million Daltons 
in mass. The multimerization process is very important as the highest molecular 
weight multimers are most effective in supporting platelet adhesion and 
aggregation. Formation of VWF multimers starts with dimerization of proVWF 
monomers in the endoplasmic reticulum (ER) (1,2). ProVWF monomers are linked 
pairwise through interchain disulfide bond(s) at the C-terminal cystine knot (CK) 
domain (3). Subsequently, multimerization occurs in the Golgi apparatus, where 
proVWF dimers are covalently linked by interchain disulfide bonds at the 
N-terminal end of the VWF molecule with concurrent removal of the 
VWF-propeptide. The resulting multimers consist of an even number of mature 
VWF subunits (1,2). VWF contains a large number of cysteine residues (8.2%) that 
all form interchain or intrachain disulfide bonds and are of great importance for 
the structural integrity of the VWF monomer and the processes of di- and 
multimerization (4). 
Alterations in the VWF gene sequence resulting in a modification of the level 
and/or function of the VWF protein may cause von Willebrand disease (VWD) (5), 
which is the most common inherited bleeding disorder. Missense mutations of 
cysteines located in the CK domain have been found both in patients with 
quantitative and qualitative VWF defects. In patients with a virtually complete 
absence of VWF, type 3 VWD, alterations of cysteine residues 2739 (6), 2754 (7), 
2804 (8) and 2806 (9) have been described. However, in the same region changes of 
cysteine residues at position 2771 (10) and 2773 (11) result in type 2A (former 
subtype IID, 2A(IID)) VWD, which is characterized by a qualitative, 
multimerization defect. We hypothesized that the differences in phenotype 
among patients with mutations at cysteine residues in the CK domain depend on 
whether the mutated cysteine residue participates in an interchain or intrachain 
disulfide bond. 
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To investigate this hypothesis we have screened a type 2A(IID) VWD family 
for a mutation in the CK domain, anticipating that this would be a mutation at a 
cysteine residue involved in the formation of an interchain disulfide bond. Indeed, 
we identified such a mutation in the CK domain (C2773S). We examined the effect 
of this novel missense mutation at the level of dimerization and multimerization 
by transient expression of the recombinant protein and compared it with the 
effects of two type 3 VWD mutations in the CK domain, C2739Y (6) and C2754W 
(7). 
 
Materials and methods 
Patients 
The proposita (III-5; Table I) has a severe bleeding tendency, manifested in 
spontaneous bruises, and bruises of abnormal size after mild trauma. She suffered 
from frequent epistaxes during childhood, heavy menorrhagia causing anaemia, 
postpartum hemorrhage requiring blood transfusion, and prolonged bleeding 
after tooth extraction. The daughter (IV-1) has a severe bleeding tendency with 
frequent epistaxes (once a week), abnormal bruising and heavy menorrhagia. At 
the age of 4 she experienced gastrointestinal bleeding. A son (IV-2) died after 
tonsillectomy. The remaining family members, the father (III-4), daughter (IV-3) 
and son (IV-4) are not affected. Patients' plasma was analyzed for factor VIII 
activity (FVIII:C), VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity 
(VWF:RCo). The bleeding time was determined according to the Ivy method using 
a micro lancet. The phenotypic characteristics of affected and unaffected family 
members are presented in Table I. The affected mother (III-5) and daughter (IV-1) 
were diagnosed as type 2A(IID) VWD based on the prolonged bleeding time, 
normal levels of VWF:Ag, strongly reduced VWF:RCo (Table I), and the typical 
VWF multimer pattern, lacking HMW multimers and including aberrant, 
odd-numbered multimers between the normal VWF multimers (Fig. 1B). The 
pedigree (Fig. 1A) shows dominant inheritance with transmission from the 
affected mother to the affected daughter and possibly the deceased son (IV-2). For 
comparative studies we used two previously described type 3 VWD mutations 
identified in patients compound heterozygous for the C2739Y mutation and a null 





Screening for mutations 
Based on the type 2A(IID) VWD phenotype of the patients, we anticipated a 
mutation to be located in the CK domain of VWF. Thus, exons 51 and 52 of the 
VWF gene of patients III-5, IV-1, the unaffected father III-4 and an unrelated 
healthy person were amplified using oligonucleotides 1 and 2 for exon 51 and 
oligonucleotides 3 and 4 for exon 52 (Table II). Both strands were sequenced by 
ABI-prism Big-Dye™ terminator cycle sequencing (PE Applied Biosystems, 
Nieuwerkerk a/d IJssel, the Netherlands). 
 
Plasmid construction 
Construction of plasmids encoding VWF-wt, VWF-C2739Y and VWF-C2754W was 
described before (12). The C2773S mutation was introduced in the pSVHVWF 
plasmid containing the full-length wt cDNA of VWF via site-directed mutagenesis 
utilizing oligonucleotides 5 and 6 (Table II) and the QuikChangeXL™ site-directed 
mutagenesis kit from Stratagene (La Jolla, CA, USA). Successful incorporation of 
the mutation was verified by restriction digestion with MnlI of the colony-PCR  
Table I: Phenotypic characteristics 
Patient Sex BT 
Ivy 




Nb (f/m) (min) (U/mL)  (U/mL)  (U/mL)   
III-4 m 2.75 2.0 1.8 1.9 A None  
III-5 f >15 0.98 1.92 <0.20 O Severe 
IV-1 f >15 0.74 1.07 <0.20 O Severe 
IV-2 m na na na na na Severe* 
IV-3 f 3.75 1.50 0.92 1.06 O None 
IV-4 m 2.5 1.60 1.36 1.34 A None 
Normal  0-4  0.5-2 0.4-2 0.5-2   
f, female. m, male. BT, bleeding time. na, not available. *Died after tonsillectomy. 





Fig. 1, sequence and multimer data of the family with 2A(IID) VWD. Pedigree 
showing the presence of the C2773S mutation (A) determined by sequencing (codon 
indicated) and by MnlI digestion (mutation present +, absent -). Individual IV-2 is 
deceased and no samples were available for analysis. nd, not determined; open 
symbol, unaffected individual; filled symbol, affected individual; square, male; circle, 
female. Analysis of VWF multimers (B) on non-reducing SDS-agarose (1.5%) gel. 
Shown are pooled normal plasma (normal), rVWF-wt (wt), recombinant co-expressed 
VWF (wt & C2773S), and plasma from the mother (III-5) and daughter (IV-1). Note the 
absence of HMW multimers and the intervening bands representing multimers with an 
odd-number of VWF subunits appearing between the normal, even, multimers both in 
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products obtained with oligonucleotide 7 in combination with oligonucleotide 8 
or 9 (Table II). Subsequently, plasmid DNA was prepared and directly sequenced 
on the ABI 310 using the ABI-Prism Big-Dye™ terminator cycle-sequencing kit and 
oligonucleotides 7 to 9. DNA containing the C2773S mutation only was digested 
with EcoRV and MunI and the mutant fragment was ligated into pSVHVWF with 
compatible sites, creating pSVHVWF-C2773S. Colonies containing the 
pSVHVWF-C2773S plasmid were selected by restriction digestion with MnlI of the 
colony PCR products and the DNA was sequenced (see above). 
Full-length ADAMTS13 cDNA was cloned from human liver cDNA essentially 
as described previously (14). In the present construct, the signal-peptide of 
ADAMTS13 was introduced via a PCR fragment generated with oligonucleotides 10 
and 11 (Table II). This fragment replaced the original sequence from the pMIB 
V5/hisC ADAMTS13 vector up to the first internal BamHI site. The resulting 
full-length ADAMTS13 sequence is identical to Genbank sequence NM_139025 and 
was cloned into the HindIII and XhoI restriction sites of pcDNA3.1 generating 
pcDNA3.1-ADAMTS13 V5/hisC. All constructs were transformed and propagated 
in E. coli DH5α. DNA used in transient transfection experiments was purified with 
the plasmid maxi kit from Qiagen (Hilden, Germany) and the preparations of 
pSVHVWF-C2773S were screened with MnlI and sequenced as described. 
 
Expression of recombinant VWF 
293T human kidney cells were transiently transfected with pSVHVWF-wt, 
pSVHVWF-C2739Y, pSVHVWF-C2754W and pSVHVWF-C2773S plasmids in single 
transfections and with pSVHVWF-wt and pSVHVWF-C2773S in co-transfections 
using the calcium phosphate precipitation method. Transfections and collection 
of conditioned medium and cell lysate were as previously described (12). 
 
N-terminal dimerization assay utilizing ADAMTS13-mediated proteolysis of VWF 
Recombinant ADAMTS13 (rADAMTS13) was produced by transient transfection of 
the pcDNA3.1-ADAMTS13 V5/hisC expression vector. 293T cells were cultured in 
T75 flasks and transfected with a total of 27 μg DNA per flask. The 
pSVHVWF-C2754W plasmid was used in single transfections while the wt and 




mimic the heterozygous state in patients. All transfections were essentially 
performed as previously described (12). Conditioned medium was collected and 
Pefabloc SC (Roche Diagnostics, Mannheim, Germany) was added to a final 
concentration of 1 mM. The medium containing either recombinant VWF (rVWF) 
or rADAMTS13 was concentrated ~10 times by centrifugation in 5 mM Tris (pH 
8.0) using Macrosep concentrators (cut-off value 100 kDa, Pall Gellman 
Laboratory, Ann Harbor, MI, USA). Protease activity in rADAMTS13 aliquots was 
determined according to the immunoblotting method of Böhm et al. (15) using 
ADAMTS13 in pooled normal plasma as a standard. Recombinant VWF substrates 
(wt, wt co-expressed with C2773S, C2773S and C2754W) were incubated at 37°C for 
24 hrs with rADAMTS13 diluted 1:5 in 5 mM Tris pH 8.0 and 1.5 M urea. Proteolysis 
was stopped by addition of EDTA. In all experiments the same batch of 
concentrated rADAMTS13, shown to be as active as ADAMTS13 in pooled normal 
plasma, was used. The distribution of VWF fragments after ADAMTS13-mediated 
proteolysis was analyzed on denaturing 5% PAGE gels. Proteins were transferred 
to a PVDF membrane by semi-dry blotting and the membrane was incubated with 
Western Blocking Reagent from Roche Diagnostics (Mannheim, Germany). VWF 
was detected with a primary polyclonal anti-human VWF antibody (A082, Dako, 
Glostrup, Denmark). Monoclonal antibodies directed against human VWF domain 
A1 (MoAb 723) and domain A3 (MoAb 400) (16) were a generous gift from Dr. D. 
Meyer (INSERM U143, Le Kremlin-Bicêtre, France). Horseradish peroxidase (HRP) 
conjugated goat anti-rabbit or anti-mouse IgG were from Bio-Rad (Veenendaal, 
the Netherlands). 
 
Quantitative and qualitative analysis of VWF 
In conditioned media and cell lysates, VWF:Ag levels were measured by ELISA (12) 
and VWF multimerization was assessed on non-reducing SDS-agarose (1.5%) gels 
essentially according to the protocol of Raines et al. (17). VWF multimers were 
detected using a polyclonal anti-human VWF antibody (A082, Dako) in 
combination with the Peroxidase Rabbit IgG ABC kit from Vectastain (PK-4001, 
Vector Laboratories, Burlingame, CA, USA). VWF was visualized with SuperSignal® 
West Pico chemoluminescent substrate kit from PIERCE (Perbio Science 
Nederland, Etten-Leur, NL) and/or precipitation colouring with 3,3'-diamino-
benzidine (DAB, Sigma-Aldrich Chemie, Steinheim, Germany). 




Screening for mutations 
The 2A(IID) phenotype suggested the presence of a mutation in the CK domain 
and sequencing of exon 52 showed a previously unreported transversion of a 
guanine to cytosine, 8318G>C, resulting in the change of cysteine 2773 to serine 
(C2773S, nomenclature according to reference (18)). Heterozygosity for this 
mutation was confirmed by the presence of an additional MnlI restriction site 
(Fig. 1A). 
 
Expression of recombinant VWF 
Single transfections 
The effect of the mutations C2773S (type 2A(IID)), C2739Y (type 3) and C2754W 
(type 3) on the quantity and the quality of recombinant VWF was studied in 
transient single transfection experiments. Two independent experiments were 
performed in triplicate for mutant and wt VWF constructs. The VWF:Ag level of 
rVWF-C2773S in conditioned medium was 138% compared with that of rVWF-wt, 
indicating a normal to high level of production and secretion of rVWF-C2773S 
(Fig. 2). However, multimer analysis revealed a complete lack of high and 
intermediate molecular weight multimers and excess of monomeric and dimeric 
rVWF-C2773S. The multimer analysis, of both conditioned media and cell lysates, 
further revealed a difference in the electrophoretic mobility of homodimeric 
rVWF-C2773S compared with homodimers of rVWF-wt and homodimers of 
rVWF-C2739Y or rVWF-C2754W. The levels of secreted rVWF-C2739Y and 
rVWF-C2754W were very low (0.5% and 5% respectively), which is in accordance 
with the type 3 VWD phenotype of the patients described with those mutations 
(6,7). The intracellular levels of rVWF-wt, rVWF-C2773S and rVWF-C2754W were 
similar (100%, 113% and 116% respectively), whereas the intracellular level of 
rVWF-C2739Y was significantly reduced (45%). 
 
Co-transfections 
The effect of the VWF-C2773S subunit on the dimerization and multimerization of 




VWF construct was added to 3 μg wt construct. We previously showed that in our 
experimental cell system the total amount of VWF produced in wt transfections 
increases linearly with the amount of DNA in the transfection and that the system 
is not overloaded by 9 μg of DNA (12). The results are shown in Fig 3. The total 
amount of rVWF produced (sum of rVWF in medium and lysate) was in all cases 
higher in the co-transfections (2.7-6.8 μg) than in the corresponding wt 
transfections (2.1-4.3 μg). A relative increase from 135% to 181% of secreted rVWF, 
and a slight increase from 99% to 110% of retained rVWF was detected when the 
Fig. 2, single transfections of wt and mutant pSVHVWF constructs in 293T cells. 
The production of mutant VWF in medium (left panel) and lysate (right panel) is 
expressed relative to that of rVWF-wt. One hundred percent of wt-VWF corresponds 
to 0.41-0.70 µg/mL in conditioned medium and 1.3-1.8 µg/mL in cell lysate. Mean and 
standard deviation are based on six measurements (two independent experiments 
with three transfections in each experiment). The corresponding multimeric patterns 
are shown in the lower panel. The construct names are indicated below each lane. 
293T corresponds to untransfected 293T cells. Pooled normal plasma (NP) was used 
as reference. Oligomers are indicated. 
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amount of pSVHVWF-C2773S construct in the transfections was increased. The 
co-transfection of mutant and wt VWF construct at a ratio of 1:1 clearly 
reproduced the phenotype of the patients: normal to high levels of VWF:Ag, lack 
of HMW multimers and odd-numbered multimers appearing between normal 
VWF multimers (Table I and Figs. 1B and 3). When more mutant construct was 
included in the co-transfection, a switch from intermediate to low molecular 
weight (LMW) multimers occurred, indicating hampered multimerization. 
Furthermore, a clear difference in the electrophoretic mobility of rVWF-wt, 
Fig. 3, co-transfections of wt and pSVHVWF-C2773S constructs. The VWF 
production in medium (left panel) and lysate (right panel) is expressed for each 
co-transfection (grey bars) relative to that of the corresponding wt transfection (black 
bars). The amount of wt and mutant (mut) construct added in each transfection is 
indicated below the bars as is the total amount (µg) of VWF produced in either 
medium or lysate. Below the multimer blots the amounts of wt and mutant (mut) 
construct in the corresponding transfections are indicated. Pooled normal plasma (NP) 
was used as a reference. Equal amounts of VWF were applied in each lane. The 




rVWF-wt co-expressed with rVWF-C2773S and rVWF-C2773S was detected for 
dimeric VWF. Two populations of dimeric VWF molecules are present in the 
patient’s plasma and in the media of co-transfections (Figs. 1B and 3). The upper 
band probably corresponds to dimers formed through dimerization at the 
N-terminus of VWF whereas the lower band corresponds to dimers formed 
through normal dimerization at the C-terminus of VWF. Increasing the ratio of 
mutant over wt in the co-transfection leads to an increase in the intensity of the 
upper band whereas that of the lower band decreases. This suggests that the bulk 
of rVWF-C2773S dimers are formed through N-terminal dimerization whereas 
rVWF-wt dimers are formed through normal dimerization at the C-terminus of 
VWF. 
 
Analysis of N- and C-terminal dimerization of VWF 
Defective dimerization and formation of dimers via the N-terminal pairing is 
suggested by the observation of excess of monomers and dimers in media of cells 
transfected with pSVHVWF-C2773S. We aimed to demonstrate the presence of 
N-terminal dimerization and the lack of C-terminal pairing. ADAMTS13 protease 
cleaves VWF in the A2 domain between aa 1605 and 1606, which enables separate 
detection of N- and C-terminal VWF fragments. To identify N- and C-terminal 
VWF fragments, we utilized monoclonal antibodies 723 and 400, which were 
raised against the A1 and A3 domain of VWF, respectively (16). In theory, cleavage 
of VWF-wt and VWF-C2773S by ADAMTS13 are expected to yield the fragments 
depicted in Fig. 4A. After proteolysis by ADAMTS13 VWF fragments were 
separated on denaturing gels both under non-reduced and reduced conditions 
and N- and C-terminal VWF fragments were detected by immunoblotting using 
the A1 and A3 specific monoclonal antibodies (Fig. 4B). ADAMTS13 proteolysis of 
normal C-terminally dimerized and N-terminally multimerized VWF should yield 
dimeric VWF fragments linked at either the C- or N-terminus of VWF, designated 
Cd and Nd, respectively (Fig. 4A). 
Proteolysis of HMW VWF purified from normal plasma and rVWF-wt indeed 
resulted in formation of Cd and Nd, indicating intact dimerization and 
multimerization of VWF (Fig. 4B). Alteration of C2773 may seriously affect the 
ability of VWF to form C-terminal dimers in the ER resulting in an excess of 
monomeric VWF and possibly N-terminally formed dimers as depicted in Fig. 4A.  
 





Fig. 4, analysis of N- and C-terminal dimerization of VWF. A schematic overview of 
expected proteolysis products (dimers and smaller) after ADAMTS13 digestion of VWF-wt 
and VWF-C2773S dimers and multimers are shown in panel A. The site of proteolysis is 
depicted with a triangle and lies between the recognition sites in the A1 and the A3 region 
for the two monoclonal antibodies 723 and 400, respectively. This enables detection of 
proteolysis products with the N-terminal (aa 764-1605, 1N) or C-terminal (aa 1606-2813, 
1C) part of VWF. VWF was also detected with polyclonal antibody A082. Dimers formed 
through disulfide bonding at the C- or N-terminus of VWF are designated Cd+2N and 
Nd+2C. Complete ADAMTS13 digestion of VWF results in C-terminal dimers (Cd) and/or 
N-terminal dimers (Nd). The composition of non-reduced recombinant VWF of C2773S, co-
expressed (1:1 ratio of wt and C2773S), wt, C2754W and high molecular weight VWF 
(HMW VWF) purified from plasma after 24 h of ADAMTS13-mediated proteolysis was 
studied by separation on four different 5% SDS-PAGE gels (B). Reduction of VWF 
samples resulted in detection of the mature VWF subunit, N-terminal and C-terminal 
fragments of VWF (results not shown). Molecular marker (Mw, is shown in lane 12) and is 




Proteolysis of monomers and N-terminally formed dimers would then yield an 
excess of free C-terminal VWF (1C) and Nd. Indeed, proteolysis of rVWF-C2773S 
resulted in main bands corresponding to N-terminally formed dimers and free 
C-terminal which were detected with MoAbs 723 and 400, respectively (Fig. 4B). 
Further, normal C-terminally linked (Cd) rVWF-C2773S was detected only as a 
faint band with MoAb 400 confirming that alteration of cysteine 2773 results in a 
dimerization defect. Proteolysis of co-expressed rVWF-wt and rVWF-C2773S (at a 
ratio of 1:1) resulted in detection of both normal C-terminal dimerization (Cd) and 
N-terminal multimerization (Nd) similar to rVWF-wt. Additionally, excess of free 
C-terminal fragments (1C) is detected indicating N-terminal dimerization similar 
as observed for rVWF-C2773S (Fig. 4B). These results may be explained by the 
segregation of dimerization and multimerization of VWF to different 
compartments in the cell. While C-terminal dimerization of rVWF-wt remains 
intact and generates normal dimers in the ER most C2773S will be monomeric due 
to its defective dimerization. Therefore it is unlikely that C2773S interacts with 
either wt or mutant VWF subunits (Figs. 3 and 4B) in the ER. In the Golgi wt 
dimers and mutant monomers both participate in multimerization leading to the 
addition of mutant monomers to wt multimers hampering further 
multimerization of wt multimers but also N-terminal dimerization of mutant 
monomers (Fig. 3). 
ADAMTS13 digestion of rVWF-C2754W also resulted in Nd and free 
C-terminal VWF (1C) as the main end products (Fig. 4B). The intensity of Cd, Nd 
and free C-terminal VWF bands were assessed by densitometric analysis of the 
second blot in Fig. 4B (VWF detected with polyclonal antibody A082). The ratio of 
Nd vs Cd VWF was 1:0.63 for C2754W and 1:0.15 for C2773S. This indicates a 
four-fold higher level of relative residual C-terminal pairing for VWF-C2754W 
compared with the very low level observed for VWF-C2773S, which may explain 
the detection of octamers in single transfections of C2754W and only tetramers 
for C2773S. Further, a 1.4-fold increase in the relative ratio of free C-terminal 
versus Nd was observed for C2773S compared with the ratio detected for C2754W. 
This also indicates that VWF-C2773S dimerizes less efficiently at the C-terminus 
than VWF-C2754W does. 
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Analysis of altered electrophoretic mobility of VWF 
Analysis of reduced samples of VWF on denatured polyacrylamide gels (Fig. 5) 
excluded differences in the subunit size of wt and mutant VWF as the cause of the 
altered electrophoretic mobility observed for the dimeric VWF molecules (Fig. 3). 
In lysates of cells transfected with wt or mutant constructs, proVWF of all mutant 
constructs appeared to have the same mobility (Fig. 5, left panel). Also the 
apparent size of the mature VWF subunit of wt, C2773S and plasma VWF was 
similar. Further, no difference in subunit size was found between the mature VWF 
in plasma of patients III-5 and IV-1 and the VWF secreted by 293T cells 
co-transfected with wt and C2773S VWF constructs (Fig. 5, right panel). This 
suggests that the altered electrophoretic mobility of dimeric VWF is most likely 
explained by a difference in the conformation of the VWF-wt homodimers formed 
through conventional C-terminal pairing versus the conformation of homodimeric 
VWF-C2773S formed by dimerization at the N-terminus. Interestingly, while the 
Fig. 5, SDS-PAGE analysis of the subunit size of recombinant VWF. Recombinant 
VWF in lysates or medium was reduced and separated by electrophoresis on 
denaturing 5% PAGE gels. VWF was detected with polyclonal antibody A082. 
Recombinant VWF from lysates of single transfections of wt and mutants; C2739Y, 
C2754W, and C2773S (left panel). Lysate and medium of recombinant VWF of wt, 
co-transfected (wt & C2773S) and mutant C2773S (C2773S), and for comparison 
reduced plasma VWF from patients III-5 and IV-1 (right panel). There is no difference 
in subunit size between the different recombinant C-terminal mutants and the pooled 
normal plasma (NP) and patient plasmas. The mutants C2739Y and C2754W show 
only proVWF and no mature VWF in lysates indicating reduced intracellular 




same intensity of proVWF and mature VWF was detected for rVWF-wt and 
rVWF-C2773S in cell lysates (Fig. 5, right panel), only the proVWF form was 
detected for rVWF-C2739Y and rVWF-C2754W (Fig. 5, left panel). This indicates 
similar intracellular processing of rVWF-wt and rVWF-C2773S suggesting that the 
C2773S subunits can participate in multimerization in the Golgi and are processed 
to mature VWF. In contrast, the absence of mature rVWF-C2739Y or 
rVWF-C2754W subunits in the lysates suggests hampered processing and 
intracellular retention and rapid degradation of these mutant subunits. 
 
Discussion 
Cysteine residues play a crucial role in determining the three-dimensional 
structure of VWF. All cysteine residues in VWF participate in either inter- or 
intrachain disulfide bonds (4). Biosynthesis of VWF is complex and involves the 
formation of proVWF dimers in the ER through covalent interchain disulfide 
bonds located in the CK domain of VWF (3). HMW multimers are generated in the 
Golgi apparatus through the formation of cysteine bonds at the N-termini of 
proVWF dimers. Concomitant removal of the VWF-propeptide renders HMW 
multimers consisting of mature VWF subunits linked together via interchain 
disulfide bonds at the C- and N-terminus. 
Alterations of cysteine residues 2771 (10) and 2773 (11) in the CK domain of 
VWF have been identified in type 2A(IID) VWD patients, while changes of 
cysteines 2739 (6), 2754 (7), 2804 (8) and 2806 (9) were described in type 3 VWD. 
Although these mutations probably all cause a dimerization defect, as was 
demonstrated for 2771 (10), 2773 (11) and 2754 (7), they result in completely 
different VWD phenotypes. Interestingly, when we categorized the mutated 
cysteines by their involvement in either interchain or intrachain disulfide bonds, 
we noticed that the cysteines mutated in the two previously reported type 2A(IID) 
VWD patients might form interchain disulfide bonds and that the four cysteines 
mutated in type 3 VWD patients were all involved in the formation of intrachain 
disulfide bonds (3). Therefore, we hypothesized that the phenotypic discrepancies 
(VWD type 2A(IID) vs type 3) observed in patients with cysteine mutations in the 
CK domain may depend on whether the mutated cysteine residue participates in 
an inter- or intrachain disulfide bond. 
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First, we screened for mutations in the CK domain in an additional family 
with type 2A(IID) VWD anticipating, based on our hypothesis, to find a mutated 
cysteine that is involved in an interchain disulfide bond. We identified a 
transversion of guanine at nucleotide 8318 to a cytosine, resulting in the change 
of cysteine 2773 to a serine (C2773S). This cysteine is indeed, as expected, involved 
in an interchain disulfide bond (3). The C2773S mutation involves the same 
cysteine as the C2773R mutation previously reported by Schneppenheim et al. (11). 
Co-expression experiments of recombinant wt and mutant VWF exactly 
reproduced the type 2A(IID) phenotype of the heterozygous patients carrying this 
mutation: normal to high VWF:Ag level, absence of HMW multimers, and 
intervening bands between the normal multimers (Figs. 1 and 3). 
To test the hypothesis that loss of inter- and intrachain disulfide bonds in the 
CK domain of VWF may give rise to different types of VWD, we compared the VWF 
phenotype of the novel C2773S mutation in 293T cells with that of two type 3 
VWD mutations, C2739Y and C2754W that affect the formation of intrachain 
bonds. Whereas high production and secretion of rVWF-C2773S was 
demonstrated, the secretion of rVWF-C2739Y and rVWF-C2754W was strongly 
reduced (Fig. 2). In the conditioned media of cells co-transfected with wt and 
C2773S constructs as well as in the plasma of heterozygous carriers of the C2773S 
mutation, we observed a difference in the electrophoretic mobility of presumed 
homodimers of VWF-C2773S compared with that of homodimeric VWF-wt 
(Figs. 1-3), which was not observed for VWF-C2739Y and VWF-C2754W. The 
observed difference in electrophoretic mobility was not due to differences in 
subunit size of the reduced mutant, wt and plasma VWF (Fig. 5). Most likely it 
reflects a conformational change associated with the formation of N-terminally 
linked dimers by the VWF-C2773S subunit. 
All three cysteine mutations that we have studied have impaired C-terminal 
dimerization as evidenced by excess of VWF monomer observed in media and 
lysates (Fig. 2) and the disrupted multimerization (Figs. 2 and 3). Furthermore, the 
C2773S and C2754W mutant proteins display VWF dimers despite the C-terminal 
dimerization defect (Figs. 2-3 and 4B). Utilizing ADAMTS13 proteolysis of VWF in 
combination with SDS-PAGE and immunoblotting with polyclonal and monoclonal 
antibodies, we could demonstrate that these mutant VWF dimers are the result of 
N-terminal dimerization (Fig. 4). The dimerization defect at the C-terminus of 




and N-terminally formed VWF dimers (Nd) and almost no C-terminally linked 
VWF dimers (Cd) (Fig. 4). The majority of the VWF-C2773S dimers are thus formed 
through interchain disulfide bonds at the N-terminus. The detection of low 
concentrations of tetrameric VWF-C2773S in the media of single transfected cells 
(Fig. 2) suggests the participation of more than one cysteine residue in 
dimerization in the CK domain of VWF which supports the model proposed by 
Katsumi et al. (3) where three cysteine residues (C2771, C2773 and C2811) sustain 
dimerization rather than C2773 alone. The mutation of cysteine 2773 has 
previously been shown to have a slightly greater impact on dimerization than 
mutation of cysteine 2771. While recombinant expression of a full-length VWF 
construct encoding VWF-C2773R resulted in the secretion of tetramers (7), 
expression of VWF-C2771S and VWF-C2771Y led to the secretion of octamers (10). 
In fact, when C2811 was mutated to an alanine in a C-terminal VWF construct (aa 
2720-2813), recombinant dimers of VWF were still secreted while altering either 
C2771 or C2773 to an alanine prevented VWF from dimerization (3). These data 
indicate that the cysteines at position 2771 and 2773 play a key role in the 
dimerization of VWF and that the cysteine positioned at 2811 most likely only has 
a minor contribution to normal dimerization of VWF. 
Recombinant VWF-C2754W also forms N-terminal dimers, but based on the 
ratio of dimers formed at the C- and N-terminus (Cd and Nd) the ability of C2754W 
to dimerize at the C-terminus seems less compromised than for VWF-C2773S. This 
may be explained by the fact that C2754W is not directly involved in the 
dimerization through interchain disulfide bonds (3), but probably hampers 
dimerization through conformational changes of the VWF monomer. The 
conclusion that rVWF-C2754W has more residual C-terminal dimerization 
capacity than rVWF-C2773S is also supported by the fact that single transfections 
of C2754W show a considerable amount of trimers. The other type 3 VWD 
mutation C2739Y also shows trimers in cell lysates of single transfections (Fig. 2). 
The formation of trimers requires N- as well as C-terminal disulfide bond 
formation. However, rVWF-C2773S does not show trimers in single transfection 
experiments indicating a strong preferential formation of N-terminal disulfide 
bonds. The formation of tetramers and no trimers for rVWF-C2773S (Fig. 2) may 
be explained by the abundance of monomeric rVWF-C2773S in comparison to the 
minute amounts of dimeric rVWF-C2773S in the ER. In the Golgi rVWF-C2773S 
dimers are outnumbered by monomeric rVWF-C2773S leading to the addition of 
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C2773S monomers by multimerization which results in the generation of 
tetramers. 
Based on the different characteristics of mutated cysteines in the CK domain 
involved in either type 2A(IID) or type 3 VWD, we propose the following model to 
explain the differences in phenotype. So far, the mutated cysteines in the CK 
domain identified in type 2A(IID) VWD are all involved in the formation of 
interchain disulfide bonds while all the cysteines mutated in type 3 VWD are 
involved in forming intrachain disulfide bonds. Disruption of an intrachain 
disulfide bond severely affects the conformation of the VWF monomer. Due to this 
conformational change, the mutant VWF is retained in the cell and probably 
cannot efficiently dimerize in the ER and pass through to the Golgi. The abnormal 
intracellular processing is illustrated by our finding of only proVWF and not 
mature VWF in lysates of transfections with C2739Y and C2754W (Fig. 5). This 
intracellular retention results in a quantitative reduction of VWF, mimicking a 
null allele. In the homozygous situation this leads to nearly complete absence of 
VWF. In the heterozygous state this leads to a reduction of about 50% of VWF as 
most of the mutant subunits will be retained in the ER, but the normal VWF 
dimers (from the normal allele) will be transported to the Golgi and form normal 
multimers. The small amount of mutant monomers that do pass to the Golgi can 
contribute to the formation of odd-numbered multimers by N-terminal pairing as 
we have shown before (12). In heterozygous carriers or co-transfections of wt 
with mutant C2739Y or C2754W constructs, the minute amount of mutant subunit 
that passes the ER to participate in multimerization in the Golgi would be 
outnumbered by the large majority of wt subunits. Consequently, this would not 
lead to a dominant negative effect (12). In this model, loss of cysteines in the CK 
domain that are involved in intrachain bonds will lead to a recessive, quantitative 
VWF deficiency, i.e., type 3 VWD. 
On the contrary, alterations of cysteines involved in interchain bonds are not 
expected to have a severe effect on the secondary structure of the VWF monomer. 
Although loss of these cysteines results in a dramatic decrease in the ability to 
form C-terminal dimers, these mutant subunits can pass from the ER to the Golgi. 
VWF dimers may then be formed through dimerization at the N-terminus (Fig. 4). 
Co-expression of wt and mutant alleles (as in heterozygous patients) would result 
in a mixture of normal dimerization at the C-terminus of wt VWF and addition of 




and 3). This leads to the characteristic type 2A(IID) multimer pattern in which 
further multimerization is halted by the addition of monomeric mutant subunits 
to the N-terminus of the growing multimer. This leads to a dominant negative 
effect on the multimerization as the number of mutant monomers transported to 
the Golgi is relatively high. The effect is progressive with increasing amounts of 
mutant in co-transfections as illustrated in Fig. 3. In this model loss of cysteines in 
the CK domain involved in formation of interchain bonds will lead to a dominant 
negative defect of VWF with abnormal multimers, i.e., type 2A(IID) VWD. 
In conclusion, we have identified a novel mutation, C2773S, that causes type 
2A(IID) VWD. Furthermore, we have shown that mutations causing a dimerization 
defect at the C-terminus of VWF can form dimers through N-terminal pairing of 
VWF monomers. Based on quantitative and qualitative characteristics of mutated 
cysteines associated with type 2A(IID) and type 3 VWD, we propose that mutated 
cysteines in the CK domain of VWF will lead to a recessive, quantitative VWF 
deficiency if intrachain disulfide bonds are involved, and to a dominant negative, 
qualitative defect of VWF if interchain bonds are involved. 
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The number of patients receiving anticoagulant treatment with vitamin K 
antagonists (VKA) is still increasing and a substantial number of these patients 
experience major bleeding complications as a consequence of this therapy, 1-3% 
yearly (1,2). It is of utmost importance to prevent bleeding complications from 
anticoagulant treatment. Identification of risk factors for bleeding complications 
will help to improve the safety of VKA treatment. 
It is well known that the intensity of VKA treatment is the major 
determinant of the risk of bleeding in VKA-treated patients. However, other 
factors also contribute to the risk and play a significant role (1,3). In the search for 
novel risk factors associated with bleeding in VKA treated patients, the FACTORS 
(FACTors in ORal anticoagulation Safety) study was initiated (3). The FACTORS 
study is a case-control study including patients on VKA treatment that have 
(cases) or have not (controls) experienced major bleeding. The definition of major 
bleeding was: bleeding leading to death, hospitalization or a decrease of more 
than 1.25 mM of hemoglobin; intracranial bleeding; and muscle, joint, or 
intraocular bleeding. The indications for VKA treatment of the patients 
participating in the FACTORS study were atrial fibrillation, venous 
thromboembolism, post operative prophylaxis, mechanical heart valve, vascular 
surgery, and ischemic heart disease. In the study, cases and controls were 
recruited from the Thrombosis Services in Leiden and Amsterdam and they were 
matched for the indication of VKA treatment, age, gender, intensity and type of 
VKA (acenocoumarol or phenprocoumon). The FACTORS study was previously 
described in detail (3). It has been shown that high levels of soluble 
thrombomodulin (s-TM) are associated with an increased risk of bleeding (4). 
However, the risk was only linked to the highest quartile of s-TM in the FACTORS 
study (3). Thus additional, possibly novel genetic risk factors may play a role in 
the bleeding in patients treated with VKA. 
A candidate genetic risk factor is the von Willebrand factor (VWF) Y1584C 
polymorphism. This polymorphism was shown to be linked to increased 
susceptibility of VWF to proteolysis by ADAMTS13 (5). The VWF Y1584C 
polymorphism was found at a frequency of 1% (heterozygotes) in two different 
cohorts of normal individuals (2/200 (5) and 1/100 (6)). A much higher frequency 




patients in a Canadian study (6). However, the polymorphism did not always 
co-segregate with VWD and some of the heterozygous carriers were unaffected 
and showed normal VWF antigen (VWF:Ag) levels and VWF multimer patterns 
(5,6). Even in the presence of normal VWF:Ag levels this polymorphism may affect 
the formation of the platelet plug through increased in vivo proteolysis of VWF 
multimers under shear stress as suggested by Bowen et al. (5). Hence, the effect of 
this polymorphism on VWF multimer survival in vivo and primary hemostasis may 
be substantial. Consequently it may modulate the risk for bleeding and may be 
considered a potential general risk factor for bleeding, particularly in patients 
already hemostatically challenged by VKA treatment. 
 
Materials and methods 
To investigate whether VWF Y1584C is indeed associated with bleeding, we 
screened 327 patients from the FACTORS study for the presence of the VWF 
Y1584C polymorphism; 110 of these were patients with bleeding episodes during 
VKA treatment (cases) and 217 were patients without bleeding episodes during 
VKA treatment (controls). 
The screening was performed on genomic DNA by amplification of exon 28 
by PCR with a forward oligonucleotide specific for the VWF gene, 5'-TGG 
TTCTGGATGTGGCGTTC (complementary to nts 24/1015-1034), and a reverse 
oligonucleotide, 5'-CAAGGCCATGCCAGCCCTCG (complementary to nts 24/ 
1622-1641, numbering according to Mancuso (7)). The use of a gene-specific 
oligonucleotide prevents inadvertent co-amplification of the VWF pseudogene. 
Subsequently, the 627 bp PCR product was digested with the restriction enzyme 
Acc65I. Homozygosity for the common allele would yield two fragments of 269 and 
358 bp, whereas heterozygosity would yield three fragments of 269, 358 and 627 
bp, due to the loss of the Acc65I site in the 1584C allele. 
 
Results and discussion 
In the population of 327 individuals, two patients that were included because of 
bleeding (cases) were heterozygous for the polymorphism (Table I). The first 
patient was an 81-year old male using VKA for atrial fibrillation and who had 
experienced gastrointestinal bleeding. His VWF:Ag level was 196%. The second 
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patient was a 68-year old female who received VKA for atrial fibrillation and 
ischemic stroke. She experienced muscle hemorrhage and her VWF:Ag level was 
155%. No heterozygotes were observed in the control group of 217 individuals 
that did not experience major bleeding. 
In conclusion, we present some evidence that the VWF Y1584C 
polymorphism may be associated with bleeding in VKA-treated patients. 
However, because of the rarity of this polymorphism in our population, a much 
larger group of patients and controls would be required to assess reliably the 
bleeding risk associated with this polymorphism. In the two patients tested 
positive for the Y1584C polymorphism VWF levels were high. Although the 
polymorphism was previously found to be associated with type 1 VWD (5), it can 
not be considered a causative VWD mutation. The contribution to bleeding risk in 
other patient categories than those treated with VKA remains to be determined. 
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Table I: Distribution of the VWF Y1584C polymorphism in cases and controls 
VWF Case Control OR* CI 95%‡ 
 Bleeding + Bleeding –   
YY1584 108 217 1†  
YC1584 2 0 ∞ 0.37-∞ 
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Since the publication in 1926 by Erik von Willebrand on "hereditary 
pseudohemophilia" the lack of functional von Willebrand factor (VWF) has been 
identified as the cause of this bleeding disorder (1-3). This factor has been shown 
to play an important role in both primary and secondary hemostasis. In primary 
hemostasis, it functions as a molecular glue between platelets and subendothelial 
structures (reviewed in (4,5)); in secondary hemostasis it shields FVIII from 
premature activation and inactivation by proteases and from receptor-mediated 
clearance (6-8). 
Von Willebrand disease (VWD) is the most common bleeding disorder in the 
population. It is characterized by symptoms ranging from very mild to severe 
bleeding, and is caused by alterations in the very large VWF gene. These may 
influence the level of VWF (quantitative defect; type 1 or type 3) or may affect the 
function of VWF (qualitative defect; type 2A, 2B, 2M, 2N) (9). To yield functional 
VWF, correct processing is paramount. Especially important is the formation of 
disulfide linked bonds. Intrachain linking is essential for the monomer structure. 
Interchain linking between the CK domains of two monomers is required for 
dimerization and interchain linking across D3 domains of proVWF dimers is 
necessary for multimerization. All cysteine residues in the mature VWF subunit 
(169 or 8.2%) participate in these intra- or interchain disulfide bonds (10). The 
interaction between proVWF dimers ultimately yields high molecular weight VWF 
that is active in primary hemostasis in the bloodstream. 
The main aims of the studies reported in this thesis were to examine how 
loss of cysteines located in different domains of VWF results in quantitative and 
qualitative VWF defects; how these mutations interfere with dimerization and 
multimerization; and how they influence intracellular routing, secretion and 
clearance of VWF. The effects of mutated cysteines in different domains of VWF 
are reported in Chapters 2-5. Finally, in Chapter 6 we evaluated whether the 
additional cysteine in carriers of the Y1584C mutation in VWF is associated with 





Cysteine mutations in the CK domain 
The 151 C-terminal amino acids in VWF are sufficient to support dimerization of 
proVWF molecules in the endoplasmic reticulum (ER) (11). The 90 most 
C-terminal amino acids comprise the cystine knot (CK) domain (12). This is a motif 
that is common in proteins that form dimers and oligomers. In VWF this motif 
consists of 11 cysteine residues of which eight are involved in intrachain disulfide 
bonds forming a ring-like structure and of which the remaining three are 
suggested to form interchain disulfide bonds supporting dimerization. 
We were intrigued by the fact that replacement of cysteine residues in the 
CK domain causes two completely different VWD phenotypes. Loss of cysteines 
C2739 (13), C2754 (14), C2804 (15), and C2806 (16) results in type 3 VWD with 
nearly complete absence of VWF and loss of C2771 (17) and C2773 (18) results in 
type 2A(IID) VWD with a structural defect of VWF (Fig. 1). Interestingly, we 
noticed that cysteines described in type 3 VWD are all involved in intrachain 
disulfide bonds, whereas those in type 2A(IID) VWD are proposed to be involved in 
formation of interchain disulfide bonds (12). How missense mutations result in a 
quantitative defect is an especially intriguing aspect, since point mutations are 
not expected to either affect the stability of mRNA or translation and thus do not 
provide a straightforward mechanism for a quantitative defect. 
We therefore hypothesized that loss of intrachain disulfide bonds may result 
in a conformational change leading to a quantitative VWF defect when the mutant 
monomer is retained in the ER and subsequently degraded. This would mimic the 
phenotype of a null allele. We further hypothesized that loss of an interchain 
disulfide bond has less impact on the monomer structure of VWF allowing both 
mutant and normal VWF to enter the Golgi and participate in random 
multimerization. This would explain the dominant negative effect that these 
mutations have on multimerization of VWF and the occurrence of odd-numbered 
VWF multimers in the plasma of heterozygous type 2A(IID) patients. Furthermore, 
it would explain the strictly qualitative effect on VWF as only a minor amount of 





Quantitative and qualitative VWF defects: Intrachain versus interchain disulfide bonds 
Type 3 VWD 
Expression studies by us (Chapter 2a) and by Schneppenheim and colleagues 
showed that missense mutations of cysteines could reproduce the quantitative 
VWF defect observed in type 3 VWD and thereby mimic the effect of a null allele 
(14,19). The quantitative defect appeared to be caused by the strong intracellular 
retention of the mutant protein (19), which is supported by the presence of only 
minute amounts of VWF in platelets (14). We observed that for mutant C2739Y 
and C2754W VWF only unprocessed proVWF was present intracellularly, while for 
the wt mature VWF as well as proVWF was observed (Chapter 5). This confirmed 
 
Fig. 1, localization in VWF of selected residues according to VWD phenotype. In 
this schematic overview of the VWF preproprotein, mutations which are located in the 
same domain and cause the same VWD phenotype (grey tabs) are grouped. 
Mutations are discussed in different sections of the text. Cysteines in the CK domain, 
for which no mutations have yet been found (bold), are arranged according to the 
predicted VWD phenotype, based on their role in the formation of intra- or interchain 
disulfide bonds. Signal peptide (SP), VWF-propeptide and mature VWF are indicated 
as well as the domains (A-D, CK) and regions involved in dimerization (CK domain; aa 
2724-2813) and multimerization (D'-D3 domains; aa 769-1242). Letters and numbers 





that loss of these intrachain bonds indeed severely affected the processing of 
proVWF subunits by preventing transport to the Golgi apparatus where removal 
of the VWF-propeptide occurs. The strong effect that loss of these disulfide bonds 
has on processing may be explained by their participation in the formation of the 
cystine knot in which intrachain disulfide bonds participate in a ring-like 
structure (12). The loss of this structure probably severely affects the monomer 
conformation resulting in a misfolded protein that is retained in the ER. 
Katsumi and co-workers identified the following intrachain disulfide bonds: 
C2724-C2774, C2750-C2804, C2754-C2806 and C2739-C2788 (12). Apart from the 
C2739Y and C2754W mutations (13,14,19), mutations of C2804 (15) and C2806 (16) 
have also been implicated in a type 3 VWD phenotype (Fig. 1). This further 
supports our hypothesis that intrachain disulfide bonds severely affect the VWF 
monomer structure since loss of either C2754 or C2806, which together form one 
intrachain disulfide bond, results in the same severe quantitative VWD 
phenotype. Additional evidence for our hypothesis is found in co-transfections of 
wt and mutant VWF (C2739Y or C2754W) leading to ~50% reduction of secreted 
VWF:Ag also mimicking the effects of a null allele (19). Mutations of cysteines 
C2724, C2750, C2774, or C2788 have not yet been reported. Our hypothesis, 
however, predicts that mutations at these positions all will result in a quantitative 
defect as seen in type 3 VWD. 
 
Type 2A(IID) VWD 
Not all cysteine mutations in the CK domain result in a quantitative VWF defect. 
Some result in a rare qualitative VWF defect, called type 2A(IID) VWD. Changes of 
C2771 to tyrosine or serine (17) and C2773 to arginine (18) were detected in this 
uncommon VWD phenotype (Fig. 1). The importance of both C2771 and C2773 in 
dimerization of VWF was stressed by the complete abolishment of the formation 
of VWF dimers due to the incorporation of either C2771A (12) or C2773A/R (12,18) 
in C-terminal fragments of VWF. In Chapter 5 we screened a family with type 
2A(IID) VWD anticipating to identify a mutated cysteine involved in an interchain 
disulfide bond. Indeed, in two affected individuals we identified a novel mutation 
of C2773S. 
In agreement with our hypothesis the introduction of the C2773S mutation 
in VWF did not lead to impaired expression or secretion of VWF (Chapter 5). In 




wt VWF. Similar results were observed in expression studies of C2773R VWF (14) 
and C2771Y/S VWF (17). Furthermore, the observation of both mature and 
proVWF C2773S in the intracellular compartment supports the idea that loss of 
interchain disulfide bonds only has a minor effect on conformation and the initial 
processing of proVWF (Chapter 5). Finally, all these mutations have a major effect 
on dimerization of VWF and subsequently on multimerization. This ultimately 
results in secretion of mainly monomers, dimers, tetramers, some trimers, and 
sometimes hexamers and octamers of VWF (Chapter 5) (14,17). 
In co-expression studies we and others were able to recreate the dominant 
2A(IID) VWD phenotype with its normal to high levels of VWF:Ag and peculiar 
VWF multimer pattern (Chapter 5) (17,20). This pattern is characterized by 
odd-numbered multimers located in-between the normal even-numbered 
multimers and loss of intermediate- and high molecular weight multimers (21). 
Together these data support our hypothesis that loss of interchain disulfide bonds 
in the CK domain only induces minor changes of the monomer conformation 
which results in a qualitative VWF defect in the heterozygous state. This is caused 
by the incorporation of the mutant monomer in the growing multimer in the 
Golgi apparatus, thus hampering further multimerization of VWF. 
Additionally, it may be interesting to investigate whether replacement of 
proline residues have a strong effect on the structure and conformation of the CK 
domain of VWF. This may result in a similar phenotype as loss of cysteine 
residues. To date only two such mutations have been reported in the VWF 
database (http://www.sheffield.ac.uk/vwf). These are the alteration of P2776 and 
P2781 to lysine and serine, respectively. They result in two separate phenotypes, 
the former leads to a quantitative VWF defect (type 1 VWD) while the latter 
results in a qualitative defect (type 2M VWD). The absence of additional data, 
expression studies and a three-dimensional structure of this region makes it hard 
to generalize the effects of such mutations on VWD phenotype. 
In summary, loss of intrachain bonds in the CK domain of VWF has been 
found to result in type 3 VWD in homozygous patients, whereas loss of interchain 
disulfide bonds results in type 2A(IID) VWD in heterozygous patients. 
Investigation of other cysteine residues in the CK domain may provide more clues 
as to whether the model that links loss of intrachain bonds to type 3 VWD and loss 




N- and C-terminal dimerization of VWF 
The observation of tetramers (C2773R/S) and even hexamers and octamers 
(C2771Y/S) of full-length VWF (Chapter 5) (14,17) indicated that although 
alteration of either C2771 or C2773 in VWF has a profound effect on dimerization 
of C-terminal VWF fragments (12,18) this effect is milder in full-length VWF. The 
difference in the effect of these mutations on dimerization of VWF between 
truncated (12,18) and full-length VWF (Chapter 5) (14,17) may possibly be due to 
additional interactions between two proVWF molecules in full-length VWF. These 
interactions may have a stabilizing effect on the conformation of the full-length 
protein and thereby facilitate the formation of disulfide bonds in the CK domain. 
This may not occur in truncated VWF and therefore result in stronger effects of 
the introduced mutations on dimerization of the truncated VWF protein than in 
the full-length version. 
The identification of VWF multimers higher than dimers of full-length C2771 
or C2773 VWF shows that C-terminal dimerization is still possible to some degree 
in full-length C2771Y/S (17) and C2773R/S VWF(Chapter 5) (14). This suggests 
either that two C2771 or two C2773 residues pair, or that C2771 pairs with C2773, 
in which case a third disulfide bond is expected (see below) and is necessary to 
explain the observed oligomers in the mutants. If dimerization would be solely 
dependent on either C2771 or C2773, the highest molecular weight species would 
be VWF dimers assuming that N-terminal pairing of mutant monomers will occur 
in the Golgi apparatus. N-terminal pairing was previously suggested by 
Schneppenheim et al. and Enayat et al. (14,17). It was, however, not directly 
demonstrated that C2771Y, C2771S or C2773R form N-terminal dimers. 
In Chapter 5 we addressed this issue by treatment of recombinant C2773S 
VWF with ADAMTS13. This will allow the separation of N-terminal and C-terminal 
fragments, which subsequently can be detected with specific monoclonal 
antibodies. As anticipated, N-terminal dimers and free C-terminal chains were 
readily detected, whereas C-terminal dimers of C2773S VWF were barely visible. 
This clearly shows that mutant C2773 is able to form dimers through N-terminal 
pairing in the Golgi and that the mutant subunit only has low residual binding 
capacity at the C-terminus, which explains the occasional formation of tetramers. 
In co-transfections of C2773S and wt, a mixed pattern of both N- and C-terminal 
dimers and free C-terminal chains was observed, indicating normal dimerization 




odd-numbered multimers in the heterozygous transfection indicates that mutant 
subunits also interact with the wt multimers in the Golgi apparatus, thus 
explaining the dominant negative effect on multimerization. 
 
CK structure 
Katsumi and co-workers suggested that neighbouring proVWF molecules are 
linked by either one or three interchain disulfide bonds involving residues C2771, 
C2773 and C2811 (12). They showed that residues C2771 and C2773 are crucial for 
dimerization of a CK VWF fragment while C2811 was not. Therefore, a model is 
favoured in which three cysteines rather than a single one form the interchain 
disulfide link needed for dimerization (12). How exactly these interchain disulfide 
bonds link these subunits is unknown. The model based on the crystal structure of 
transforming growth factor β2 (TGF-β2) which has a similar CK structure suggests 
crossed linkage between C2771 and C2773 of adjacent subunits and a C2811-C2811 
interchain bond (12). Even though the absolute requirement of C2771 and C2773 
and the minor effect of changes of C2811 are in line with this model, it does not 
explain the observation of up to octamers in homozygous transfections of C2771Y 
or C2771S (17) whereas only up to tetramers is observed in homozygous 
transfections of C2773R or C2773S (Chapter 5) (14). If crosslinkage occurs between 
C2771 and C2773 in two proVWF subunits, then the effect of C2771S and C2773S on 
dimerization and multimerization of VWF is expected to be similar, since in each 
case both bonds are lost. A comparative study utilizing the same expression 
system and multimer analysis of VWF still has to show whether this apparent 
milder effect of C2771Y/S on multimerization is biologically relevant or a result of 
the expression system. It is interesting to speculate whether the apparent milder 
effect of C2771Y/S is related to how C2771, C2773 and C2811 are linked. 
It may be that the structure of the VWF CK domain deviates more from the 
structure of TGF-β2, since the VWF CK domain lacks one of the TGF-β2 cysteines 
and contains four additional cysteines residues (12). In light of these differences, 
one may envisage that the three interchain disulfide bonds are formed between 
the corresponding cysteines of the two subunits, e.g., C2771-C2771, as opposed to 
the crossing-bonds model. If a C2771 or C2811 interchain bond is lost in this 
hypothetical model, this may have a smaller effect on the structure, still allowing 




bonds may have a stronger effect on the conformation of the protein. The 
three-dimensional structure of the CK domain is probably the only way to resolve 
this issue, since distinct separation of intrachain and interchain disulfide bonds 
using proteolytic fragments of VWF dimers is extremely difficult. 
 
Cysteine mutations in the D3 domain of VWF 
Several missense mutations of cysteine residues in the D3 domain that is required 
for multimerization (22) have been reported in the VWF mutation database 
(http://www.sheffield.ac.uk/vwf). Interestingly, these mutations lead to different 
phenotypes. Some cause quantitative defects: C1130F and C1149R (type 1 VWD, 
(23)) and C1071F (type 3 VWD, (24)); others cause qualitative defects: C1060R (type 
2N VWD, (25)), C1153Y and C1173R (type 2A (IIE), (26,27)); C1101R/W, C1157F, 
C1196R and C1234W cause as yet unclassified VWD phenotypes (http:// 
www.sheffield.ac.uk/vwf, unpublished data) (Fig. 1). 
Although type 1 VWD patients represent the largest group of VWD cases, 
only few mutations had been reported until recently. This has changed since the 
start of the European multicentre study "Molecular and Clinical Markers for 
Diagnosis and Management of Type 1 VWD" (MCMDM-1VWD) which aimed to 
characterize the genotype-phenotype relationship in type 1 VWD. The study led 
to the identification of 126 candidate mutations throughout the VWF gene (28). 
The majority of these (81%) are missense mutations and of these 29% are found in 
the D' and D3 domains. Some amino acids have a higher mutation frequency than 
others. Interestingly, one of those is C1130, which was altered to three different 
amino acids, namely glycine, arginine and phenylalanine (28). The clinical 
penetrance of the C1130G/R/F mutations was very high in the investigated 
families (93%) (29). The patients were characterized by very low VWF:Ag levels 
(MCMDM-1VWD, personal communication). This is in line with the dominant 
effect of mutations described in type 1 VWD patients (23,29). A similar phenotype 
has been described for C1149R (23). Our hypothesis that the strikingly low VWF:Ag 
level in patients with these mutations is caused by an interaction of mutant, 
C1130F or C1149R, and wt VWF subunits resulting in intracellular retention, was 
only partly supported in expression studies of these proteins (Chapter 2a) (19). 
Our results and those of the MCMDM-1VWD study showed normal synthesis and 




contributed to the decreased secretion of VWF. Firstly, intracellular retention of 
C1130F or C1149R homodimers, and heterodimers of wt and these mutant proteins 
(19,23,31), and secondly, proteasomal degradation of retained wt and C1149R 
heterodimers (31). Although loss of C1130 and C1149 do affect secretion and 
retention of VWF, the moderate effects in in vitro culture cannot explain the 
strikingly low levels of VWF in heterozygous patients. This suggests that other 
factors like in vivo clearance may contribute to the type 1 VWD phenotype 
(Chapter 3) (32). 
All mutations, C1130G/R/F and C1149R, are associated with the absence of 
HMW multimers in plasma (19,30). In co-transfections of wt and C1130F or C1149R 
VWF, the observed small reduction in the HMW multimers seems to be in 
accordance with the plasma multimer pattern in patients (19,23). Multimerization 
of VWF is facilitated by the VWF-propeptide and occurs under slightly acidic 
conditions (pH<6.5) in the Golgi apparatus (4,33). In Chapter 3 the interaction of 
C1130F and C1149R VWF with the VWF-propeptide was studied at different pH 
(32). The interaction was severely reduced at all pHs (5.2-7.4) which may explain 
the observed multimerization defect in vitro as well as in vivo (32). The effects of 
the C1130F and C1149R mutations may stretch even further considering the 
crucial roles of the D'-D3 domain of VWF in the interactions with the 
VWF-propeptide and P-selectin. The former interaction facilitates storage of VWF 
to Weibel-Palade bodies (WPB) (33); through the latter, P-selectin is recruited to 
WPBs (34). P-selectin may have a key role in in vivo cleavage by anchoring released 
ultra-large VWF multimers and thereby facilitating their unfolding and 
subsequent cleavage by ADAMTS13 (35). Finally, the physiological function of 
VWF was suggested to depend on its tubular storage in endothelial WPBs (36). It 
was proposed that these tubules are VWF multimers coiled into a constrained 
spring at low pH which requires a pH-dependent interaction of the 
VWF-propeptide with VWF, and that, upon exocytosis, dissociation of the 
VWF-propeptide-VWF complex allows unfurling of VWF tubules to long 
platelet-catching VWF filaments. This new mechanism could explain the rapid 
exocytosis of ultra-large VWF without generating tangled VWF filaments. 
Since obstruction of the above described interactions would probably affect 
the function of VWF in the bloodstream, it would be interesting to further 
investigate the C1130F, C1149R and other missense mutations in the D'-D3 




and the VWF-propeptide, which may affect storage of VWF in WPBs, resulting in 
tangled VWF instead of organized VWF tubules (36). Upon exocytosis, tangled 
VWF may be less capable of recruiting platelets (36). However, if the mutations do 
not interfere with the tubular storage of VWF, but instead affect its binding to 
P-selectin then ultra-large VWF may be secreted, potentially with thrombogenic 
effect (34,35). Alternatively, mutations leading to increased affinity of VWF to 
P-selectin may result in rapid cleavage of ultra-large VWF to LMW species (35,37), 
which are less efficient in recruiting platelets (36) and may have a negative effect 
on the ability of VWF to support primary hemostasis.  
Another important problem that has to be tackled is the troublesome 
discrimination between the diagnosis of type 1 or type 2 VWD of these patients, 
which often depends on the generation of a reliable and reproducible multimer 
pattern. Standardization of multimer analysis by the European Study of type 1 
VWD has facilitated this discrimination and showed that mutations C1130G/R are 
associated with subtle multimerization defects in patients previously diagnosed 
with type 1 VWD (30). Although the quantitative defect is the most prominent 
phenotype in these patients, the multimer patterns of the index cases were 
abnormal with a relative decrease or even absolute loss of HMW multimers which 
points to a qualitative type 2 (IIE) VWF defect (MCMDM-1VWD, personal 
communication). Incorrect diagnosis may result in an overestimation of the type 1 
VWD patient group at the expense of the type 2 VWD group and more importantly 
it may affect the choice of treatment for these patients.  
Interestingly, the MCMDM-1VWD study also suggested that the C1130F/R 
mutations may not only affect quantity and quality of VWF multimers, but may 
also have an effect on VWF:FVIII binding activity (VWF:FVIIIB) (38). This is in line 
with our findings of reduced VWF:FVIIIB of C1130F and C1149R in Chapter 3 (32). 
The FVIII binding site is located in the amino-terminal 272 aa residues of VWF 
(39). Other cysteine mutations in the D3 domain have been reported to have 
reduced or absent FVIII binding activity (40-42). C1060R (40), C1157F (42), C1225G 
(41) and C1234W (42) affect the affinity of VWF to bind FVIII to a varying degree 
suggesting that missense mutations located outside the FVIII binding site itself 
(39) change the affinity for FVIII, possibly due to conformational changes. The 
C1060R, C1157F and C1234W mutations all showed a strong effect on 
multimerization resulting in loss of HMW multimers, whereas C1225G only leads 




cysteine residues that has been suggested to be involved in an interchain disulfide 
bond (43,44). This suggests that mutations of cysteines involved in the formation 
of interchain disulfide bonds do not affect the three-dimensional structure of the 
protein to the same extent as mutations of cysteines involved in intrachain 
disulfide bonds. 
The number of interchain disulfide bonds in the D3 domain is uncertain since 
it is not clear for all cysteine residues in this domain whether they participate in 
an inter- or intrachain disulfide bond. This makes it highly speculative to predict 
the effects of these mutations on biosynthesis, multimerization or FVIII binding 
capacity to their possible involvement in inter- or intrachain bond formation. 
However, the effects of these mutations and the relation to their involvement in 
inter- or intrachain disulfide bonds remains an interesting question that may be 
answered by the resolution of the crystal structure of VWF or VWF domains 
which will reveal the true number and location of cysteine bonds linking the 
separate VWF subunits as well as the intricate web of intrachain disulfide bonds. 
 
Cysteine mutations outside the CK and D3 domains 
C2362F VWF 
The C2362F mutation has been identified in several Italian families with an 
autosomal recessive severe quantitative VWF defect (45). It is located in the B3 
domain of VWF to which so far no specific structural or functional property has 
been assigned (Fig. 1). Only one other cysteine mutation has been found in this 
region, C2304Y, which is located in the neighbouring B1 domain and leads to a 
partial quantitative defect of VWF (46). 
The C2362F (Chapter 4) (47) as well as the C2304Y (46) mutation results in 
poor secretion and strong intracellular retention of VWF, which completely 
explains the quantitative VWF defect observed in patients homozygous for C2362F 
(47). This was unexpected since increased in vivo proteolysis has been suggested to 
contribute to the quantitative defect (48). Both mutations had similar effects on 
processing of VWF resulting in lack of HMW and IMW VWF multimers (46,47). 
Unfortunately, no data on co-expression of wt and C2304Y VWF have been 
published until now. This makes it difficult to identify a common effect of 




Our results suggest that the major contributor to the quantitative defect is 
the loss of the disulfide bridge in which C2362 normally participates (47). This is 
presumably an intrachain disulfide bond since this region is not involved in 
dimerization or multimerization of VWF. Loss of this covalent bond most likely 
induces a conformational change hampering processing of mutant proVWF to 
mature VWF, as suggested by the relative abundance of proVWF in cell lysates 
(47), and resulting in intracellular degradation of most of the mutant protein. This 
is supported by undetectable and barely detectable VWF:Ag in platelets of 
patients homozygous or compound heterozygous for the C2362F mutation, 
respectively, whereas it was readily detectable in platelets of a heterozygous 
subject (47). Support for a conformational change is obtained from the alteration 
in electrophoretic mobility of recombinant as well as the plasma C2362F VWF 
multimers, while no size difference between wt and mutant VWF subunits of 
reduced VWF was observed (47). Interestingly, such an increase in electrophoretic 
mobility of the mutant protein was also observed for C2304Y VWF in the 
MCMDM-1VWD study (46). A conformational change of the VWF mutant subunit 
may explain the quantitative defect through intracellular retention and 
degradation of VWF (47). The smeary VWF multimer pattern observed in the 
plasma of the homozygous patient may also be explained by the altered cysteine 
residues in VWF as has been reported previously (27). 
We were unable to detect increased in vivo proteolysis of the mutant C2362F 
subunit by ADAMTS13 (47). However, a system utilizing a more physiological 
setting, e.g., unfolding VWF by shear flow instead of urea, may be capable of 
detecting a subtle increase in susceptibility to this protease that is overlooked in 
the rather crude approach of chemical unfolding of VWF. Although the decreased 
half-life of endogenous C2362F VWF supports the suggestion of increased 
clearance via a receptor or proteolysis, further investigation of the contribution 
of these factors to the quantitative defect is probably of limited value since the 
level of secreted C2362F VWF is already very low (47). It is still puzzling how the 
very low VWF:Ag observed in these patients results in a sustained high level of 
FVIII:C even four hours after initiation of DDAVP infusion (47,49). This aspect 
remains especially intriguing, considering the normal binding affinity of C2362F 






The C2671Y mutation (Chapter 2a) is located in the connecting region between 
the C2 and the CK domain of VWF (Fig. 1). It was found in a patient with type 3 
VWD who was compound heterozygous for C2671Y and a complete deletion of the 
other allele (50). In this region only one other cysteine mutation, C2693Y, has 
been identified in a patient with type 1 VWD in the MCMDM-1VWD study 
(personal communication). Surprisingly, expression studies of C2671Y VWF did 
not at all reproduce the severe quantitative defect that was observed in the 
patient (19). Co-expression of wt and C2671Y VWF generated a normal multimer 
pattern which was also observed in the patient heterozygous for the C2693Y 
mutation, confirming that C2671 and C2693 are dispensable for dimerization (19). 
These two cysteines are most likely involved in intrachain bonds since they are 
located just outside the CK domain. To evaluate whether alterations of cysteines 
in this part of VWF have less impact on routing of VWF in general it would be 
interesting to compare the effects that loss of C2671 and C2693 have with the 
remaining five cysteines in this area. 
The effect that the loss of an intrachain disulfide bond may have depends on 
its importance in the determination of the local and overall protein structure. If 
one assumes, e.g., that the disulfide bond with C2671 only results in a minor 
change in the structure of VWF, then the effect on the level of VWF may be 
limited too. The compound heterozygous proband (C2671Y/deletion) with very 
low VWF:Ag (0.02-0.04 U/mL) showed increased levels of the VWF proteolysis 
products of 189, 176 and 140 kDa in patient plasma (50,51). These data suggested 
that other mechanisms than decreased synthesis and secretion of VWF, such as 
increased in vivo clearance and/or increased proteolysis of VWF may be involved 
in the development of the severe phenotype. The contribution of several aspects 
of clearance, such as ADAMTS13 cleavage, and survival of endogenous C2671Y 
VWF as well as recombinant C2671Y in a murine model was studied in Chapter 3 
of this thesis and will be discussed later. 
 
The impact of amino acid identity on VWD phenotype 
Strikingly, the majority of the cysteine mutations reported in the human VWF 




charged amino acid residues (Chapter 2b). We hypothesized that the replacement 
of a cysteine residue with such amino acids may introduce disadvantageous 
effects on the conformation of the protein in addition to the loss of the cysteine 
bond. These changes may affect the biosynthesis and secretion of VWF. 
To investigate this hypothesis we studied the differential effect of alteration 
of C2362 to alanine instead of phenylalanine (Chapter 4) (47) and of C2671 to 
alanine instead of tyrosine (Chapter 2b). We found that alteration of C2671 to an 
alanine indeed resulted in a slightly higher secretion of VWF compared to the 
C2671Y mutation (Chapter 2b). The observed decrease of intracellular retention of 
VWF was however not statistically significant. Both mutant proteins showed an 
indistinguishable multimer pattern on sodium dodecyl sulfate agarose gel 
electrophoresis. Apparently, loss of C2671 and its disulfide bond is the key 
contributor to the decreased level of VWF secreted and not necessarily the 
introduction of a tyrosine residue. Similar results were obtained for the C2362F 
and C2362A mutations (47), even though the C2362F mutation is not located in the 
same domain of VWF as C2671. The comparison of these two cysteines suggests 
that the introduced amino acid side chain does not introduce additional, 
detrimental conformational changes. However, the effect that alterations of 
cysteine residues to bulky, charged or small and uncharged residues have, may 
rely on the exact position of the cysteine in VWF and whether the cysteine in 
question forms an intrachain bond with a nearby or distant partner. A more 
general estimation of such effects would require the study of several cysteines at 
different positions and separate domains including alterations to an alanine, 
glycine and serine to allow a better understanding of a possible additional effect 
of introduced amino acid side chain. 
 
Clearance of VWF 
In Chapter 3 we investigated whether missense mutations of cysteine residues 
could result in increased clearance. We showed that the discrepancy observed 
between the relatively high levels of recombinant C1130F, C1149R and C2671Y 
VWF secreted in vitro and the distinct decrease of plasma VWF:Ag observed in vivo 
(19) may be explained by increased clearance of mutant VWF (32). The increase in 
clearance was not explained by increased susceptibility to ADAMTS13 cleavage of 




R1205H and the S2179F mutation, which is located in the D4 domain of VWF, also 
result in increased clearance of VWF (Fig. 1) (52,53). This indicates that single 
point mutations in several specific regions of VWF may result in increased 
clearance of VWF possibly by allosteric effects on receptor-mediated clearance. 
Unfortunately, functional characterization of C1130F, C1149R, R1205H and C2671Y 
did not reveal any specific regions in VWF that could be involved in such 
enhanced clearance (32). However, increased clearance of VWF may still be an 
interesting contributor to the type 1 VWD phenotype as observed by Brown and 
co-workers (54). They assessed the half-life of VWF:Ag after infusion of DDAVP in 
patients with type 1 VWD or mild hemophilia A. Firstly, they found a two-fold 
reduction in the median half-life of VWF in the type 1 VWD patient group 
compared with the mild hemophilia A group. Secondly, they found lower baseline 
levels of VWF:Ag to be associated with a reduced half-life of VWF. This suggests 
that increased clearance may be the pathogenic mechanism in some cases of type 
1 VWD. Further studies of those type 1 VWD patients and their families is 
necessary to reveal whether the increased clearance is due to a mutation in the 
VWF gene, the glycosylation status of VWF or whether it is a consequence of 
intrinsic high clearance of the patients. Infusion studies of VWF in these patients 
could exclude the latter as the causative factor. The contribution of alterations in 
the VWF gene can then be assessed in the murine model, possibly revealing 
specific regions to be involved in this mechanism. If no mutations are present, 
this indicates that, as observed for many type 1 VWD patients, other factors may 
be involved such as the glycosylation of VWF (ABO group, sialylation (55)) or 
other modifying loci. This may be the case in as many as one third of the patients, 
in which no VWF gene defect was detected in the MCMDM-1VWD study (28). 
There is an ongoing discussion whether these patients should be classified as type 
1 VWD, since the low VWF levels are not correlated with mutations in the VWF 
coding sequence (28), but they are more likely the result of the large variation of 
VWF:Ag levels in the normal population (56) which is caused by ABO blood group 
and possibly some other loci. 
 
Y1584C polymorphism in VWF 
Alterations of amino acid residues that introduce or replace a cysteine residue 




are normally involved in disulfide bonds. These unpaired cysteines may interfere 
with the normal paring scheme by the introduction of alternative disulfide bonds, 
thereby possibly affecting structure and function of the protein. In this view it is 
also interesting to evaluate the effects that introduction as well as loss of 
cysteines may have on expression, secretion and survival of VWF. 
The alteration of tyrosine 1584 to a cysteine was initially detected in a type 
2A VWD patient compound heterozygous for Y1584C and S1506L (57). Y1584C was 
reported to be a polymorphism rather than a candidate mutation, since it was 
found in three unaffected family members as well as in 3% of normal individuals 
(57) (Fig. 1). Recently, heterozygosity for this polymorphism has been found at a 
high frequency in affected participants in Canadian (14%), UK (25%) and European 
(8%) studies of type 1 VWD (28,29,58,59). However, the polymorphism has been 
detected at a low frequency in the general population in the Canadian (1%) and 
the European (0.4%) type 1 VWD studies (29,58). This difference in frequency 
suggests that Y1584C may be a candidate mutation rather than a polymorphism. 
The effect of this candidate mutation in relation to type 1 VWD is unclear; since 
co-expression experiments of the Y1584C mutation indicated only a mild effect on 
secretion and intracellular retention of VWF (58); since the Y1584C mutation does 
not always co-segregate with the type 1 VWD phenotype (58-60); and since 
increased susceptibility of VWF to proteolysis by ADAMTS13 co-segregates 
completely with the Y1584C mutation in unaffected as well as affected individuals 
(59,61). Even though this indicates that Y1584C may not be a causative mutation, 
it still may increase the risk of bleeding in type 1 VWD, especially in combination 
with blood group O which is prevalent among type 1 VWD patients (59,60). 
To evaluate whether the Y1584C mutation itself is a mild risk factor for 
bleeding we screened cases and controls in the FACTors in ORal anticoagulant 
Safety (FACTORS) study for the presence of this mutation (Chapter 6) (62). The 
study includes patients on vitamin K antagonist (VKA) treatment that have (cases) 
and do not have (controls) experienced major bleeding and was initiated to search 
for novel risk factors associated with bleeding in VKA treated patients (63). 
However, due to the limited size of the study and the low frequency of the 
mutation we were not able to obtain a reliable estimate of the contribution of this 
mutation to the bleeding risk (62). Our results, however, do not exclude that this 




It is intriguing that one individual with the Y1584C mutation and blood 
group O has the type 1 VWD phenotype whereas another does not (58). This 
suggests that other factors contribute to the difference in phenotype. Possibly the 
activity of the ADAMTS13 protease may differ between these individuals and tip 
the balance (64). It remains to be shown whether the Y1584C mutation and blood 
group O affect proteolysis of VWF in a negative manner under physiological 
circumstances. If so, it would be interesting to evaluate the contribution of these 
factors to the risk of bleeding and the protective effect they may have in 
development of arterial thrombosis and cardiovascular disease (64). 
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Von Willebrand factor (VWF) is a large plasma protein with essential functions in 
primary hemostasis. It is vital for the generation of a platelet plug as it has the 
ability to adhere to exposed extracellular matrix such as collagens at the site of 
injury and to then capture platelets. This leads to adhesion and subsequent 
aggregation of the platelets generating a seal of the injured area. This plug is 
reinforced by the insoluble fibrin fibres which are generated via localized 
activation of the coagulation cascade. Although VWF itself is not directly involved 
in this cascade it is important for this process as it functions as a carrier of 
factor VIII which is an important co-factor in this cascade. Loss of functional VWF 
leads to a bleeding disorder called von Willebrand disease (VWD). The severity of 
this disease varies widely and depends on the type of VWF defect. VWD is divided 
into quantitative and qualitative VWF defects. Type 1 VWD corresponds to partial 
loss of VWF, while type 3 VWD corresponds to almost complete loss of VWF. 
Type 2 VWD encompasses all qualitative dysfunctions of VWF. 
VWF contains a large number of cysteine residues which all form either 
intrachain or interchain disulfide bonds. Intrachain disulfide bonds are important 
for the structure of the individual subunit, the monomer, while interchain 
disulfide bonds are crucial for the generation of high molecular weight (HMW) 
multimers. In the endoplasmic reticulum (ER), two proVWF monomers are linked 
via interchain disulfide bonds between the cystine knot (CK) domains (the 90 
C-terminal amino acids) to form dimers. HMW multimers of VWF are formed in 
the Golgi where proVWF dimers are linked via interchain bonds between cysteine 
residues in the D3 domain of VWF. The multivalency of this protein is of utmost 
importance for its function as a molecular glue between exposed subendothelial 
structures and the rapidly passing platelets. Ultra-large VWF multimers are stored 
in α-granules of platelets or in Weibel-Palade bodies of endothelial cells and can 
be secreted on demand. A detailed introduction to the biosynthesis of VWF, its 
structure and function, its role in hemostasis and a description of the different 
types of VWD is given in Chapter 1. 
The main goal of the research described in this thesis was to investigate the 
effect that missense mutations of cysteine residues in different domains of VWF 
have on dimerization and multimerization of VWF, how these mutations 
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influence the intracellular routing and secretion of VWF, and how this can result 
in the generation of quantitative or qualitative VWF defects. 
In Chapters 2-5 the effects of mutated cysteines in different domains of VWF 
were studied by expression of the full-length human VWF protein in a human 
kidney cell line, 293T cells. In all of these studies single transfections as well as 
co-transfections of the wild-type (wt) and mutant constructs were performed. 
Subsequently, the quantity and quality of the secreted and the intracellular 
recombinant VWF protein were analyzed by ELISA and SDS-agarose 
electrophoresis and in some instances VWF was reduced and separated by 
SDS-polyacrylamide gel electrophoresis.  
In Chapter 2a the effects of five cysteine mutations, that all were found in 
patients with a quantitative defect of VWF, were investigated. The effects of these 
mutations on dimerization and multimerization and the quantity of produced 
VWF are described in relation to the characteristics of the patients. The results 
obtained in single transfection and co-transfections of wt and either C2739Y or 
C2754W agreed with the VWD phenotype observed in patients with these 
mutations. This shows that missense mutations of cysteine residues in the 
CK domain of VWF can result in a quantitative VWF defect, and mimic the 
phenotype of a null allele. This was, however, not the case for the C1130F, C1149R 
and C2671Y mutations. In our cell system these mutations had a milder effect on 
secretion which did not agree with the low levels of VWF antigen (VWF:Ag) 
detected in patients with these mutations. 
Having shown that the low levels of VWF:Ag observed in patients with 
C1130F, C1149R or the C2671Y mutation was not due to decreased synthesis, and 
could not be explained completely by the decrease in secreted VWF or 
intracellular retention of VWF, we explored the possibility of increased clearance 
of the mutant VWF protein. In Chapter 3 we investigated the sensitivity of 
recombinant VWF to the VWF-cleaving protease (ADAMTS13) in an in vitro system 
using urea as an unfolding agent of VWF. In addition, we estimated the in vivo 
survival of the mutant proteins in patients after infusion of 1-deamino-
8-D-arginine vasopressin (DDAVP) and of recombinant mutant VWF in a 
VWF-deficient mouse model. Several parameters pointed to an increase in the 
clearance of the mutant proteins both in the patients and the mouse model. The 
increased ratio between VWF-propeptide and mature VWF, its reduced survival, 
and the four-fold increased clearance rate of the mutants in mice appeared not to 
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be linked with an increase in sensitivity to proteolysis by ADAMTS13. We were 
unable to identify any common functional or structural characteristics between 
the different mutant proteins that could be associated with increased clearance of 
VWF. 
In several Italian families with autosomal recessive, severe VWD with a 
predominantly quantitative VWF defect the C2362F mutation has been identified 
(Chapter 4). The low level of secreted mutant protein and the strong intracellular 
retention of C2362F VWF in vitro could readily explain the quantitative VWF 
defect observed in patients carrying this mutation. The two-fold decrease in 
half-life of C2362F VWF observed in vivo was, however, not explained by increased 
sensitivity of the mutant protein to ADAMTS13 in vitro. The contribution of 
clearance mechanisms, indicated by the reduced half-life of C2362F, to the VWD 
phenotype appeared minimal and the VWF defect is most likely the result of 
impaired secretion and intracellular retention and rapid degradation of the 
misfolded mutant protein. 
We noted that most cysteine mutations identified in VWD patients are 
alterations to bulky amino acids with a charged or a hydrophobic side chain. To 
investigate whether such amino acid side chains induce effects on the 
conformation of the VWF subunit in addition to those generated by the loss of the 
disulfide bond per se, the alanine variants of the C2671Y (Chapter 2b) and the 
C2362F (Chapter 4) VWF mutants were expressed. Only minor differences in 
secretion and intracellular levels of C2671Y and C2362F vs respectively C2671A 
and C2362A were observed. Thus for cysteines at these positions in VWF the 
quantitative VWF defect observed in the patients could be attributed to the loss of 
their respective disulfide bonds. 
We also noted that alterations of cysteines in the CK domain of VWF, which 
result in a dimerization defect of VWF, have been identified in both qualitative 
type 2A (IID) and quantitative type 3 VWD (Chapter 2a). We hypothesized that this 
difference in phenotype is related to whether the mutated cysteine residue is 
involved in the formation of an interchain or intrachain disulfide bond 
(Chapter 5). The effect of the novel 2A(IID) VWD mutation, C2773S, on quantity 
and quality of VWF was compared with the effects of two type 3 VWD mutations, 
C2739Y and C2754W. In contrast to the C2739Y and C2754W mutations, the C2773S 
mutation did not affect the quantity of secreted VWF. This showed that loss of 
either one of the intrachain bonds formed by cysteines 2739 and 2754 have a more 
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profound effect on the conformation of the VWF subunit than loss of the 
interchain disulfide bond formed by cysteine 2773. C2773S VWF did, however, 
have a major effect on the multimerization process of wt VWF due to N-terminal 
multimerization of C2773S proVWF monomers to wt proVWF dimers. This 
hindered further multimerization of wt proVWF dimers and the generation of 
HMW multimers. This ultimately results in the typical 2A(IID) VWD multimer 
pattern with the occurrence of odd-numbered multimers in between 
even-numbered multimers, and the lack of HMW multimers that was observed in 
co-transfections of C2773S and wt VWF constructs. This suggests that loss of a 
single disulfide bond in the CK domain of VWF will lead to a recessive, 
quantitative VWF deficiency if an intrachain disulfide bond is involved, and to a 
dominant negative, qualitative defect of VWF if an interchain disulfide bond is 
involved. 
In Chapter 6, we screened cases and controls in the FACTORS (FACTors in 
ORal anticoagulation Safety) for the presence of the Y1584C VWF polymorphism. 
This study was initiated to search for novel risk factors that contribute to the risk 
of bleeding in patients that are treated with vitamin K antagonists. The Y1584C 
VWF polymorphism has been reported at high frequency in patients with type 1 
VWD and is associated with rapid proteolysis by ADAMTS13 in an in vitro assay. We 
found a first indication that the Y1584C VWF polymorphism may be associated 
with bleeding in patients treated with vitamin K antagonists. Unfortunately, the 
limited size of the study and the low frequency of Y1584C did not allow a reliable 
estimate of the contribution of this polymorphism to the risk of bleeding in this 
patient group. 
Finally, in Chapter 7 the results obtained in our studies are discussed in a 
broader perspective and placed against a background of results reported by 
others. Our studies of the effects of mutated cysteine residues in VWF have 
contributed to the steadily increasing knowledge of the effects that mutated 
cysteine residues in VWF may have on expression, secretion and intracellular 
retention, processing, and clearance of VWF in relation to the phenotype 




De von Willebrand factor (VWF) is een groot eiwit met belangrijke functies in de 
primaire hemostase. VWF is essentieel voor de vorming van een bloedplaatjes 
plug doordat het op de plaats van de verwonding zowel aan de vrijgekomen 
extracellulaire matrix, zoals collageen, als aan bloedplaatjes kan binden. Dit leidt 
tot adhesie en vervolgens aggregatie van de bloedplaatjes waardoor uiteindelijk 
de verwonding afgedekt wordt. De plaatjes plug wordt vervolgens versterkt door 
fibrinedraden die door gelocaliseerde activatie van de stollingscascade ontstaan. 
VWF is zelf niet direct betrokken bij deze cascade maar levert wel een belangrijke 
bijdrage als drager van factor VIII, dat wel een belangrijke functie als co-factor in 
deze cascade vervult. Gebrek aan functioneel VWF kan leiden tot een 
bloedingsziekte, genaamd de ziekte van von Willebrand. De ernst van deze ziekte 
varieert sterk en is afhankelijk van het type van het VWF defect. De ziekte van 
von Willebrand wordt onderverdeeld in kwantitative en kwalitatieve VWF 
defecten. Bij type 1 ziekte van von Willebrand is VWF gedeeltelijk afwezig, terwijl 
type 3 correspondeert met een bijna volledige afwezigheid van het eiwit. Type 2 
ziekte van von Willebrand omvat alle kwalitative defecten van de VWF. 
VWF bevat een groot aantal cysteïneresiduen die allemaal zwavelbruggen 
vormen. De zwavelbruggen zijn onderverdeeld in bruggen binnen de VWF 
subeenheid (intramoleculaire zwavelbruggen) en bruggen tussen verschillende 
subeenheden van VWF (intermoleculaire zwavelbruggen). De intramoleculaire 
zwavelbruggen zijn van groot belang voor het behoud van de structuur van de 
individuele subeenheid van VWF, de monomeer. De intermoleculaire 
zwavelbruggen zijn noodzakelijk voor het genereren van multimeren van 
hoogmoleculair gewicht (HMG). De 90 C-terminale aminozuren van VWF vormen 
het zogenaamde Cysteïne Knoop (CK) domein. In het endoplasmatisch reticulum 
(ER) worden proVWF dimeren gevormd door intermoleculaire zwavelbruggen 
tussen de CK domeinen van twee proVWF moleculen. In het Golgi worden HMG 
multimeren van VWF gevormd door het verbinden van proVWF dimeren via 
intermoleculaire zwavelbruggen tussen cysteïneresiduen in het D3 domein van 
VWF. Het repetitieve karakter van VWF is zeer belangrijk voor de functie als 
moleculaire lijm tussen vrijgekomen subendotheliale structuren en de snel 
passerende bloedplaatjes. VWF multimeren van zeer hoog molecuulgewicht 
worden in de α-granulae van bloedplaatjes of in Weibel-Palade lichaampjes van 
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endotheliale cellen opgeslagen en worden naar behoefte uitgescheiden. In 
Hoofdstuk 1 wordt de biosynthese van VWF, de structuur en functie, de rol in de 
primaire hemostase en de verschillende types van de ziekte van von Willebrand in 
detail beschreven. 
Het hoofddoel van het onderzoek beschreven in dit proefschrift was het 
bestuderen van de effecten die missensemutaties van cysteïneresiduen in 
verschillende domeinen van VWF hebben op dimerisatie en multimerisatie van 
VWF, hoe deze mutaties de intracellulaire routing en secretie van VWF 
beïnvloeden, en hoe deze mutaties tot kwantitative en kwalitative WVF defecten 
kunnen leiden. 
In Hoofdstukken 2-5 werden de effecten van veranderde cysteïnes in 
verschillende domeinen van VWF bestudeerd door humaan VWF in menselijke 
293T niercellen tot expressie te brengen. In alle studies zijn zowel transfecties met 
enkele constructen als co-transfecties van wildtype (wt) en mutante constructen 
uitgevoerd. De kwantiteit en kwaliteit van het uitgescheiden en intracellulaire 
recombinant VWF werden vervolgens bestudeerd door middel van ELISA en 
SDS-agarose elektroforese, en in een aantal gevallen werd VWF gereduceerd en 
gescheiden door SDS-polyacrylamide gel elektroforese. 
In Hoofdstuk 2a werden de effecten onderzocht van vijf cysteïnemutaties, die 
allemaal in patiënten met een kwantitatief VWF defect zijn gevonden. De effecten 
van deze mutaties op dimerisatie en multimerisatie, en de kwantiteit van 
geproduceerd VWF werden beschreven in relatie tot de eigenschappen van de 
patiënten met die mutaties. De resultaten van transfecties met een enkel 
construct en co-transfecties van wt met C2739Y of C2754W kwamen overeen met 
het fenotype van patiënten met deze mutaties. Dit laat zien dat missense mutaties 
van cysteïneresiduen in het CK domein van VWF een kwantitatief defect kunnen 
veroorzaken en het fenotype van een nul allel kunnen nabootsen. Dit was niet het 
geval voor de C1130F, C1149R en C2671Y mutaties. In ons celsysteem hadden deze 
mutaties een milder effect op de secretie van VWF, hetgeen niet geheel 
overeenkwam met het lage niveau van VWF antigeen (VWF:Ag) in patiënten met 
dezelfde mutaties. 
Nadat we hadden laten zien dat het lage niveau van VWF:Ag in de patiënten 
met de C1130F, C1149R of de C2671Y mutatie niet veroorzaakt werd door 
verlaagde synthese en niet geheel uitgelegd kon worden door de verlaagde 
secretie van VWF of intracellulaire retentie van VWF, onderzochten wij de 
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mogelijkheid van versnelde klaring van de mutante VWF eiwitten. In Hoofdstuk 3 
werd de gevoeligheid van mutant VWF voor het VWF-splitsende protease 
(ADAMTS13) onderzocht in een in vitro test met ureum als ontvouwings reagens 
van VWF. Verder werd de halfwaardetijd van mutante VWF eiwitten in vivo 
bepaald door middel van intraveneuze toediening van 1-deamino-8-D-arginine 
vasopressin (DDAVP) in patiënten met de mutaties en uit de overleving van 
mutant recombinante VWF in VWF-deficiënte muizen. Meerdere parameters 
wezen op een verhoogde klaring van het mutante VWF zowel in de patiënten 
alsook in het muismodel. De verhoogde verhouding tussen VWF-propeptide en 
matuur VWF, de verkorte overleving van mutant VWF, en de viermaal hogere 
klaringssnelheid van de mutanten in de muizen bleek niet gerelateerd te zijn aan 
een verhoogde gevoeligheid voor proteolyse door ADAMTS13. Wij konden geen 
gemeenschappelijke functionele of structurele karakteristieken tussen de 
verschillende mutanten aantonen die met verhoogde klaring van VWF 
geassocieerd zouden kunnen zijn. 
In meerdere Italiaanse families met een ernstige vorm van de ziekte van von 
Willebrand, die autosomaal recessief overgeërfd wordt en voornamelijk in een 
kwantitatief VWF defect resulteert, is de C2362F mutatie gevonden (Hoofdstuk 4). 
Het lage niveau van uitgescheiden mutant eiwit en de hoge intracellulaire 
retentie van C2362F VWF in vitro kan het kwantitatief VWF defect, dat in patiënten 
met deze mutatie wordt gevonden, helemaal verklaren. De tweevoudig verlaagde 
in vivo halfwaardetijd van C2362F VWF lijkt niet veroorzaakt te zijn door 
verhoogde gevoeligheid van C2362F VWF voor ADAMTS13 in vitro en suggereert 
dat gestoorde klaring een bijdrage kan leveren aan het fenotype van de ziekte van 
von Willebrand. Die bijdrage leek echter beperkt en het lage VWF gehalte is 
waarschijnlijk het resultaat van verminderde secretie in combinatie met 
intracellulaire retentie en versnelde afbraak van het verkeerd gevouwen eiwit. 
Het viel ons op dat de meeste cysteïnemutaties die in patiënten zijn 
gevonden veranderingen naar grote aminozuren met geladen of met hydrofobe 
zijketens zijn. Om te onderzoeken of zulke aminozuurzijketens een extra invloed 
hebben op de conformatie van de VWF subeenheid naast de effecten, die het 
verlies van de zwavelbrug op zich hebben, werden de alaninevarianten van de 
C2671Y (Hoofdstuk 2b) en de C2362F (Hoofdstuk 4) VWF mutanten tot expressie 
gebracht. Er werden alleen kleine verschillen in secretie en intracellulaire niveaus 
van C2671Y en C2362F VWF geobserveerd vergeleken met de alaninevarianten. 
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Dus voor cysteïne mutaties in deze posities in VWF kan het kwantitatieve VWF 
defect worden uitgelegd door de afwezigheid van de respectievelijke 
zwavelbruggen. 
Wij merkten ook op dat gerapporteerde veranderingen van cysteïnes in het 
CK domein van VWF die tot dimerisatie defecten van VWF leiden geïdentificeerd 
zijn in zowel kwalitatief type 2A(IID) ziekte van von Willebrand als kwantitatief 
type 3 ziekte van von Willebrand (Hoofdstuk 2a). Wij postuleerden dat dit verschil 
in het fenotype van de ziekte van von Willebrand veroorzaakt wordt door de 
betrokkenheid van het gemuteerde cysteïneresidu bij een inter- of 
intramoleculaire zwavelbrug in VWF (Hoofdstuk 5). Het effect van de door ons 
gevonden type 2A(IID) ziekte van von Willebrand mutatie, C2773S, op kwantiteit 
en kwaliteit van VWF werd vergeleken met de effecten van twee type 3 ziekte van 
von Willebrand mutaties, C2739Y en C2754W. In tegenstelling tot de C2739Y en 
C2754W mutaties, resulteerde de C2773S mutatie niet in een kwantitatief effect op 
VWF secretie. Dit wijst erop dat verlies van elke van de intramoleculaire 
zwavelbruggen die cysteïnes 2739 en 2754 vormen een sterker effect heeft op de 
conformatie van de VWF subeenheid dan het verlies van de intermoleculaire 
zwavelbrug gevormd door cysteïne 2773. De C2773S VWF mutatie had echter wel 
een groot effect op de multimerisatie van wt VWF door de N-terminale 
multimerisatie van C2773S proVWF monomeren aan wt proVWF dimeren. Dit 
verhinderde verdere multimerisatie van wt proVWF dimeren en de productie van 
HMG multimeren. Dit resulteert uiteindelijk in het kenmerkende 2A(IID)-
multimerenpatroon dat bestaat uit multimeren opgebouwd uit een oneven aantal 
monomeren naast multimeren met een even aantal monomeren, en uit de 
afwezigheid van HMG multimeren zoals dat werd waargenomen in co-transfecties 
van C2773S en wt VWF constructen. Dit suggereert dat verlies van één zwavelbrug 
in het CK domein van VWF resulteert in een recessief, kwantitatief VWF defect 
wanneer het een intramoleculaire zwavelbrug betreft, en in een dominant-
negatief, kwalitatief defect van VWF wanneer het een intermoleculaire 
zwavelbrug betreft. 
In Hoofdstuk 6, zochten wij in het patiënt-controle onderzoek FACTORS 
(FACToren in de veiligheid van ORale antistollingsmiddelen) naar de 
aanwezigheid van het Y1584C-VWF-polymorfisme. Deze studie was opgezet om 
nieuwe risicofactoren te identificeren die bijdragen aan het risico op bloedingen 
in patiënten, die worden behandeld met vitamine-K-antagonisten. Het Y1584C-
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VWF-polymorfisme blijkt vaak voor te komen in patiënten met type 1 ziekte van 
von Willebrand en gaat gepaard met versnelde proteolyse van VWF door 
ADAMTS13 in een in vitro test. Wij vonden een milde aanwijzing dat bloedingen in 
patiënten, die behandeld worden met vitamine-K-antagonisten, geassocieerd zijn 
met het Y1584C-polymorfisme. Helaas maakte de beperkte omvang van de studie 
en de lage frequentie van Y1584C het niet mogelijk om een betrouwbare schatting 
te maken van de bijdrage van dit polymorfisme aan het risico op bloedingen in 
deze patiënten groep. 
Ten slotte werden in Hoofdstuk 7 onze resultaten in een breder perspectief 
geplaatst en gespiegeld aan de bevindingen van andere onderzoeken. Onze studies 
van de effecten van gemuteerde cysteïneresiduen in VWF hebben bijgedragen aan 
de gestaag toenemende kennis van de effecten die veranderingen van 
cysteïneresiduen in VWF hebben op expressie, secretie en intracellulaire retentie, 
processing, en klaring van VWF in relatie tot de fenotypes beschreven in 




Von Willebrand faktor (VWF) är ett stort protein med viktiga funktioner i primära 
hemostasen. VWF är väsentlig för bildandet av en blodplättsplugg genom att 
binda molekyler som frilagts i den skadade blodkärlsbädden, och genom att binda 
blodplättar. Detta leder till adhesion av, och följaktligen aggregation av 
blodplättarna vilket resulterar i att det skadade området täcks. Blodplättspluggen 
förstärks av fibrintrådar som bildas genom lokal aktivering av koagulations-
kaskaden. VWF deltar inte direkt i denna kaskad men är viktigt genom sin 
funktion som bärare av faktor VIII som har en viktig funktion som kofaktor i 
denna kaskad. Brist på fungerande VWF kan orsaka blödarsjukan von Willebrands 
sjukdom. Sjukdomens allvarlighetsgrad varierar och beror på vilken typ av 
VWF-defekt patienten har. Von Willebrands sjukdom indelas i kvantitativa och 
kvalitativa VWF-defekter. Typ 1 von Willebrands sjukdom karakteriseras av 
partiell brist på VWF, medan typ 3 von Willebrands sjukdom innebär nästintill 
fullständig avsaknad av proteinet. Typ 2 von Willebrands sjukdom omfattar alla 
sorters kvalitativa defekter av VWF. 
VWF innehåller ett stort antal av aminosyran cystein vilka alla bildar 
kovalenta svavelbryggor. Svavelbryggorna är fördelade i bindningar inom 
VWF-molekylen, så kallade intramolekylära svavelbryggor, och bindningar mellan 
enskilda VWF-molekyler, så kallade intermolekylära svavelbryggor. De 
intramolekylära svavelbryggorna är mycket viktiga för formen hos de enskilda 
VWF-molekylerna, så kallade monomerer. De intermolekylära svavelbryggorna är 
oumbärliga för bildandet av VWF-multimerer med hög molekylär vikt (HMV). De 
90 mest C-terminala aminosyrorna av VWF bildar den så kallade 
cysteinknutdomänen (CK-domänen) i VWF. I det endoplasmatiska retikelet (ER) 
bildas proVWF-dimerer via intermolekylära svavelbryggor mellan cysteiner 
belägna i CK-domänerna i två proVWF-molekyler. I Golgi-apparaten bildas 
VWF-multimerer med HMV via intermolekylära svavelbryggor mellan cysteiner i 
D3-domänen i proVWF-dimerer. Den repetetiva karaktären hos VWF med HMV är 
mycket viktigt för proteinets funktion som molekylärt klister mellan frilagda 
subendoteliala strukturer och de snabbt förbipasserande blodplättarna. 
VWF-multimerer med särdeles hög molekylärvikt lagras i α-granula i blodplättar 
eller i Weibel-Palade-kroppar i endotelceller och utsöndras vid behov. I Kapitel 1 
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beskrivs biosyntesen av VWF, dess struktur och funktion, dess roll i den primära 
hemostasen och de olika typerna av von Willebrands sjukdom i detalj. 
Syftet med studierna som beskrivs i denna avhandling var att undersöka 
effekterna som förändringar av cysteiner belägna i olika delar av VWF har på 
proteinets förmåga att bilda dimerer (dimerisera) och att bilda multimerer 
(multimerisera), samt att se hur dessa förändringar (mutationer) påverkar 
syntesen, proteinets intracellulära routing och utsöndringen av VWF, och hur 
dessa mutationer kan orsaka kvantitativa och kvalitativa VWF-defekter. 
I Kapitel 2-5 beskrivs effekterna av förändrade cysteiner i olika domäner av 
VWF genom att uttrycka humant VWF i 293T celler som är njurceller av mänskligt 
ursprung. I alla studier utfördes både transfektioner av 293T celler med ett 
konstrukt (enkla transfektioner) och med en kombination av ett konstrukt med 
normal VWF med ett konstrukt med mutant VWF (co-transfektioner). Kvantiteten 
och kvaliteten av utsöndrad och intracellulär rekombinant VWF studerades med 
hjälp av ELISA och SDS-agarose gelelektrofores och i vissa fall reducerades VWF 
och skildes genom SDS-polyakrylamid gelelektrofores. 
I Kapitel 2a redogörs för effekterna utav fem cysteinmutationer, vilka alla 
har identifierats i patienter med en kvantitativ VWF-defekt. Effekterna av dessa 
mutationer på dimerisering och multimerisering, och kvantiteten av det 
producerade VWF jämfördes med de egenskaper VWF har i patienter med dessa 
mutationer. Resultaten från transfektioner med enkla konstrukt och sådana från 
co-transfektioner av normal VWF i kombination med C2739Y eller C2754W stämde 
bra överens med fenotypen hos patienter med dessa mutationer. Detta visar att 
förändringar av cysteiner till en annan aminosyra (missense mutation) i 
CK-domänen av VWF kan förorsaka en kvantitativ VWF defekt som liknar effekten 
av en noll allel (en mutation som förhindrar produktion av protein). Detta var inte 
fallet för mutationerna C1130F, C1149R och C2671Y. I vårt cellsystem hade dessa 
mutationer en mildare effekt på utsöndringen av VWF, vilket inte stämde överens 
med den låga nivån av VWF-antigen (VWF:Ag) i plasma hos patienter med samma 
mutationer. 
Efter det att vi hade visat att den låga nivån av VWF:Ag i patienter med 
förändringar av C1130, C1149 eller C2671 inte orsakas av minskad syntes av VWF, 
och inte kunde förklaras av den något lägre utsöndringen av VWF eller 
intracellulär retention av VWF undersökte vi ifall den låga VWF:Ag nivån i 
patienterna orsakades av ökad omsättning av de förändrade proteinerna. I 
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Kapitel 3 beskrivs hur känsligheten av förändrat VWF för det VWF-klyvande 
proteaset (ADAMTS13) undersöktes i ett test in vitro med ureum som 
denatureringsreagens. Dessutom bestämdes halveringstiden för de förändrade 
VWF-proteinerna (C1130F, C1149R och C2671Y) in vivo genom intravenös infusion 
av 1-deamino-8-D-arginine vasopressin (DDAVP) i patienter med dessa 
mutationer, och genom injektion av mutant rekombinant VWF i möss som ej 
syntetiserar egen VWF. Flera parametrar pekade mot en ökad omsättning av 
mutant VWF både i patienterna och i musmodellen. Det förhöjda förhållandet 
mellan VWF-propeptid och VWF, den förkortade halveringstiden av mutant VWF, 
och den fyra gånger högre omsättningen av mutant protein i mössen var inte 
kopplade till en ökad känslighet för proteolys av ADAMTS13 in vitro. Vi kunde inte 
upptäcka en gemensam funktionell eller strukturell faktor mellan de olika 
mutanterna som var direkt kopplad till den ökade omsättningen av VWF. 
I flera Italienska familjer med en allvarlig form av von Willebrands sjukdom, 
som ärvs autosomalt och recessivt och huvudsakligen resulterar i en kvantitativ 
VWF-defekt, har mutationen C2362F identifierats (Kapitel 4). Den låga nivån av 
utsöndrad C2362F VWF och den höga intracellulära nivån av C2362F VWF in vitro 
kan helt förklara den kvantitativa VWF-defekten som observerats i patienter med 
denna mutation. Den förkortade halveringstiden av C2362F VWF in vivo verkar 
inte vara resultatet av en förhöjd känslighet av C2362F VWF för ADAMTS13 vilket 
indikerar att en störning av omsättningen av VWF bidrar till fenotypen. Detta 
bidrag verkar dock vara begränsat och den låga VWF-nivån är troligtvis resultatet 
av en minskad utsöndring, intracellulär retention och förmodligen snabb 
nedbrytning av C2362F VWF på grund av dess felaktiga konformation. 
Vi lade märke till att de flesta förändringar av cysteiner i VWF som 
identifierats i patienter med von Willebrands sjukdom är förändringar till 
aminosyror med stora laddade eller hydrofoba sidokedjor. För att undersöka om 
dessa sidokedjor har en extra effekt på konformationen av VWF-monomeren, 
utöver den effekt som förlusten av svavelbryggan har, studerades 
alaninvarianterna av C2671Y (Kapitel 2b) och av C2362F (Kapitel 4). Endast små 
skillnader i utsöndring och intracellulära nivåer av C2671Y och C2362F VWF 
observerades i jämförelse med deras respektive alaninvarianter. För cysteiner i 
dessa positioner i VWF kan den kvantitativa VWF-defekten förklaras av frånvaron 
av deras respektive svavelbryggor. 
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Vi lade även märke till att de funna förändringarna av cysteiner i 
CK-domänen av VWF som leder till dimeriseringsdefekter i VWF kan orsaka både 
kvalitativ typ 2A(IID) von Willebrands sjukdom och kvantitativ typ 3 von 
Willebrand sjukdom (Kapitel 2a). Vi postulerade att denna skillnad i 
sjukdomsfenotyp beror på om det muterade cysteinet deltar i en inter- eller 
intramolekylär svavelbrygga i VWF (Kapitel 5). Effekten av den av oss funna 
typ 2A(IID) mutationen, C2773S, på kvantitet och kvalitet av VWF jämfördes med 
effekterna av två typ 3 von Willebrand sjukdoms mutationer, C2739Y och C2754W. 
I motsats till resultaten för mutationerna C2739Y och C2754W resulterade C2773S 
mutationen inte i en kvantitativ effekt på utsöndringen av VWF. Detta visar att 
förlust av en av de intramolekylära svavelbryggor som cystein 2739 eller 2754 
ingår i har en starkare effekt på konformationen av VWF-monomeren än 
förlusten av den intermolekylära svavelbryggan som cystein 2773 deltar i. 
VWF-mutationen C2773S har dock en stark effekt på normal VWF:s förmåga att 
bilda multimerer genom N-terminal multimerisering utav C2773S VWF-
monomerer till normala proVWF-dimerer. Detta förhindrar vidare multi-
merisering av normal proVWF-dimerer och produktionen av HMV-multimerer. 
Slutligen resulterar detta i det multimermönster som är karakteristiskt för 2A(IID) 
von Willebrands sjukdom. Detta mönster består av multimerer med ett ojämnt 
antal monomerer, förutom multimerer bestående av ett jämnt antal monomerer, 
och karakteriseras av brist på HMV-multimerer. Det typiska 2A(IID) mönstret 
observerades i co-transfektioner av normal och C2773S VWF och visar att förlust 
av en svavelbrygga i CK-domänen utav VWF resulterar i en recessiv, kvantitativ 
VWF-defekt vid förlust av en intramolekylär svavelbrygga medan det resulterar i 
en dominant-negativ, kvalitativ defekt vid förlust av en intermolekylär 
svavelbrygga. 
I Kapitel 6, rapporteras resultaten från vår undersöking av patient-kontroll 
studien FACTORS (FAKTorer i säkerhet av ORal antikoagulationsmedel) för 
närvaro av Y1584C VWF-polymorfismen. Denna studie initierades för att 
identifiera nya riskfaktorer som bidrar till risken för blödning i patienter som 
behandlas med vitamin K-antagonister. Y1584C VWF-polymorfismen förekommer 
frekvent hos patienter med typ 1 von Willebrands sjukdom och leder till en 
snabbare proteolys av VWF genom ADAMTS13 in vitro. Vi fann endast en svag 
indikation att blödningar i patienter som behandlas med vitamin K-antagonister 
är associerad med denna polymorfism. Tyvärr gjorde den ringa storleken på 
Sammanfattning 
184 
studien och den låga frekvensen av Y1584C att det var omöjligt att trovärdigt 
uppskatta bidraget av denna polymorfism till risken för blödning i denna 
patientgrupp. 
Slutligen diskuteras våra resultat i ett bredare perspektiv i Kapitel 7 där de 
speglas gentemot andra forskares resultat. Våra studier har bidragit till en ökad 
kunskap om de effekter som förändringar av aminosyran cystein i VWF har på 
syntesen, utsöndring och intracellulär retention, processing, och omsättning av 
VWF i förhållande till fenotypen beskriven hos patienter med samma mutationer. 
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